ovarian cancer (Cancer)
Information
- Disease name
- ovarian cancer
- Disease ID
- DOID:2394
- Description
- "A female reproductive organ cancer that is located_in the ovary." [url:http\://www.cancer.gov/dictionary?CdrID=445074]
Disease area statistics
Chromosome band
Gene symbol | Chromosome | Start | Stop | The number of variant |
---|---|---|---|---|
PMS2 | 7 | 5,970,957 | 6,009,122 | 186 |
MSH6 | 2 | 47,783,145 | 47,806,953 | 152 |
FBXO11 | 2 | 47,806,920 | 47,906,498 | 132 |
MSH2 | 2 | 47,403,156 | 47,483,223 | 116 |
TP53 | 17 | 7,668,421 | 7,687,490 | 44 |
EPCAM | 2 | 47,369,311 | 47,387,020 | 32 |
MLH1 | 3 | 36,993,518 | 37,050,846 | 28 |
KCNK12 | 2 | 47,509,290 | 47,570,985 | 28 |
BRCA1 | 17 | 43,044,295 | 43,125,483 | 20 |
ARID1A | 1 | 26,696,015 | 26,782,104 | 14 |
Annotation
Genes | Mutation | Description | Source | Links |
---|
NCT ID | Status | Phase | Summary | Start date | Completion date |
---|---|---|---|---|---|
NCT03382340 | Active, not recruiting | Phase 1/Phase 2 | IMX-110 in Patients With Advanced Solid Tumors | February 15, 2018 | December 31, 2023 |
NCT03596281 | Active, not recruiting | Phase 1 | Pembrolizumab in Combination With Bevacizumab and Pegylated Liposomal Doxorubicin in Patients With Ovarian Cancer | December 5, 2018 | April 2023 |
NCT01439659 | Active, not recruiting | Phase 2 | Juice Plus+ and Juice Plus+ Complete in Ovarian Cancer | February 18, 2003 | March 1, 2026 |
NCT01081951 | Active, not recruiting | Phase 2 | Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer | February 4, 2010 | December 31, 2024 |
NCT03246074 | Active, not recruiting | Phase 1 | Clinical Trial of Combined Fostamatinib and Paclitaxel in Ovarian Cancer | April 3, 2018 | October 1, 2024 |
NCT05840029 | Active, not recruiting | VATS IN PATIENTS WITH ADVANCED OVARIAN MALIGNANCIES | June 1, 2021 | April 30, 2023 | |
NCT00657878 | Active, not recruiting | Phase 3 | Efficacy Study of Chemotherapy to Treat Ovarian Cancer Recurrence by Prolonging the Platinum Free Interval | November 2008 | December 2023 |
NCT04511988 | Active, not recruiting | N/A | Using Liquid Biopsy in Newly Diagnosed Patients With High Grade Adenocarcinoma of Ovarian Origin, Fallopian Tubes or Primary Peritoneal | July 17, 2021 | July 2026 |
NCT02043158 | Active, not recruiting | Biobehavioral and Sociodemographic Characteristics of Long Term Survivors of Ovarian Cancer | January 16, 2014 | December 30, 2026 | |
NCT04116320 | Active, not recruiting | Phase 1 | Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors | November 21, 2019 | February 2024 |
NCT04214964 | Active, not recruiting | Clinical Characters of the Diagnosis and Treatment of Gynecological Malignant Tumors in China : A Real World Study | April 11, 2020 | December 2024 | |
NCT03891576 | Active, not recruiting | Phase 2 | Newton Study (NEW Dosing mainTenance Therapy Ovarian caNcer) | November 13, 2019 | December 31, 2024 |
NCT02321228 | Active, not recruiting | N/A | Early Salpingectomy (Tubectomy) With Delayed Oophorectomy in BRCA1/2 Gene Mutation Carriers | January 2015 | January 2035 |
NCT04525183 | Active, not recruiting | N/A | REVITALIZE: A Telehealth Intervention for Women With Advanced Ovarian Cancer and PARP Inhibitor-Related Fatigue | December 2, 2020 | December 28, 2023 |
NCT04570839 | Active, not recruiting | Phase 1/Phase 2 | COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors. | August 31, 2020 | August 2024 |
NCT01226316 | Active, not recruiting | Phase 1 | Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules | December 1, 2010 | December 31, 2024 |
NCT03519230 | Active, not recruiting | Phase 3 | Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian Cancer | May 14, 2018 | June 30, 2026 |
NCT04498117 | Active, not recruiting | Phase 3 | Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery | August 25, 2020 | August 26, 2027 |
NCT03249142 | Active, not recruiting | Phase 1/Phase 2 | Immunotherapy With Neo-adjuvant Chemotherapy for OVarian Cancer | October 18, 2017 | December 31, 2024 |
NCT03836352 | Active, not recruiting | Phase 2 | Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors | December 21, 2018 | December 31, 2023 |
NCT04248153 | Active, not recruiting | Phase 2 | Optimal Timing of BR55 CEUS of the Ovaries | October 14, 2019 | March 31, 2024 |
NCT04625270 | Active, not recruiting | Phase 2 | A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation | December 21, 2020 | December 2026 |
NCT04068896 | Active, not recruiting | Phase 1/Phase 2 | Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy | October 16, 2019 | January 2025 |
NCT05483933 | Active, not recruiting | Phase 1 | Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers | August 18, 2022 | April 2025 |
NCT03934827 | Active, not recruiting | Phase 1 | MRx0518 in Patients With Solid Tumours Waiting Surgical Removal of the Tumour | April 10, 2019 | December 31, 2022 |
NCT03691012 | Active, not recruiting | Circulating Tumour DNA as a Marker of Residual Disease & Response to Adjuvant Chemotherapy in Stage I-IV Ovarian Cancer | May 9, 2017 | May 9, 2025 | |
NCT05931445 | Active, not recruiting | N/A | Patient Reported Outcomes Study Using Electronic Monitoring System for Advanced or Metastatic Solid Cancer | January 26, 2021 | March 31, 2027 |
NCT02873962 | Active, not recruiting | Phase 2 | A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib | November 10, 2016 | July 2026 |
NCT05041257 | Active, not recruiting | Phase 2 | Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers (PICCOLO) | August 31, 2021 | December 13, 2024 |
NCT04553133 | Active, not recruiting | Phase 1/Phase 2 | PF-07104091 as a Single Agent and in Combination Therapy | September 16, 2020 | March 6, 2025 |
NCT02109367 | Active, not recruiting | Diagnostic Utility of Culdocentesis in Patients With a Suspicious Adnexal Mass | February 2014 | June 2024 | |
NCT05311618 | Active, not recruiting | Phase 1 | Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors | May 11, 2022 | June 2025 |
NCT04853017 | Active, not recruiting | Phase 1 | A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors | October 4, 2021 | March 2026 |
NCT02470299 | Active, not recruiting | N/A | Evaluation of GTPase Inhibition by Post-operative Intravenous Ketorolac in Ovarian Cancer Patients | October 29, 2015 | October 8, 2025 |
NCT02828618 | Active, not recruiting | N/A | Trial on Radical Upfront Surgery in Advanced Ovarian Cancer | July 2016 | February 2025 |
NCT05116189 | Active, not recruiting | Phase 3 | Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65) | December 13, 2021 | August 31, 2027 |
NCT00587886 | Active, not recruiting | Estrogen, Diet, Genetics and Endometrial Cancer | September 25, 2001 | December 31, 2024 | |
NCT04051502 | Active, not recruiting | ICG-Enabled Mapping of Ovarian Sentinel Lymph Nodes: A Feasibility Study | August 5, 2019 | August 2024 | |
NCT02891824 | Active, not recruiting | Phase 3 | ATALANTE: Atezolizumab vs Placebo Phase III Study in Late Relapse Ovarian Cancer Treated With Chemotherapy+Bevacizumab | September 22, 2016 | September 2024 |
NCT02869217 | Active, not recruiting | Phase 1 | Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors | September 2016 | September 2024 |
NCT03614689 | Active, not recruiting | Assessment of the Minimal Residual Disease in Ovarian Cancer From Circulating Tumor DNA and Immune Repertoire | November 25, 2017 | June 2024 | |
NCT04675320 | Active, not recruiting | Immuno Monitoring in Patient With Epithelial Ovarian Cancer Eligible to PARP Inhibitors | July 7, 2020 | November 10, 2024 | |
NCT06320418 | Active, not recruiting | The Epigenetic Regulatory Role of P-element Induced Wimpy Testis (Piwi) Interacting RNA-823 (piR-823) in Ovarian Cancer Progression | June 15, 2022 | June 2024 | |
NCT03776630 | Active, not recruiting | N/A | Exploring the Potential of Novel Biomarkers Based on Plasma microRNAs for a Better Management of Pelvic Gynecologic Tumors | May 23, 2019 | May 2027 |
NCT03667716 | Active, not recruiting | Phase 1 | COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. | September 6, 2018 | May 31, 2024 |
NCT05693974 | Active, not recruiting | Early Detection of Ovarian Cancer Using Plasma Cell-free DNA Fragmentomics (Retrospective Study) | October 1, 2022 | April 2023 | |
NCT03532139 | Active, not recruiting | Phase 2 | Pilot Study of Rosuvastatin and Enoxaparin Thromboprophylaxis Following Ovarian Cancer Surgery (O-STAT Study) | July 25, 2018 | May 31, 2024 |
NCT02562365 | Active, not recruiting | Phase 2 | Adjuvant Chemotherapy of Three-step Regimen in Ovarian Cancer | November 2015 | November 2023 |
NCT03907852 | Active, not recruiting | Phase 1/Phase 2 | Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer | April 15, 2019 | November 2, 2028 |
NCT04152018 | Active, not recruiting | Phase 1 | Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors. | November 13, 2019 | August 30, 2024 |
NCT03054298 | Active, not recruiting | Phase 1 | CAR T Cells in Mesothelin Expressing Cancers | April 6, 2017 | March 2025 |
NCT03363867 | Active, not recruiting | Phase 2 | BEACON - ABC in Recurrent Platinum Resistant HGSOC | July 10, 2018 | June 30, 2025 |
NCT04227522 | Active, not recruiting | Phase 3 | Rucaparib MAintenance After Bevacizumab Maintenance Following Carboplatin Based First Line Chemotherapy in Ovarian Cancer Patients | June 8, 2020 | January 2025 |
NCT02854215 | Active, not recruiting | N/A | Cost Utility of Radical Surgery in Ovarian Cancer | January 18, 2017 | June 2025 |
NCT02009449 | Active, not recruiting | Phase 1 | A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors | November 15, 2013 | August 25, 2024 |
NCT05979298 | Active, not recruiting | Phase 2 | Efficacy of Plasmid Elenagen in Combination With Gemcitabine in Patients With Platinum-resistant Ovarian Cancer | November 15, 2019 | December 30, 2024 |
NCT00799110 | Active, not recruiting | Phase 2 | Vaccination of Patients With Ovarian Cancer With Dendritic Cell/Tumor Fusions With Granulocyte Macrophage Colony-stimulating Factor (GM-CSF) and Imiquimod | August 2008 | December 2024 |
NCT04731467 | Active, not recruiting | Phase 1/Phase 2 | A Study of CM24 in Combination With Nivolumab in Adults With Advanced Solid Tumors | March 19, 2021 | January 2025 |
NCT03877796 | Active, not recruiting | Clinical Pre-screening Protocol for Ovarian Cancer | April 11, 2019 | December 2024 | |
NCT04739527 | Active, not recruiting | Phase 1 | Phase 1 Study to Evaluate the Safety, Feasibility and Immunogenicity of an Allogeneic, Cell-based Vaccine (DCP-001) in High Grade Serous Ovarian Cancer Patients After Primary Treatment | June 10, 2021 | June 1, 2026 |
NCT04024878 | Active, not recruiting | Phase 1 | NeoVax With Nivolumab in Patients With Ovarian Cancer | November 20, 2020 | April 30, 2029 |
NCT03162289 | Active, not recruiting | N/A | Intermittent Fasting Accompanying Chemotherapy in Gynecological Cancers | May 10, 2017 | June 10, 2025 |
NCT05368207 | Active, not recruiting | N/A | Pembrolizumab in Small Cell Carcinoma of Ovary - Hypercalcemic Type Patient | December 6, 2021 | November 2, 2024 |
NCT05082025 | Active, not recruiting | Phase 2 | Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations | September 27, 2022 | October 29, 2026 |
NCT03997968 | Active, not recruiting | Phase 1/Phase 2 | A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors | October 9, 2019 | December 30, 2024 |
NCT05200364 | Active, not recruiting | Phase 1 | A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer | March 22, 2022 | January 2026 |
NCT03225989 | Active, not recruiting | Phase 1/Phase 2 | Trial Investigating an Immunostimulatory Oncolytic Adenovirus for Cancer | March 1, 2018 | August 22, 2024 |
NCT01767675 | Active, not recruiting | Phase 2 | Outcomes After Secondary Cytoreductive Surgery With or Without Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Followed by Systemic Combination Chemotherapy for Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | January 8, 2013 | January 2025 |
NCT04913337 | Active, not recruiting | Phase 1/Phase 2 | Study of NGM707 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies | June 9, 2021 | July 2025 |
NCT04470921 | Active, not recruiting | STOP OVarian CAncer; Implementation of the Opportunistic Salpingectomy in the Netherlands | January 1, 2019 | December 31, 2025 | |
NCT04454450 | Active, not recruiting | N/A | Using Advanced Imaging Studies to Develop a Profile of High-grade Serous Ovarian Cancer | June 22, 2020 | June 2025 |
NCT04729387 | Active, not recruiting | Phase 3 | Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected | July 2, 2021 | January 31, 2026 |
NCT02568267 | Active, not recruiting | Phase 2 | Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) | November 19, 2015 | April 1, 2025 |
NCT04608409 | Active, not recruiting | Phase 1 | Dose Escalation of Lapatinib With Paclitaxel in Ovarian Cancer | March 17, 2021 | June 30, 2025 |
NCT03355976 | Active, not recruiting | Phase 2 | BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas | April 30, 2018 | December 2025 |
NCT05305820 | Active, not recruiting | N/A | Perioperative Exercise and Nutritional Optimisation Prehabilitation Before Surgery for Patients With Peritoneal Malignancy | September 1, 2022 | August 1, 2024 |
NCT03430700 | Active, not recruiting | Phase 2 | Trial of Pembrolizumab Following Weekly Paclitaxel for Platinum-resistant Ovarian, Fallopian Tube or Peritoneal Cancer | May 16, 2019 | March 17, 2025 |
NCT03493464 | Active, not recruiting | Phase 2 | BR55 in Characterization of Ovarian Lesions | December 13, 2018 | December 31, 2023 |
NCT05292859 | Active, not recruiting | Long-Term Follow-up Study of Subjects Treated With Autologous T Cells Using the Sleeping Beauty System to Express TCRs | October 1, 2022 | June 2039 | |
NCT04931342 | Active, not recruiting | Phase 2 | A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors | October 7, 2021 | December 31, 2028 |
NCT03748186 | Active, not recruiting | Phase 1 | Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers | February 1, 2019 | November 2024 |
NCT03132922 | Active, not recruiting | Phase 1 | MAGE-A4ᶜ¹º³²T for Multi-Tumor | May 15, 2017 | September 2032 |
NCT04908787 | Active, not recruiting | Phase 3 | A Phase III Study of BD0801 Combined With Chemotherapy in Recurrent, Platinum-resistant Epithelial Ovarian Cancer | June 11, 2021 | December 2024 |
NCT05194735 | Active, not recruiting | Phase 1/Phase 2 | Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors | April 4, 2022 | November 30, 2024 |
NCT04204811 | Active, not recruiting | Prehabilitation Care for Women With Advanced Ovarian Cancer Receiving Neoadjuvant Chemotherapy | December 16, 2019 | December 16, 2024 | |
NCT02571725 | Active, not recruiting | Phase 1/Phase 2 | PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer | February 23, 2016 | July 15, 2027 |
NCT03983954 | Active, not recruiting | Phase 1 | Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumors | October 10, 2019 | October 1, 2026 |
NCT03761914 | Active, not recruiting | Phase 1/Phase 2 | Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers | June 28, 2019 | April 30, 2023 |
NCT03561207 | Active, not recruiting | 3D Prediction of Patient-Specific Response | June 11, 2018 | December 2024 | |
NCT02346747 | Active, not recruiting | Phase 2 | A Trial of Vigil for Participants With Ovarian Cancer | February 2015 | December 2025 |
NCT00579488 | Active, not recruiting | Clinical Significance of Germline BRCA Mutations | July 1996 | July 2025 | |
NCT04332653 | Active, not recruiting | Phase 1/Phase 2 | NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors | June 10, 2020 | March 31, 2025 |
NCT02758652 | Active, not recruiting | Molecular Mechanisms Leading to Chemoresistance in Epithelial Ovarian Cancer | May 2016 | May 2026 | |
NCT04503265 | Active, not recruiting | Phase 1/Phase 2 | A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies | August 12, 2020 | January 2025 |
NCT00326456 | Active, not recruiting | Phase 3 | MITO-2: A Study Comparing 2 Chemotherapy Regimens (Carboplatin/Liposomal Doxorubicin vs Carboplatin/Paclitaxel) in Patients With Ovarian Cancer | January 1, 2003 | December 2023 |
NCT02125513 | Active, not recruiting | Phase 2 | Neoadjuvant Chemotherapy in Epithelial Ovarian Cancer | January 2014 | December 2023 |
NCT00579514 | Active, not recruiting | N/A | Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients | March 2000 | March 2025 |
NCT05256381 | Active, not recruiting | Phase 2 | A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors | June 21, 2022 | December 14, 2025 |
NCT00515372 | Active, not recruiting | Phase 1 | Depression Treatment and Screening in Ovarian Cancer Patients | December 20, 2002 | December 31, 2027 |
NCT04724031 | Active, not recruiting | Real World Data Analysis of PARP Inhibitors Use in Patients With Ovarian Cancer | November 1, 2019 | September 30, 2023 | |
NCT03170960 | Active, not recruiting | Phase 1/Phase 2 | Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | September 5, 2017 | August 2024 |
NCT00660842 | Active, not recruiting | Phase 3 | Study Comparing Weekly Versus Every 3 Week Chemotherapy in Patients With Ovarian Cancer | November 2008 | November 2024 |
NCT04234113 | Active, not recruiting | Phase 1 | Study of SO-C101 and SO-C101 in Combination With Pembro in Adult Patients With Advanced/Metastatic Solid Tumors | June 13, 2019 | November 2024 |
NCT06451263 | Active, not recruiting | N/A | Nudge to Gynecologic Oncology | January 19, 2024 | May 31, 2025 |
NCT05348356 | Active, not recruiting | Phase 2 | Nirogacestat in Ovarian Granulosa Cell Tumors | August 30, 2022 | December 2027 |
NCT03797326 | Active, not recruiting | Phase 2 | Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005) | February 12, 2019 | December 20, 2024 |
NCT05652283 | Active, not recruiting | Phase 2 | Pamiparib Combined With Surufatinib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer | November 6, 2022 | May 1, 2026 |
NCT04383210 | Active, not recruiting | Phase 2 | Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors | September 29, 2020 | March 2025 |
NCT01223248 | Active, not recruiting | Phase 3 | Randomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation Therapy | October 2010 | October 2024 |
NCT03763838 | Active, not recruiting | N/A | Acupressure for Fatigue in Ovarian Cancer Survivors | October 7, 2019 | June 18, 2024 |
NCT03732768 | Active, not recruiting | Phase 1 | Study of Radspherin® in Recurrent Ovarian Cancer Subjects With Peritoneal Carcinomatosis | June 8, 2020 | August 2025 |
NCT01061619 | Active, not recruiting | Pathway to Diagnosis of Ovarian Cancer | January 2010 | November 2024 | |
NCT02489006 | Active, not recruiting | Phase 2 | A Study of Olaparib Prior to Surgery and Chemotherapy in Ovarian, Primary Peritoneal, and Fallopian Tube Cancer | July 19, 2016 | December 31, 2025 |
NCT01471483 | Active, not recruiting | Geriatric Assessment and Nursing Telephone Intervention in Elderly Women With Ovarian Cancer | November 2011 | November 2024 | |
NCT04398446 | Active, not recruiting | Phase 2 | Effect of Hemp-CBD on Patients With CIPN | May 27, 2020 | April 1, 2023 |
NCT04817449 | Active, not recruiting | Spectroscopy in Ovarian Cancer | June 28, 2021 | October 2024 | |
NCT01706120 | Active, not recruiting | Phase 4 | Study of Clinical and Biological Prognostic Factors in Patients With Ovarian Cancer Receiving Carboplatin +Paclitaxel With Bevacizumab | October 2012 | December 2024 |
NCT05059522 | Active, not recruiting | Phase 3 | Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing | September 29, 2021 | September 30, 2026 |
NCT05748353 | Active, not recruiting | Endocrine Disruptors and Life STILe in Breast Cancer Development | January 1, 2012 | July 15, 2024 | |
NCT03029403 | Active, not recruiting | Phase 2 | Phase 2 Study of Pembrolizumab, DPX-Survivac Vaccine and Cyclophosphamide in Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer | February 12, 2018 | February 12, 2025 |
NCT04780217 | Active, not recruiting | Phase 1/Phase 2 | Intravenous T3011 Given as a Single Agent and in Combination With Other Therapy in Subjects With Advanced Solid Tumors | August 10, 2021 | August 2025 |
NCT04024254 | Active, not recruiting | Phase 2/Phase 3 | A Study of Serum Folate Levels in Patients Treated With Olaparib | July 21, 2020 | December 31, 2024 |
NCT04145388 | Active, not recruiting | N/A | Family History Study on Cancer Risk | July 1, 2020 | August 31, 2025 |
NCT01953159 | Active, not recruiting | Assessment of Paclitaxel-Induced Neuropathy | August 29, 2013 | December 2025 | |
NCT04201561 | Active, not recruiting | Phase 3 | High Dose Inorganic Selenium for Preventing Chemotherapy Induced Peripheral Neuropathy | December 24, 2019 | December 31, 2024 |
NCT05451849 | Active, not recruiting | Phase 1/Phase 2 | A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer | June 21, 2022 | October 30, 2028 |
NCT03740165 | Active, not recruiting | Phase 3 | Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036) | December 18, 2018 | May 29, 2026 |
NCT03079687 | Approved for marketing | Expanded Access Program for Olaparib Tablets as Maintenance Therapy in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer. | |||
NCT04681248 | Available | Expanded Access Use of DKN-01 for the Treatment of Advanced Solid Tumors | |||
NCT05974410 | Available | Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients | |||
NCT04566393 | Available | Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies | |||
NCT02498665 | Completed | Phase 1 | A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies | November 2015 | September 2018 |
NCT03159572 | Completed | Homologous Recombination Inquiry Through Ovarian Malignancy Investigations | March 28, 2017 | February 16, 2022 | |
NCT00006981 | Completed | Phase 1 | Immunotoxin Therapy in Treating Patients With Advanced Cancer | December 2000 | |
NCT02897375 | Completed | Phase 1 | Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors | October 24, 2016 | October 15, 2021 |
NCT01669798 | Completed | Phase 2 | BIBF 1120 in Bevacizumab Resistant, Persistent, or Recurrent Epithelial Ovarian Cancer | February 2013 | February 2018 |
NCT00006041 | Completed | Phase 1 | Vaccine Therapy in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer | February 2000 | February 2002 |
NCT00287885 | Completed | Phase 1 | Docetaxel in Treating Patients With Refractory or Recurrent Advanced Gynecologic Cancer | March 2004 | December 2008 |
NCT03652077 | Completed | Phase 1 | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | September 24, 2018 | August 18, 2021 |
NCT00138242 | Completed | Phase 2 | Docetaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer | December 2004 | October 2006 |
NCT00088413 | Completed | Phase 1/Phase 2 | PANVAC-V and PANVAC-F Vaccines Plus Sargramostim to Treat Advanced Cancer | July 21, 2004 | May 31, 2018 |
NCT00004604 | Completed | Phase 1 | Biological Therapy in Treating Patients With Metastatic Cancer | February 1997 | July 2002 |
NCT00170664 | Completed | Phase 2 | Taxol/ Carboplatin as First Line Therapy in Patients With Epithelial Ovarian Cancer | January 1999 | September 2004 |
NCT00058552 | Completed | Phase 2 | A Study to Evaluate the Effect of HER2 Activation on rhuMAb 2C4 (Pertuzumab) in Subjects With Advanced Ovarian Cancer | May 2003 | July 2004 |
NCT00031954 | Completed | Phase 2 | Combination Chemotherapy in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer | August 2001 | |
NCT02928549 | Completed | Factors Associated With the Use of a High Volume Cancer Center by Black Women With Ovarian Cancer: A Qualitative Study | September 22, 2016 | August 26, 2019 | |
NCT00407758 | Completed | Phase 2 | Enzastaurin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer | November 2006 | |
NCT02631876 | Completed | Phase 3 | A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer | March 2, 2016 | January 2020 |
NCT02537444 | Completed | Phase 2 | Acalabrutinib (ACP-196) Alone and in Combination With Pembrolizumab in Ovarian Cancer (KEYNOTE191) | November 2015 | October 2018 |
NCT00628654 | Completed | Glycan Analysis in Diagnosing Cancer in Women With Ovarian Epithelial Cancer and in Healthy Female Participants | October 2005 | March 10, 2016 | |
NCT03119285 | Completed | Genes Contributing to Hereditary Ovarian Cancer in Women and BRCA1/2 Wildtype Families | April 2013 | January 31, 2022 | |
NCT00030108 | Completed | Phase 1 | Ixabepilone in Treating Young Patients With Solid Tumors or Leukemia That Haven't Responded to Therapy | November 2001 | April 2010 |
NCT03367182 | Completed | Real-World Effectiveness of Bevacizumab Based on AURELIA in Platinum-resistant Recurrent Ovarian Cancer | September 1, 2017 | January 31, 2018 | |
NCT04392102 | Completed | Phase 2 | A Study of Niraparib in Patients With Relapsed Ovarian Cancer | August 4, 2020 | August 11, 2022 |
NCT01196559 | Completed | Phase 2 | Vinorelbine and Gemcitabine Combination In Platinum Resistant Recurrent Ovarian Cancer | January 2011 | October 2014 |
NCT04430842 | Completed | Phase 1 | Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S | July 20, 2020 | December 22, 2022 |
NCT00303940 | Completed | Phase 1 | Talabostat Combined With Temozolomide or Carboplatin in Treating Young Patients With Relapsed or Refractory Brain Tumors or Other Solid Tumors | December 2005 | February 2010 |
NCT00478452 | Completed | Phase 1 | Dendritic Cell Vaccine for High Risk Ovarian Cancer Patients | August 2005 | August 2008 |
NCT00002538 | Completed | Phase 2 | Laparoscopic Staging in Patients With Ovarian, Fallopian Tube, or Other Primary Abdominal Cancers | September 1993 | |
NCT02351479 | Completed | N/A | Hula, a Physical Activity Intervention for Female-Cancer Survivors | September 2013 | December 2017 |
NCT00436644 | Completed | Phase 2 | Lapatinib and Topotecan in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Did Not Respond to Cisplatin or Carboplatin | March 2007 | November 2012 |
NCT00002508 | Completed | Phase 1/Phase 2 | Combination Chemotherapy Followed by Bone Marrow or Stem Cell Transplantation in Treating Patients With Relapsed or Refractory Germ Cell Tumors | November 1990 | September 2001 |
NCT00049556 | Completed | Phase 2 | Gefitinib in Treating Patients With Cervical Cancer | October 2002 | August 2006 |
NCT02910622 | Completed | Pilot Study Evaluating the Oncogramme: Analysis of Response to Induction Treatment of Patients With Breast or Ovarian Cancer. | June 2012 | June 2016 | |
NCT01247779 | Completed | N/A | Perioperative Morbidity in Gyneco-oncology According to the Procedure : Coelioscopy Versus Robot-assisted Coelioscopy | December 2010 | November 2017 |
NCT01358071 | Completed | Phase 2 | Phase II Study of NGR-hTNF in Combination With Doxorubicin in Platinum-resistant Ovarian Cancer | June 2011 | December 2016 |
NCT00470366 | Completed | Phase 2 | Combination Chemotherapy and Pegfilgrastim in Treating Patients With Previously Untreated Germ Cell Tumors | March 2007 | June 2016 |
NCT02582931 | Completed | Phase 1 | MRI-Guided Stereotactic Body Radiation Therapy (SBRT) for Ovarian Cancer | December 2, 2015 | December 13, 2018 |
NCT04068675 | Completed | N/A | Effects of Centering Pre-operative Counseling on Patient Reported Anxiety | February 24, 2020 | June 30, 2021 |
NCT01469793 | Completed | Phase 1 | A Study of DMOT4039A in Participants With Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer | November 2011 | December 2015 |
NCT02608684 | Completed | Phase 2 | A Study of Pembrolizumab With Standard Treatment in Patients With Recurrent Platinum-resistant Ovarian Cancer | February 8, 2016 | March 7, 2022 |
NCT01544049 | Completed | Fallopian Tube Removal as a Method of Ovarian Cancer Prevention: A Descriptive Study | December 2011 | September 4, 2018 | |
NCT00002901 | Completed | Phase 1 | Docetaxel in Treating Patients With Solid Tumors and Abnormal Liver Function | December 1996 | |
NCT00403429 | Completed | Phase 2 | MITO-6: Capecitabine in Platinum Resistant Ovarian Cancer | March 2006 | July 2008 |
NCT00002600 | Completed | Phase 1 | Combination Chemotherapy, Bone Marrow Transplantation, and Peripheral Stem Cell Transplantation in Treating Patients With Ovarian Epithelial Cancer | October 21, 1994 | July 25, 2001 |
NCT00006235 | Completed | Phase 1 | Liposomal Doxorubicin and Carboplatin in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | ||
NCT03940196 | Completed | Phase 3 | Effect of Tumor Treating Fields (TTFields, 200 kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer (ENGOT-ov50 / GOG-3029 / INNOVATE-3) | March 22, 2019 | May 18, 2023 |
NCT01538498 | Completed | Development for the Peritoneal Carcinomatosis Index (PCI) in Ovarian Cancer | April 2008 | February 2013 | |
NCT00867503 | Completed | Phase 2 | Open Trial of Bendamustine Hydrochloride in Women With Advanced Ovarian Cancer | February 2009 | April 2013 |
NCT01691144 | Completed | Follow-up of Gynecological Cancer Patients, Their Needs and Expectations, A Cooperation Project | September 2012 | December 2015 | |
NCT00740116 | Completed | Phase 4 | Tranexamic Acid in Surgery of Advanced Ovarian Cancer | March 2008 | June 2012 |
NCT00003449 | Completed | Phase 2 | Combination Chemotherapy in Treating Patients With Platinum-Resistant Recurrent Ovarian Cancer | May 1998 | February 2004 |
NCT00757952 | Completed | Early Detection of Ovarian Cancer: GC/FT-ICR Mass Spectrometry and Canine Olfaction | November 2007 | December 2012 | |
NCT03189108 | Completed | Collection of Malignant Ascites, Pleural Fluid, and Blood From People With Solid Tumors | May 22, 2017 | May 18, 2023 | |
NCT00325494 | Completed | Phase 1 | A Study of MORAb-009 in Subjects With Pancreatic Cancer, Mesothelioma, or Certain Types of Ovarian or Lung Cancer | May 2006 | September 2008 |
NCT00086892 | Completed | Phase 2 | Cetuximab and Carboplatin in Treating Patients With Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer | June 2004 | |
NCT00117442 | Completed | Phase 2 | A Study of Carboplatin/Paclitaxel With Pegfilgrastim Supported by Haematopoietic Progenitor Cell Re-Infusion in Whole Blood | August 2002 | December 2004 |
NCT02121990 | Completed | Phase 1 | Dose-Escalation Study of Intraperitoneal (IP) Cisplatin, IV/IP Paclitaxel, IV Bevacizumab, and Oral Olaparib for Newly Diagnosed Ovarian, Primary Peritoneal, and Fallopian Tube Cancer | April 21, 2014 | August 19, 2020 |
NCT03171506 | Completed | N/A | Targeted Disruption to Cancer Metabolism and Growth Through Dietary Macronutrient Modification | November 9, 2015 | July 18, 2017 |
NCT02287519 | Completed | N/A | Sexual Therapy and Rehabilitation After Treatment for Ovarian Cancer (START-OC): A Pilot Intervention | November 2014 | December 2019 |
NCT03514121 | Completed | Early Phase 1 | FPA150 in Patients With Advanced Solid Tumors | March 27, 2018 | May 10, 2021 |
NCT03804866 | Completed | Phase 2 | NGR-hTNF in Combination With an Anthracycline in Platinum-resistant Ovarian Cancer (NGR018) | March 2013 | December 2016 |
NCT00230542 | Completed | Phase 2 | Carboplatin and Pemetrexed in Recurrent Platinum Sensitive Ovarian Cancer | September 2005 | April 2011 |
NCT00620295 | Completed | Phase 1 | Bortezomib and Gemcitabine in Treating Older Patients With Advanced Solid Tumors | March 2007 | October 2009 |
NCT00967577 | Completed | Phase 1 | 177Lu-J591 Antibody in Patients With Nonprostate Metastatic Solid Tumors | July 2009 | December 31, 2021 |
NCT00170690 | Completed | Phase 3 | Preference Study With Elderly Patients Recurrent Ovarian Cancer | August 2004 | April 2012 |
NCT02107066 | Completed | Phase 3 | Women's Activity and Lifestyle Study in Connecticut | May 2009 | June 2013 |
NCT03452982 | Completed | Phase 2 | Sentinel Lymph Node in Early Ovarian Cancer | March 23, 2018 | August 21, 2019 |
NCT00005026 | Completed | Phase 1 | Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer | February 2000 | |
NCT03023319 | Completed | Phase 1 | Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors | December 10, 2019 | May 10, 2022 |
NCT01037751 | Completed | M. D. Anderson Symptom Inventory - Ovarian Cancer | December 30, 2009 | July 18, 2018 | |
NCT00825201 | Completed | Phase 1 | Intraperitoneal Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Cancer of the Peritoneal Cavity | January 2009 | January 16, 2018 |
NCT04545632 | Completed | Docetaxel Ethanol-induced Symptoms; The Incidence and Risk Forecating Factor | June 10, 2020 | June 24, 2021 | |
NCT00579007 | Completed | Decision-making Regarding Prophylactic Mastectomy and Oophorectomy in Women Seeking Genetic Counseling and Testing for BRCA1/2 Mutations | March 11, 2003 | November 20, 2019 | |
NCT00709462 | Completed | Phase 1 | A Study of CDX-1307, in Patients With Incurable Breast, Colorectal, Pancreatic, Ovarian or Bladder Cancer (CDX 1307-01) | March 2004 | June 2010 |
NCT00003773 | Completed | Phase 1 | IM-862 in Treating Patients With Recurrent Ovarian Cancer | February 1999 | August 2001 |
NCT00423852 | Completed | Phase 1/Phase 2 | Paclitaxel, Ifosfamide, and Carboplatin Followed By Autologous Stem Cell Transplant in Treating Patients With Germ Cell Tumors That Did Not Respond to Cisplatin | August 2006 | February 2013 |
NCT02092363 | Completed | Phase 1 | Dose Escalation Study of OMP-54F28 in Combination With Paclitaxel and Carboplatin in Patients With Recurrent Platinum-Sensitive Ovarian Cancer | January 2014 | December 2017 |
NCT00889382 | Completed | Phase 1/Phase 2 | A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors) | August 5, 2009 | August 25, 2014 |
NCT00002485 | Completed | Development of Strategies to Increase Enrollment in Clinical Trials for Children With Cancer | February 1992 | September 2005 | |
NCT00593580 | Completed | Phase 2 | Bone Health in Gynecologic Cancers-does FOSAVANCE Help? | February 2008 | June 2011 |
NCT00043472 | Completed | Removal of the Ovaries/Fallopian Tubes and CA-125 Screening to Reduce the Risk of Ovarian Cancer in Women at Increased Genetic Risk | July 9, 2003 | ||
NCT00028912 | Completed | Phase 1 | Bortezomib and Carboplatin in Treating Patients With Recurrent or Progressive Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer | November 2001 | |
NCT00087087 | Completed | Phase 2 | Pemetrexed Disodium in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer | July 2004 | |
NCT00753545 | Completed | Phase 2 | Assessment of Efficacy of AZD2281 in Platinum Sensitive Relapsed Serous Ovarian Cancer | August 28, 2008 | October 12, 2023 |
NCT00020150 | Completed | Phase 1 | Temozolomide and O6-benzylguanine in Treating Children With Solid Tumors | June 2000 | |
NCT01778803 | Completed | Phase 1 | Phase I/Ib Study of Paclitaxel in Combination With VS-6063 in Patients With Advanced Ovarian Cancer | February 26, 2013 | February 23, 2015 |
NCT01601548 | Completed | N/A | Cancer and Mindfulness-Based Cancer Recovery After Chemotherapy | July 2012 | July 2013 |
NCT01253681 | Completed | Phase 1 | Study of AMG 386 in Combination With Paclitaxel and Carboplatin in Subjects With Ovarian Cancer | November 2010 | January 2015 |
NCT01982500 | Completed | Observation of Bevacizumab Plus Front-line Chemotherapy in Patients With Ovarian Cancer | March 2012 | July 2017 | |
NCT00545792 | Completed | Phase 2 | Safety Study Of Avastin And Pelvic Radiation In Women With Recurrent Gynecological Cancers | May 2007 | October 2013 |
NCT00016224 | Completed | Phase 2 | Thalidomide in Treating Patients With Refractory or Resistant Epithelial Ovarian Cancer | January 2001 | March 2004 |
NCT00338026 | Completed | Phase 1 | A Phase I Study of ECO-4601 in Patients With Advanced Cancer | February 2006 | August 2007 |
NCT01689636 | Completed | Phase 1 | Safety and Biodistribution of Technetium Tc 99m EC20 in Normal Volunteers and Ovarian Cancer Patients | August 2000 | July 2002 |
NCT01248273 | Completed | Phase 1 | Unimolecular Pentavalent (Globo-H-GM2-sTn-TF-Tn) Immunization of Patients With Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer in First Remission | November 2010 | March 2017 |
NCT00003896 | Completed | Phase 2 | S9912 Combination Chemo in Stage III Ovarian Cancer, | September 1999 | February 2008 |
NCT02764333 | Completed | Phase 2 | TPIV200/huFR-1 (A Multi-Epitope Anti-Folate Receptor Vaccine) Plus Anti-PD-L1 MEDI4736 (Durvalumab) in Patients With Platinum Resistant Ovarian Cancer | May 6, 2016 | January 20, 2021 |
NCT00829959 | Completed | Attitudes About Childbearing And Fertility With Inherited Breast And Ovarian Cancer Syndromes (HBOC) | February 2009 | August 2016 | |
NCT00083928 | Completed | Phase 2 | Efficacy of Å6 in Ovarian Cancer Patients Following First-Line Chemotherapy and a Rising CA125 Levels | May 2004 | December 2006 |
NCT00765973 | Completed | Phase 1 | Topotecan Liposomes Injection for Small Cell Lung Cancer (SCLC), Ovarian Cancer and Other Advanced Solid Tumors | November 10, 2008 | June 30, 2010 |
NCT00428610 | Completed | Phase 2 | A Study of Chemotherapy Treatment for Patients With Ovarian Cancer | February 2007 | January 2012 |
NCT00531284 | Completed | Phase 1/Phase 2 | Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma | September 2007 | May 22, 2017 |
NCT02530047 | Completed | Phase 1 | Mesenchymal Stem Cells (MSC) for Ovarian Cancer | May 16, 2016 | June 13, 2019 |
NCT02262455 | Completed | Phase 1 | Effects of STM 434 Alone or in Combination With Liposomal Doxorubicin in Patients With Ovarian Cancer or Other Advanced Solid Tumors | October 2014 | January 13, 2017 |
NCT00002960 | Completed | Phase 1 | SCH-58500 in Treating Patients With Primary Ovarian, Fallopian Tube, or Peritoneal Cancer (C95084) | June 1999 | July 2000 |
NCT05448586 | Completed | Opioid Free Anaesthesia in Oncologic Gynaecological Surgery: Is There Any Benefit? | February 2, 2019 | January 30, 2021 | |
NCT03395080 | Completed | Phase 2 | A Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial or Epithelial Ovarian Cancer or Carcinosarcoma | March 5, 2018 | January 27, 2021 |
NCT04580485 | Completed | Phase 1 | INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors | February 3, 2021 | February 22, 2024 |
NCT01256268 | Completed | Phase 1 | Carboplatin/Taxol/Ridaforolimus in Endometrial, Ovarian and Solids | June 13, 2011 | August 3, 2017 |
NCT02531997 | Completed | N/A | A Mind-body Intervention to Improve Body and/or Self Image | August 2015 | December 2017 |
NCT00022347 | Completed | Phase 2 | TLK286 in Treating Patients With Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | May 2001 | December 2009 |
NCT01644825 | Completed | Phase 2 | Weekly Paclitaxel With or Without Pazopanib in Platinum Resistant or Refractory Ovarian Cancer | December 2010 | December 29, 2015 |
NCT01684878 | Completed | Phase 3 | Pertuzumab in Platinum-Resistant Low Human Epidermal Growth Factor Receptor 3 (HER3) Messenger Ribonucleic Acid (mRNA) Epithelial Ovarian Cancer (PENELOPE) | October 22, 2012 | April 28, 2016 |
NCT03635489 | Completed | Phase 3 | A Study of the Efficacy and Safety of Bevacizumab in Chinese Women With Newly Diagnosed, Previously Untreated Stage III or Stage IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | August 15, 2018 | May 12, 2023 |
NCT00496106 | Completed | N/A | Stress, Immunity and Cervical Cancer: Biobehavioral Outcomes | August 2007 | February 2011 |
NCT01167842 | Completed | Analysis of Tumors From Patients With Inherited Cancers Having Had Two Surgeries (Primary + Recurrent, or 2 Separate Types of Cancer) | October 2009 | January 14, 2022 | |
NCT01734746 | Completed | N/A | Sentinel Node Detection in Clinical Early Stage Ovarian Cancer | October 2012 | October 2014 |
NCT04630327 | Completed | Validation of the Russian and Kazakh Versions of the Beck Depression Inventory and Beck Anxiety Inventory | January 13, 2020 | May 1, 2022 | |
NCT00345709 | Completed | Elizabeth Registry for Low Grade Ovarian Cancer | September 2003 | October 2014 | |
NCT00002559 | Completed | Phase 1/Phase 2 | Combination Chemotherapy in Treating Patients With Germ Cell Tumors That Have Not Responded to Previous Cisplatin | January 1994 | January 2003 |
NCT00004082 | Completed | Phase 1 | Combination Chemotherapy in Treating Patients With Previously Untreated, Newly Diagnosed Epithelial Tumors | July 1999 | December 2010 |
NCT00061308 | Completed | Phase 2 | Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer | December 2002 | |
NCT04669002 | Completed | Phase 2 | EP0057 in Combination With Olaparib in Advanced Ovarian Cancer | December 14, 2020 | May 5, 2023 |
NCT00578006 | Completed | N/A | Internet-based System for Cancer Patients to Self-report Toxicity | March 2004 | January 2017 |
NCT00003072 | Completed | Phase 2 | Combination Chemotherapy in Treating Patients With Metastatic Ovarian Cancer or Non-small Cell Lung Cancer | May 1997 | October 1998 |
NCT00817479 | Completed | Phase 4 | Tumor Gene Expression in Women With Ovarian Cancer | January 2003 | January 2013 |
NCT01975831 | Completed | Phase 1 | A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab | December 19, 2013 | July 2, 2021 |
NCT00617773 | Completed | Phase 2 | Hu3S193 in Treating Women With Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer | May 2008 | June 2012 |
NCT02855697 | Completed | Early Phase 1 | Multi-maintenance Olaparib After Disease Recurrence in Participants With Platinum Sensitive BRCAm High Grade Serous Ovarian Cancer | May 26, 2017 | December 31, 2021 |
NCT00005051 | Completed | Phase 2 | Combination Chemotherapy in Treating Patients With Advanced Ovarian Epithelial Cancer | August 1999 | |
NCT00461786 | Completed | Phase 2 | A Study of Single Agent Pemetrexed Disodium in Treating Patients With Recurrent or Persistent Ovarian or Primary Peritoneal Cancer | September 2004 | May 2008 |
NCT00005956 | Completed | N/A | Biological Therapy in Treating Patients With Advanced Cancer | February 2000 | July 2002 |
NCT02372864 | Completed | N/A | Psychosexual Consequences of Risk-reducing Salpingo-oophorectomy | February 2015 | December 2016 |
NCT00017017 | Completed | Phase 1/Phase 2 | CT-2103 in Treating Patients With Recurrent Ovarian Epithelial or Fallopian Tube Cancer or Primary Peritoneal Cancer | February 2001 | December 2009 |
NCT01686256 | Completed | Phase 1 | Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Women With Suspected Ovarian or Endometrial Cancer | August 2001 | |
NCT00059618 | Completed | Phase 1 | PS-341 Plus Carboplatin in Platinum and Taxane Resistant Recurrent Ovarian Cancer, Primary Peritoneal Cancer, and Fallopian Tube Cancer | April 2003 | April 2007 |
NCT00005590 | Completed | Phase 3 | Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma | August 1999 | September 2005 |
NCT03558139 | Completed | Phase 1 | Study of Magrolimab (Hu5F9-G4) in Combination With Avelumab in Solid Tumor Participants and Checkpoint-Inhibitor-Naive Ovarian Cancer Participants Who Progress Within 6 Months of Prior Platinum Chemotherapy | May 23, 2018 | December 3, 2020 |
NCT00002474 | Completed | Phase 2 | Combination Chemotherapy and Bone Marrow Transplant in Treating Patients With Refractory or Recurrent Ovarian Cancer | February 1991 | October 2005 |
NCT00003107 | Completed | Phase 1 | Interleukin-12 in Treating Patients With Hematologic Cancers or Solid Tumors | October 1997 | |
NCT00866697 | Completed | Phase 3 | Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | May 26, 2009 | August 24, 2017 |
NCT00610714 | Completed | Phase 2 | AZD0530 Phase II Study in Patients With Advanced Ovarian Cancer | April 2008 | January 2012 |
NCT02312167 | Completed | N/A | Feasibility Study for Robotic Endomicroscopy to Better Define Resection Strategies (PERSEE) | October 2014 | October 2015 |
NCT01185626 | Completed | N/A | ROGYcare: The Impact of a Cancer Survivorship Care Plan on Patient Reported Outcomes and Health Care Providers | April 2011 | July 2016 |
NCT00945139 | Completed | Phase 2 | Study of Bevacizumab/Doxil in Treatment of Platinum-Resistant/Refractory Ovarian Cancer (CA) | March 2007 | August 2011 |
NCT00937560 | Completed | Phase 2 | A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer | June 25, 2009 | July 1, 2013 |
NCT04881045 | Completed | Phase 1 | Study to Test the Safety and Tolerability of PF-07257876 in Participants With Selected Advanced Tumors. | August 18, 2021 | October 24, 2023 |
NCT01690598 | Completed | Phase 1/Phase 2 | Veliparib and Topotecan for Relapsed Ovarian Cancer With Negative or Unknown BRCA Status | November 2012 | February 2015 |
NCT00114166 | Completed | Phase 2 | Topotecan in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | January 2005 | |
NCT01219777 | Completed | Phase 1 | Neoadjuvant Chemotherapy IV Carboplatin With Weekly Paclitaxel \Bevacizumab for Primary Ovarian | September 2010 | May 2015 |
NCT01346761 | Completed | N/A | Risk Education and Assessment for Cancer Heredity | August 2009 | December 2012 |
NCT03863912 | Completed | N/A | Impact of Disney Movies During Chemotherapy on QOL of Gynecologic Oncology Patients | December 1, 2017 | November 29, 2018 |
NCT00746018 | Completed | N/A | Thermal Spread Into the Interstitial Portion of the Fallopian Tubes Using the Ligasure Device at Time of Hysterectomy | August 2008 | July 2017 |
NCT02383251 | Completed | Phase 2 | Paclitaxel/Pazopanib for Platinum Resistant/Refractory Ovarian Cancer | June 15, 2015 | December 31, 2020 |
NCT00028743 | Completed | Phase 3 | Combination Chemotherapy Regimens in Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | August 31, 2001 | January 10, 2013 |
NCT00662233 | Completed | Early Phase 1 | Combination Chemotherapy in Treating Patients With Sarcoma | October 1991 | October 21, 2013 |
NCT00383279 | Completed | N/A | Improving Employment in Patients Who Have Survived Cervical Cancer, Uterine Cancer, or Ovarian Cancer | February 2006 | February 2007 |
NCT00432094 | Completed | Phase 2 | Autologous Peripheral Blood Stem Cell Transplant for Germ Cell Tumors | December 19, 2006 | March 2021 |
NCT01588522 | Completed | Phase 1 | Compound 31543 (Calcitriol, USP) in Patients Receiving Taxane-based Chemotherapy Regimens for Advanced or Recurrent Disease | July 2012 | March 2017 |
NCT01580696 | Completed | Phase 1/Phase 2 | Phase I/IIa Trial of Folate Binding Protein Vaccine in Ovarian Cancer | April 2012 | July 31, 2016 |
NCT00003269 | Completed | Phase 2 | Amifostine Followed by High Dose Chemotherapy in Treating Patients With Hematologic Cancer or Solid Tumors | February 1998 | January 2001 |
NCT02133703 | Completed | N/A | Decision Support Following Genetic Testing for Breast-Ovarian Cancer Susceptibility | October 2015 | July 1, 2022 |
NCT00003002 | Completed | Phase 1 | HER-2/Neu Vaccine Plus GM-CSF in Treating Patients With Stage III or Stage IV Breast, Ovarian, or Non-small Cell Lung Cancer | April 1996 | January 2004 |
NCT04352439 | Completed | Phase 4 | Aspirin for Prevention of Venous Thromboembolism Among Ovarian Cancer Patients Receiving Neoadjuvant Chemotherapy | August 8, 2020 | March 2, 2022 |
NCT00039585 | Completed | Phase 2 | Imatinib Mesylate in Treating Patients With Refractory or Relapsed Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer, or Ovarian Low Malignant Potential Tumor | May 2002 | |
NCT01379989 | Completed | Phase 3 | INOVATYON STUDY -International, Randomized Study in Patients With Ovarian Cancer | June 2011 | December 17, 2020 |
NCT04237090 | Completed | Phase 3 | Feasibility of a Clinical Trial Comparing the Use of Cetirizine to Replace Diphenhydramine in the Prevention of Reactions Related to Paclitaxel | February 14, 2020 | September 4, 2020 |
NCT03662204 | Completed | Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors | August 23, 2018 | March 31, 2022 | |
NCT00672295 | Completed | Phase 1 | PH I SRC Kinase, Dasatinib Combo Paclitaxel & Carboplatin in Pts w Ovarian, Peritoneal, & Tubal Cancer | August 2007 | November 2012 |
NCT02725489 | Completed | Phase 2 | Pilot Study of Durvalumab and Vigil in Advanced Women's Cancers | June 3, 2016 | December 2, 2020 |
NCT03921658 | Completed | The Role of Cytomegalovirus and Inflammation on Patient Symptoms and Outcomes in Ovarian Cancer | October 22, 2019 | April 2, 2024 | |
NCT00368420 | Completed | Validation of a Score of Predictive Factors for Complete Resection in Platinum-sensitive Recurrent Ovarian Cancer | September 2006 | October 2009 | |
NCT00228319 | Completed | Phase 1/Phase 2 | Treatment of Newly Diagnosed Ovarian Cancer With Antioxidants | October 2002 | August 2007 |
NCT02118285 | Completed | Phase 1 | Intraperitoneal Natural Killer Cells and INCB024360 for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer | July 28, 2014 | November 12, 2015 |
NCT00686465 | Completed | N/A | Positron Emission Tomography/Computed Tomography (PET/CT) for the Diagnosis of Recurrent Cancer: a Feasibility Study | March 2009 | July 2012 |
NCT01610869 | Completed | Phase 2 | Low Dose Cyclophosphamide +/-- Nintedanib in Advanced Ovarian Cancer | August 2014 | January 11, 2018 |
NCT04507191 | Completed | PDL1 in Ovarian High Grade Serous Carcinoma | December 1, 2012 | December 30, 2019 | |
NCT00525460 | Completed | Young Women Diagnosed With Early Stage Ovarian Cancer: A Focus on Fertility Issues and Sexual Function | April 2006 | December 2014 | |
NCT01132014 | Completed | Early Phase 1 | Autologous OC-DC Vaccine in Ovarian Cancer | May 2010 | May 30, 2018 |
NCT02580058 | Completed | Phase 3 | A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200) | December 21, 2015 | July 12, 2022 |
NCT03704467 | Completed | Phase 1 | Phase Ib/II Study of Carboplatin + M6620 + Avelumab in PARPi-resistant Ovarian Cancer | March 4, 2019 | November 6, 2019 |
NCT00770536 | Completed | Phase 1 | AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR | January 2009 | June 2015 |
NCT04898842 | Completed | N/A | Feasibility Study of a 4 Stage Bowel Obstruction Cancer Diet | March 2, 2021 | November 2, 2022 |
NCT00033488 | Completed | N/A | Screening Women at High Genetic Risk for Ovarian Cancer | September 2000 | March 2010 |
NCT01204749 | Completed | Phase 3 | TRINOVA-1: A Study of AMG 386 or Placebo, in Combination With Weekly Paclitaxel Chemotherapy, as Treatment for Ovarian Cancer, Primary Peritoneal Cancer and Fallopian Tube Cancer | November 2010 | December 2016 |
NCT00004909 | Completed | Effect of Chemotherapy Given Either by Mouth or by Infusion on the Quality of Life of Patients With Recurrent Ovarian Epithelial Cancer | November 1999 | November 2002 | |
NCT03004391 | Completed | Development of a Decision Aid to Facilitate Ovarian Cancer Patient's Choices Regarding Biomarker CA125 | April 1, 2017 | December 31, 2022 | |
NCT00768144 | Completed | Phase 2 | Sunitinib in Recurrent and Refractory Ovarian, Fallopian Tube and Peritoneal Carcinoma | September 2008 | February 2013 |
NCT00002568 | Completed | Phase 3 | Combination Chemotherapy With or Without Surgery in Treating Patients With Stage III Ovarian Epithelial Cancer | June 1994 | |
NCT00078845 | Completed | Phase 2 | Amifostine in Treating Peripheral Neuropathy Caused by Paclitaxel in Patients With Solid Tumors | May 2004 | May 2007 |
NCT00170677 | Completed | Phase 2 | Topotecan Weekly Versus Topotecan Day 1-5 in Patient With Platin-resistant Ovarian Cancer | September 2005 | January 2013 |
NCT00900094 | Completed | UMCC 003 Cancer-Related Protein Biomarkers in Blood and Tumor Tissue of Patients With Cancer | June 2000 | October 2007 | |
NCT06379191 | Completed | N/A | The Efficacy of WeChat-based Multidisciplinary Full-course Nutritional Management Program | February 1, 2023 | October 30, 2023 |
NCT04284852 | Completed | Phase 2 | Niraparib Maintenance in Patients With Advanced Ovarian Cancer at Neoadjuvant Setting | May 1, 2020 | October 1, 2023 |
NCT03931304 | Completed | Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Peritoneal Carcinomatosis From Ovarian Cancer (Cyto-chip 2) | February 1, 2018 | September 30, 2018 | |
NCT00003385 | Completed | Phase 1 | Combination Chemotherapy in Treating Patients With Untreated Ovarian, Peritoneal, or Fallopian Tube Cancer | March 1999 | |
NCT00652691 | Completed | Phase 1 | Topotecan, High-Dose Cyclophosphamide, Carboplatin, and an Autologous Peripheral Blood Cell Transplant in Treating Patients With Recurrent Ovarian Cancer or Primary Peritoneal Cancer | August 1998 | May 4, 2016 |
NCT02001272 | Completed | Phase 2 | EWOC-1 Trial: Carboplatin +/- Paclitaxel in Vulnerable Elderly Patients With Stage III-IV Advanced Ovarian Cancer | December 2013 | February 2020 |
NCT00312988 | Completed | Phase 3 | Topotecan Vs. Topotecan + Etoposide Vs.Topotecan + Gemcitabine in Ovarian Cancer Therapy | January 2000 | December 2009 |
NCT03164980 | Completed | Phase 4 | Comparison of QoL Between Trabectedin/PLD and Standard Platinum-based Therapy in Patients With Platinum Sensitive Recurrent Ovarian Cancer | November 27, 2017 | August 8, 2023 |
NCT03082976 | Completed | Prevalence of BRCA1 and BRCA2 Mutations in Ovarian Cancer Patients in the Gulf Region | July 16, 2017 | July 24, 2019 | |
NCT02393898 | Completed | BELOVA Data Collection: Safety and Efficacy of Frontline Bevacizumab Treatment in Participants With Ovarian Cancer 70 Years and Older | April 23, 2015 | June 14, 2019 | |
NCT00007813 | Completed | Phase 1 | Peripheral Stem Cell Transplantation Plus Chemotherapy in Treating Patients With Malignant Solid Tumors | May 31, 1997 | February 1, 2005 |
NCT01610206 | Completed | Phase 2 | A Randomized Study of Safety and Efficacy of Pazopanib and Gemcitabine in Persistent or Relapsed Ovarian Cancer | September 2012 | December 31, 2020 |
NCT01432015 | Completed | Phase 4 | Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting | September 2011 | March 2015 |
NCT00014456 | Completed | Phase 1 | Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors | March 2000 | October 2005 |
NCT01440504 | Completed | Ex Vivo Evaluation of the Interest of the Association of Platinum With a Molecule BH3-mimetic ABT-737 in Samples of Ovarian Tumors | April 2010 | January 2013 | |
NCT01591772 | Completed | Structural and Functional Imaging and Cognitive Functions in Ovarian Cancer | April 24, 2012 | May 25, 2022 | |
NCT00268918 | Completed | Phase 1 | Docetaxel and PTK787 in Metastatic Breast Cancer Patients and Gynecological Cancer Patients | September 2005 | January 2011 |
NCT03509636 | Completed | Phase 1 | A Study of Fluzoparib(SHR-3162)in BRCA1/2-mutant Relapsed Ovarian Cancer | April 4, 2018 | July 23, 2020 |
NCT04803305 | Completed | Phase 1 | Study to Compare the Effects of Repeated Doses of an Investigational New Drug and a Placebo on Appetite in Advanced Cancer and Anorexia | May 11, 2021 | August 9, 2022 |
NCT01482715 | Completed | Phase 1/Phase 2 | A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II) | November 2011 | May 2019 |
NCT00263822 | Completed | Phase 3 | Erlotinib or Observation in Treating Patients Who Have Undergone First-Line Chemotherapy for Ovarian Cancer, Peritoneal Cancer, or Fallopian Tube Cancer | September 2005 | |
NCT00070096 | Completed | Phase 2 | Ixabepilone in Treating Patients With Advanced Cisplatin-Refractory Germ Cell Tumors | August 2003 | June 2007 |
NCT05476341 | Completed | Phase 1 | A Phase I Clinical Trial of Bevacizumab Injection | April 6, 2017 | August 18, 2017 |
NCT00345540 | Completed | Phase 2 | Efficacy of NOV-002 in Combination With Carboplatin in Chemotherapy-resistant Ovarian Cancer | July 2006 | June 2008 |
NCT00217568 | Completed | Phase 2 | Docetaxel and Carboplatin in Treating Patients With Relapsed Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cavity Cancer | May 2005 | |
NCT03329950 | Completed | Phase 1 | A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies | December 1, 2017 | September 13, 2022 |
NCT00179712 | Completed | Phase 1/Phase 2 | Study of Lenalidomide With Topotecan In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma | April 2005 | November 2006 |
NCT00040911 | Completed | N/A | Electroacupuncture in Treating Delayed Nausea and Vomiting in Patients Receiving Chemotherapy For Newly Diagnosed Childhood Sarcoma, Neuroblastoma, Nasopharyngeal Cancer, Germ Cell Tumors, or Hodgkin Lymphoma | April 2005 | January 2011 |
NCT00070967 | Completed | Phase 2 | Acupuncture to Improve Quality of Life in Patients With Advanced Cancer | September 2001 | February 2005 |
NCT00239980 | Completed | Phase 2 | Fragmin in Ovarian Cancer: Utility on Survival (FOCUS) | October 2005 | January 2010 |
NCT00034151 | Completed | Phase 2 | Safety and Efficacy of S-8184 in Second Line Treatment of Stage III or IV Ovarian Cancer | March 2002 | September 2007 |
NCT01357161 | Completed | Phase 2 | A Study of Adavosertib (MK-1775) in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004) | July 26, 2011 | August 8, 2016 |
NCT00870233 | Completed | Outcomes From Home in Patients Recovering From Major Gynecologic Cancer Surgery: Measuring Symptoms and Health-related Quality of Life | March 24, 2009 | February 12, 2018 | |
NCT01246440 | Completed | Phase 2 | Catumaxomab as a Consolidation Therapy in Patients With Ovarian Cancer in Second or Third Clinical Disease Remission | June 2010 | December 2014 |
NCT03414047 | Completed | Phase 2 | A Study of Prexasertib (LY2606368) in Platinum-Resistant or Refractory Recurrent Ovarian Cancer | April 10, 2018 | October 3, 2020 |
NCT01113957 | Completed | Phase 2 | A Trial of ABT-888 in Combination With Temozolomide Versus Pegylated Liposomal Doxorubicin Alone in Ovarian Cancer | March 2010 | June 2013 |
NCT03471572 | Completed | Study to Assess Prevalence of BRCA1 and BRCA2 Mutation Among Ovarian, Primary Peritoneal and Fallopian Tube Cancer Patients in India | March 22, 2018 | December 21, 2018 | |
NCT01223235 | Completed | N/A | Polyvalent Vaccine-KLH Conjugate + Opt-821 Given in Combination With Bevacizumab | October 2010 | September 2017 |
NCT00002734 | Completed | Phase 1 | Radiolabeled Monoclonal Antibody, Paclitaxel, and Interferon Alfa in Treating Patients With Recurrent Ovarian Cancer | March 1996 | |
NCT00001944 | Completed | Phase 1 | Vinorelbine and XR9576 to Treat Cancer | December 1999 | June 2001 |
NCT00465725 | Completed | Phase 1 | A Study Comparing Oral Picoplatin With Intravenous Picoplatin in Subjects With Solid Tumors | April 2007 | July 2009 |
NCT00806156 | Completed | Phase 2 | Study to Evaluate the Safety and Efficacy of NKTR-102 in Patients With Metastatic or Locally Advanced Ovarian Cancer | October 2008 | January 2013 |
NCT01372553 | Completed | Guilford Genomic Medicine Initiative (GGMI) | October 2009 | April 2012 | |
NCT00004012 | Completed | Phase 2 | Capecitabine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | December 1998 | December 2000 |
NCT00959582 | Completed | Phase 1 | Positron Emission Tomography/Computed Tomography (PET/CT) in Relapsed Ovarian Cancer (MK-0000-143) | September 2009 | October 2011 |
NCT00012090 | Completed | Phase 2 | Bicalutamide and Goserelin in Treating Patients With Cancer of the Ovary, Fallopian Tube, or Peritoneum | September 2000 | April 2004 |
NCT01402271 | Completed | Phase 1/Phase 2 | Pazopanib Hydrochloride, Paclitaxel, and Carboplatin in Treating Patients With Refractory or Resistant Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer | July 2012 | July 13, 2020 |
NCT02298855 | Completed | N/A | Individualised Versus Conventional Medical Follow-up for Women After Primary Treatment for Ovarian Cancer. | January 2006 | May 2010 |
NCT00382811 | Completed | Phase 3 | OVATURE (OVArian TUmor REsponse) A Phase III Study of Weekly Carboplatin With and Without Phenoxodiol in Patients With Platinum-Resistant, Recurrent Epithelial Ovarian Cancer | October 2006 | April 2011 |
NCT01091259 | Completed | Phase 2 | Irinotecan and Bevacizumab for Recurrent Ovarian Cancer | March 2010 | May 2015 |
NCT00003778 | Completed | Phase 2 | Dolastatin 10 in Treating Patients With Recurrent or Metastatic Soft Tissue Sarcoma | April 1999 | |
NCT00459290 | Completed | Phase 2 | Mifepristone in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer | May 2007 | July 2010 |
NCT00550784 | Completed | Phase 1 | Combination Chemotherapy and Autologous Peripheral Stem Cell Transplant in Treating Patients With Stage III, Stage IV, or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | January 2001 | October 2014 |
NCT00744718 | Completed | Phase 2 | Bevacizumab and Carboplatin for Patients With Ovarian Cancer | August 2008 | December 2015 |
NCT00587093 | Completed | N/A | A Multicenter Trial On The Utility and Impact Of Computed Tomography and Serum CA-125 In the Management of Newly Diagnosed Ovarian Cancer | July 2001 | February 16, 2018 |
NCT00098878 | Completed | Phase 3 | Carboplatin in Treating Patients With Stage IC-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | March 2004 | July 2010 |
NCT01432145 | Completed | Phase 2 | A Clinical Trial in Patients With Breast Cancer Susceptibility Gene (BRCA) Defective Tumours | May 2011 | May 2015 |
NCT01242436 | Completed | N/A | Whole Body Diffusion MRI for Non-invasive Lesion Detection and Therapy Follow-up: Study With Patients With Ovarian Cancer and Peritoneal Metastasis | January 2011 | December 2014 |
NCT03454451 | Completed | Phase 1 | CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers | April 25, 2018 | February 19, 2023 |
NCT03127098 | Completed | Phase 1/Phase 2 | QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer | June 26, 2017 | December 7, 2017 |
NCT03689192 | Completed | Phase 1 | Arginase-1 Peptide Vaccine in Patients With Metastatic Solid Tumors | December 17, 2018 | January 19, 2022 |
NCT02622776 | Completed | N/A | Advanced Methods for Cancer Detection by Vaginal Screening | February 2016 | December 2018 |
NCT00483782 | Completed | Phase 3 | Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Newly Diagnosed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer | April 2006 | |
NCT03980028 | Completed | Role of Surgery in Advanced Ovarian Cancer | January 1, 2018 | June 1, 2019 | |
NCT00250094 | Completed | Phase 1 | Clinical Benefit of Topoisomerase Downregulation | May 2004 | March 2006 |
NCT01826227 | Completed | N/A | Intraoperative Detection of Lesions Using PET (Positron Emission Tomography) Probe During Secondary Cytoreductive Surgery for Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancer | March 2013 | December 2016 |
NCT00097409 | Completed | Phase 2 | Ispinesib In Subjects With Platinum-Taxane-Refractory Or Resistant Relapsed Ovarian Cancer | December 2004 | May 2007 |
NCT02015416 | Completed | Phase 1 | A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer | November 2013 | March 2017 |
NCT04154163 | Completed | Appropriate Dosing to Optimise Personalised Cancer Treatments | January 10, 2020 | March 5, 2021 | |
NCT00346385 | Completed | Phase 1 | BB-10901 in Treating Patients With Relapsed or Refractory Solid Tumors | March 2002 | October 2011 |
NCT01953107 | Completed | Phase 4 | Oral Iron vs. Placebo in Newly Diagnosed Gynecologic Oncology Patients Who Are Surgical Candidates. | November 2013 | December 2020 |
NCT00702299 | Completed | Phase 1 | Alimta® Plus Cisplatin & Paclitaxel Given Intraperitonelly; First Line Tx Stage III Ovarian Cancer | September 2007 | October 2012 |
NCT02009631 | Completed | Phase 1 | A Study to Evaluate the Effects of Veliparib on Heart Rhythms in Patients With Solid Tumors | November 2013 | December 2014 |
NCT01306032 | Completed | Phase 2 | Phase II ABT-888 With Cyclophosphamide | January 12, 2011 | December 15, 2016 |
NCT00090610 | Completed | Phase 2 | Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer | October 2003 | October 2009 |
NCT00002903 | Completed | Phase 2 | Docetaxel in Treating Patients With Recurrent or Refractory Germ Cell Cancer | July 1995 | |
NCT04785716 | Completed | Real-life Use of Niraparib in a Patient Access Program in Norway | July 31, 2017 | August 3, 2020 | |
NCT02440425 | Completed | Phase 2 | Dose Dense Paclitaxel With Pembrolizumab (MK-3475) in Platinum Resistant Ovarian Cancer | October 20, 2015 | May 27, 2021 |
NCT01618136 | Completed | Phase 1/Phase 2 | An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors | January 2012 | July 2015 |
NCT02865811 | Completed | Phase 2 | Pembrolizumab Combined With PLD For Recurrent Platinum Resistant Ovarian, Fallopian Tube Or Peritoneal Cancer | September 15, 2016 | March 2022 |
NCT01704651 | Completed | Phase 3 | Accelerating Gastrointestinal Recovery | January 2013 | October 2015 |
NCT00006230 | Completed | Phase 2 | Nitrocamptothecin in Treating Patients With Advanced Ovarian Cancer | May 2000 | |
NCT00722592 | Completed | Phase 2 | Platinum Resistant Ovarian Cancer Evaluation of Doxil and Vintafolide (MK-8109, EC145) Combination Therapy (8109-009, EC-FV-04) | September 2008 | December 2012 |
NCT02431559 | Completed | Phase 1/Phase 2 | Phase 1/2 Study of Motolimod, Doxorubicin, and Durvalumab in Recurrent, Platinum-Resistant Ovarian Cancer | December 2, 2015 | June 10, 2021 |
NCT00856791 | Completed | Phase 2 | Effect of 2-h Infusion of ON 01910.Na in Ovarian Cancer Patients | March 2009 | July 2011 |
NCT00005049 | Completed | Phase 2 | Combination Chemotherapy in Treating Patients With Stage III Ovarian Epithelial Cancer or Gastrointestinal Cancer | May 1997 | |
NCT00343044 | Completed | Phase 2 | Ph II Study of Wkly Topotecan + Bevacizumab in Plat. Resistant/Recurrent Gyn Cancers | June 2006 | August 2011 |
NCT00667641 | Completed | Phase 1 | Paclitaxel and Bortezomib in Treating Patients With Metastatic or Unresectable Malignant Solid Tumors | March 2007 | February 2009 |
NCT00664781 | Completed | Phase 2 | Rucaparib(CO-338;Formally Called AG-014699 or PF-0136738) in Treating Patients With Locally Advanced or Metastatic Breast Cancer or Advanced Ovarian Cancer | December 2007 | January 2015 |
NCT03629756 | Completed | Phase 1 | A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies | July 24, 2018 | September 3, 2021 |
NCT00003569 | Completed | Dimesna in Treating Patients With Solid Tumors Who Are Undergoing Treatment With Cisplatin and Paclitaxel | March 1998 | ||
NCT00109993 | Completed | Phase 2 | Campath-1H + FK506 and Methylprednisolone for GVHD | January 2005 | May 2007 |
NCT05258747 | Completed | Phase 1 | A Crossover Bioequivalence Study of Olaparib Tablets, 150 mg (Lek Pharmaceuticals d.d.) and Lynparza® (Olaparib) Tablets 150 mg (AstraZeneca Pharmaceuticals LP), in Patients With BRCA Mutated Ovarian Cancer, Recurrent Ovarian Cancer or Metastatic Breast Cancer | April 7, 2022 | October 20, 2022 |
NCT02340611 | Completed | Phase 2 | A Study of Cediranib and Olaparib at the Time Ovarian Cancer Worsens on Olaparib | June 2015 | June 2018 |
NCT01831089 | Completed | Phase 1 | Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors | September 2013 | July 2016 |
NCT01954355 | Completed | Phase 1 | LDE225 and Paclitaxel in Solid Tumors | September 2013 | November 2016 |
NCT00002489 | Completed | Phase 2 | Combination Chemotherapy in Treating Children With Non-testicular Malignant Germ Cell Tumors | October 1991 | June 2002 |
NCT00877253 | Completed | Phase 1 | Determine MTD, Evaluate Efficacy and Safety of Genexol®-PM Plus Carboplatin With Advanced Ovarian Cancer | May 2008 | June 2009 |
NCT01068483 | Completed | Phase 1 | Safety of BKM120 Monotherapy in Advanced Solid Tumor Patients | November 2008 | August 2012 |
NCT00420381 | Completed | Phase 2 | Evaluation of Enzastaurin in the Treatment of Persistent or Recurrent Ovarian or Primary Peritoneal Cancer | January 2007 | December 2014 |
NCT00479817 | Completed | Phase 2 | Phase 2 AMG 386 in Comb. Paclitaxel for Subjects With Advanced Recurrent Epithelial Ovarian or Primary Peritoneal Cancer | July 5, 2007 | December 9, 2019 |
NCT00043082 | Completed | Phase 3 | S0200 Carboplatin With or Without Doxil in Patients With Recurrent Ovarian Cancer | August 2002 | July 2011 |
NCT00003657 | Completed | Phase 2 | High-dose ICE With Amifostine | July 1998 | June 2002 |
NCT00335491 | Completed | N/A | Exercise in Improving Mobility and Reducing Fatigue and/or Weakness in Older Cancer Survivors | March 2006 | March 2010 |
NCT04334239 | Completed | Effectiveness of Care in Certified Cancer Centres in Germany | May 1, 2017 | August 31, 2021 | |
NCT02856841 | Completed | The Preoperative Predictors of Optimal Cytoreductive Surgery in Women With Advanced Ovarian Cancer | January 2015 | June 2016 | |
NCT00526617 | Completed | Phase 1 | A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer Patients | August 2007 | |
NCT04630769 | Completed | Phase 1 | FT516 and IL2 With Enoblituzumab for Ovarian Cancer | April 2, 2021 | January 1, 2022 |
NCT01521325 | Completed | Phase 1 | A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers | September 2011 | March 2013 |
NCT01040312 | Completed | An Observational Study of CPT-11 Plus Platinum Analogues Regimens and UGT1A1 Genotypes in Solid Tumors | October 15, 2009 | September 2, 2015 | |
NCT00096993 | Completed | Phase 2 | A Study to Evaluate rhuMab 2C4 and Gemcitabine in Subjects With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | January 2005 | September 2007 |
NCT00711932 | Completed | The Effect of TRA-8 on Ovarian Cancer Tissue | August 2008 | January 2013 | |
NCT00032162 | Completed | Phase 1/Phase 2 | Liposomal Doxorubicin and Carboplatin in Treating Patients With Gynecologic Cancer | August 2001 | |
NCT00004060 | Completed | Phase 2 | Chemotherapy in Treating Patients With Recurrent, Metastatic, or Unresectable Ovarian, Fallopian Tube, or Peritoneal Cancer | July 1999 | September 2000 |
NCT00006043 | Completed | Phase 2 | Temozolomide in Treating Patients With Metastatic Germ Cell Tumors That Have Not Responded to Cisplatin | February 2000 | November 2001 |
NCT02916875 | Completed | Individual Survivorship Program for Ovarian Cancer Patients Based on PROM's and Shared Decision Making | October 2016 | January 2022 | |
NCT00426257 | Completed | Phase 3 | Secondary Debulking Surgery +/- Hyperthermic Intraperitoneal Chemotherapy in Stage III Ovarian Cancer | February 2007 | August 16, 2017 |
NCT02867956 | Completed | Phase 2 | Apatinib and Etoposide in Patients With Platinum Resistant or Refractory Ovarian Cancer | August 10, 2016 | September 10, 2019 |
NCT00165152 | Completed | N/A | Counseling Interventions for BRCA 1/2 Cancer Susceptibility Testing | July 1998 | June 2005 |
NCT00321932 | Completed | Phase 2 | Zoledronic Acid in Preventing Osteoporosis in Patients Undergoing Donor Stem Cell Transplant | July 2005 | March 2012 |
NCT00569673 | Completed | Phase 2 | Docetaxel, Trabectedin, and G-CSF or Pegfilgrastim in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer | March 2008 | |
NCT00436410 | Completed | Early Phase 1 | Tumor Necrosis Factor in Patients Undergoing Surgery for Primary Cancer or Metastatic Cancer | December 2006 | August 2009 |
NCT05490407 | Completed | N/A | Role of the ATP7A Transporter in Ovarian Cancer | March 17, 2021 | January 1, 2024 |
NCT01416038 | Completed | Phase 1 | Phase 1 Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer | December 2011 | May 2013 |
NCT03073525 | Completed | Phase 2 | A Trial of Atezolizumab and Vigil in Patients With Advanced Gynecological Cancers | May 31, 2017 | May 18, 2022 |
NCT02714621 | Completed | N/A | MR-HIFU for Recurrent Gynaecological Cancer | May 2016 | March 31, 2020 |
NCT00004157 | Completed | Phase 2 | Interleukin-11 Plus Filgrastim Prior to Peripheral Stem Cell Transplantation in Patients With Non-Hodgkin's Lymphoma, Hodgkin's Disease, Breast Cancer, or Other Solid Tumors | August 2000 | April 2002 |
NCT03989336 | Completed | Phase 2 | An Open-label, Phase I/II Study of the Pan-immunotherapy in Patients With Relapsed/Refractory Ovarian Cancer | December 23, 2020 | December 10, 2023 |
NCT03042702 | Completed | Phase 2 | A Phase 2 Study of Kevetrin in Subjects With Ovarian Cancer | February 9, 2017 | November 10, 2017 |
NCT01042847 | Completed | How Our Immune System Can Help Fight Cancer | January 2010 | February 2015 | |
NCT02069769 | Completed | N/A | Ensuring Communication in Hospice by Oncology Study (ECHO) | January 2014 | January 2017 |
NCT00025441 | Completed | Phase 2 | Combination Chemotherapy in Treating Children With Metastatic Rhabdomyosarcoma or Other Malignant Mesenchymal Tumors | November 1998 | March 2010 |
NCT02305498 | Completed | N/A | Yoga Practice for Breast or Ovarian Cancer Patients | November 24, 2014 | March 11, 2019 |
NCT00582322 | Completed | Genetic Studies in Breast Cancer | February 1992 | July 2009 | |
NCT03505307 | Completed | Lynparza Ovarian Cancer Clinical Experience Investigation (All Case Investigation) | May 21, 2018 | December 7, 2020 | |
NCT03180307 | Completed | Phase 3 | OTL38 for Intra-operative Imaging of Folate Receptor Positive Ovarian Cancer | January 26, 2018 | October 16, 2020 |
NCT03783949 | Completed | Phase 2 | European Trial on Enhanced DNA Repair Inhibition in Ovarian Cancer | November 30, 2018 | September 1, 2023 |
NCT00004934 | Completed | Phase 3 | Paclitaxel and Carboplatin With or Without Epirubicin in Treating Patients With Stage IIB, Stage III, or Stage IV Invasive Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer | August 1999 | May 2003 |
NCT00014690 | Completed | Phase 2 | ZD9331 With or Without Topotecan in Treating Patients With Refractory or Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | March 2001 | February 2004 |
NCT00072267 | Completed | Phase 2 | UCN-01 and Topotecan in Treating Patients With Recurrent, Persistent, or Progressive Advanced Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer | January 2004 | |
NCT01309230 | Completed | Phase 2 | A Trial of FANG™ Vaccine for Participants With Ovarian Cancer | March 8, 2011 | February 2, 2022 |
NCT00245050 | Completed | Phase 3 | Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Liposomal Doxorubicin for Cancer | April 2004 | September 2011 |
NCT04440943 | Completed | Phase 1 | A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies | August 4, 2020 | April 6, 2023 |
NCT05372692 | Completed | N/A | Study of LD013 in Subjects With Refractory or Relapsed Mesothelin -Positive Ovarian Cancer | April 12, 2022 | February 1, 2023 |
NCT00008138 | Completed | Phase 2 | S0009 Combination Chemo and Surgery in Stage III or Stage IV Ovarian Cancer | March 2001 | November 2009 |
NCT02593422 | Completed | N/A | Writing About Experiences With Ovarian Cancer | April 2015 | December 2016 |
NCT01065662 | Completed | Phase 1 | AZD2171 and Temsirolimus in Patients With Advanced Gynecological Malignancies | February 2010 | March 2021 |
NCT02222883 | Completed | Prevalence of BRCA in Patients With Ovarian Cancer | March 2015 | April 1, 2021 | |
NCT02681237 | Completed | N/A | A Study of Cediranib and Olaparib at Disease Worsening in Ovarian Cancer | April 29, 2016 | March 25, 2022 |
NCT01096394 | Completed | Collection of Tissue Samples From Patients With Stage III or Stage IV Ovarian Epithelial Cancer | November 2009 | October 2015 | |
NCT01739218 | Completed | Phase 2 | A Study of Bevacizumab (Avastin) in Neoadjuvant Therapy in Participants With International Federation of Gynecology and Obstetrics (FIGO) Stage IIIC/IV Ovarian, Tubal, or Peritoneal Cancer, Initially Unresectable | February 1, 2013 | August 17, 2016 |
NCT00846612 | Completed | Phase 1 | Pharmacokinetic Study of Avastin and Doxil in Ovarian Cancer | January 2008 | June 2012 |
NCT02517554 | Completed | A Study Of TeleGenetics Versus Usual Care To Increase Access To Cancer Genetic Services | August 2015 | November 2019 | |
NCT00058032 | Completed | N/A | CA125 and Ultrasound in Detecting Ovarian Cancer in Postmenopausal Women | April 17, 2001 | June 30, 2020 |
NCT00004876 | Completed | Phase 2 | Carboplatin With or Without Thalidomide in Treating Patients With Ovarian Epithelial Cancer | August 1999 | |
NCT01863693 | Completed | An Observational Study of Avastin (Bevacizumab) in Combination With Chemotherapy as First-Line Treatment in Patients With Advanced Ovarian Cancer (OSCAR 1) | May 10, 2013 | June 15, 2018 | |
NCT05204342 | Completed | Evaluation of Prognostic Factors for Tubo-ovarian Cancer in France | January 1, 2012 | December 30, 2021 | |
NCT00003345 | Completed | Phase 2 | Cisplatin Plus Irinotecan in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer | October 1997 | October 2001 |
NCT00003334 | Completed | Phase 2 | Combination Chemotherapy in Treating Patients With Endometrial Cancer, Fallopian Tube Cancer, or Sarcoma of the Female Reproductive Tract | March 1997 | |
NCT00091273 | Completed | Phase 1 | Vaccine Therapy in Treating Patients With Ovarian Epithelial or Primary Peritoneal Cancer | June 2004 | June 2007 |
NCT00508378 | Completed | Chemotherapy-Related Toxicities In Ovarian Cancer Patients | January 2001 | November 3, 2020 | |
NCT01623349 | Completed | Phase 1 | Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer | September 2012 | December 2020 |
NCT00063401 | Completed | Phase 2 | Phase II Study in Patients With Epidermal Growth Factor Receptor (EGFR) + Advanced Stage Ovarian, Primary Peritoneal and Fallopian Tube Cancer | September 2003 | June 2006 |
NCT00569257 | Completed | Phase 2 | Antitumoral Activity and Safety of AEZS-108 in Women With LHRH Receptor Positive Gynecological Tumors | December 2007 | July 2011 |
NCT00002558 | Completed | Phase 1/Phase 2 | Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Germ Cell Tumors | January 1994 | April 2009 |
NCT02984423 | Completed | FLABRA: Frontline Approach for BRCA Testing in OC Treatment naïve Population. A LATIN AMERICA Epidemiologic Study | December 27, 2016 | June 30, 2019 | |
NCT00006454 | Completed | Phase 3 | Paclitaxel Plus Carboplatin With or Without Topotecan in Treating Patients With Stage IIB, Stage III, or Stage IV Ovarian Epithelial Cancer | December 1999 | August 2006 |
NCT00856180 | Completed | Phase 2 | Sequential Angiogenic Blockade for the Treatment of Recurrent Mullerian Malignancies | February 2009 | January 2014 |
NCT00313599 | Completed | Phase 1 | Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors | February 2006 | December 2013 |
NCT01834469 | Completed | Phase 1/Phase 2 | Imaging of Peritoneal Carcinomatosis From Ovarian Carcinoma Patients | March 2013 | October 2014 |
NCT00296816 | Completed | Phase 2 | TEACO: Taxotere, Eloxatin, Avastin in Cancer of the Ovary | March 2006 | August 2011 |
NCT00002977 | Completed | Phase 1 | Melphalan and Thiotepa Followed by Peripheral Stem Cell Transplantation in Treating Patients With Epithelial Ovarian Cancer in Complete Remission | January 1997 | |
NCT00986206 | Completed | Lysophosphatidic Acid Assay in Patients With Ovarian Cancer or Who Are at Risk for Ovarian Cancer | June 2009 | July 2015 | |
NCT02960594 | Completed | Phase 1 | hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse | December 2014 | November 9, 2018 |
NCT00189566 | Completed | Phase 2 | Taxol® in Monotherapy or in Combination With Topotecan or Carboplatin in Patients With Epithelial Ovarian Cancer in Early Relapse | April 2004 | April 2009 |
NCT01968213 | Completed | Phase 3 | Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous or Endometrioid Ovarian Cancer (ARIEL3) | April 7, 2014 | July 7, 2022 |
NCT00526149 | Completed | Phase 2 | BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors | July 2007 | |
NCT02178722 | Completed | Phase 1/Phase 2 | Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers | July 17, 2014 | November 6, 2020 |
NCT02326064 | Completed | Prospective Multicenter Study in Patients With a Tumor Benign Ovarian Presumed on the Use of Algorithms Such as Roma and RMI and Tumor Markers Such as CA125 and HE4 | May 2015 | June 2016 | |
NCT00900523 | Completed | Prostaglandin Metabolite in Urine Samples From Patients With Ovarian Cancer | November 2006 | July 2008 | |
NCT02418624 | Completed | Phase 1 | Phase I of Carboplatin-Olaparib Followed by Olaparib Monotherapy in Advanced Cancer | May 2015 | January 2019 |
NCT00837993 | Completed | Ancillary Study GOG 158: Survival Analysis Based on Reclassification to a Two-Tier Grading System | August 2007 | December 2012 | |
NCT00191334 | Completed | Phase 2 | Gemcitabine in Ovarian Cancer | December 2004 | December 2007 |
NCT00315692 | Completed | Risk of Ovarian Cancer in Patients With a Pelvic Mass | December 2005 | February 2007 | |
NCT00019552 | Completed | Phase 2 | Irofulven in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Peritoneal Cancer | September 1998 | April 2004 |
NCT00003588 | Completed | Phase 1 | Gene Therapy in Treating Patients With Ovarian Cancer | September 1998 | |
NCT00019136 | Completed | Phase 1 | Gene Therapy and Biological Therapy in Treating Patients With Ovarian Epithelial Cancer | February 1997 | |
NCT01170299 | Completed | N/A | Low-Fiber Diet or High-Fiber Diet in Preventing Bowel Side Effects in Patients Undergoing Radiation Therapy for Gynecological Cancer, Bladder Cancer, Colorectal Cancer, or Anal Cancer | October 2009 | January 2014 |
NCT01583322 | Completed | Phase 2 | Vargatef in Addition to First Line Chemotherapy With Interval Debulking Surgery in Patients With Ovarian Cancer | June 2012 | March 2016 |
NCT00010179 | Completed | Phase 2 | Lurtotecan Liposome in Treating Patients With Advanced or Recurrent Ovarian Epithelial Cancer | October 31, 2000 | September 22, 2008 |
NCT02399592 | Completed | Phase 2 | Tocotrienol as a Nutritional Supplement in Patients With Advanced Ovarian Cancer | March 2015 | July 2019 |
NCT00231075 | Completed | Phase 2 | Evaluation of the Safety and Efficacy of Paraplatin in Combination With Taxol in Patients of 70 Years and Older With Ovary Cancer F.I.G.O. Stages III-IV | January 2001 | May 2007 |
NCT00036959 | Completed | Phase 1 | ABT-751 in Treating Young Patients With Refractory Solid Tumors | March 2002 | February 2010 |
NCT01670799 | Completed | Early Phase 1 | Availability & Effect of Post-OP Ketorolac on Ovarian, Fallopian Tube or Primary Peritoneal Cancer | March 2012 | December 2015 |
NCT00267696 | Completed | Phase 2 | Study of Gemcitabine/Carboplatin/Bevacizumab to Treat Ovarian, Fallopian Tube or Primary Peritoneal Cancer | November 2005 | December 2013 |
NCT00003214 | Completed | Phase 3 | Chemosensitivity Testing to Assign Treatment for Patients With Stage III or Stage IV Ovarian Cancer | July 1996 | April 2000 |
NCT03394885 | Completed | Phase 1/Phase 2 | Atezolizumab With Neoadjuvant Chemotherapy for Patients With Newly-Diagnosed Advanced-Stage Ovarian Cancer | June 19, 2018 | July 20, 2020 |
NCT00004008 | Completed | Phase 2 | Bryostatin 1 in Treating Patients With Ovarian Epithelial Cancer | July 1999 | May 2003 |
NCT00003763 | Completed | N/A | Radiolabeled Folic Acid and Imaging to Detect Ovarian Cancer | December 8, 1997 | May 3, 2000 |
NCT00002526 | Completed | Phase 2 | Chemotherapy in Treating Patients With Advanced Sarcoma | January 1993 | September 1995 |
NCT03205176 | Completed | Phase 1 | AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas | June 30, 2017 | April 8, 2021 |
NCT00776958 | Completed | Lynne Cohen Consortium Project: Multi-Center Database/Registry | July 2008 | ||
NCT03507543 | Completed | Phase 1 | The Safety and Pharmacokinetics of IMP4297 in Patients With Advanced Solid Tumors | February 3, 2017 | March 17, 2021 |
NCT01196741 | Completed | Phase 2/Phase 3 | Saracatinib and Paclitaxel in Platinum-resistant Ovarian Cancer | March 2011 | January 2014 |
NCT00003998 | Completed | Phase 3 | Carboplatin Plus Paclitaxel or Docetaxel in Treating Patients With Ovarian Epithelial Cancer | October 1998 | December 2004 |
NCT02529150 | Completed | N/A | WISER After Ovarian Cancer - Exercise Pilot Study | May 2015 | May 6, 2016 |
NCT02914470 | Completed | Phase 1 | Carboplatin-cyclophosphamide Combined With Atezolizumab | January 2017 | October 2021 |
NCT01824615 | Completed | Phase 2 | Sunitinib® in Patients With Recurrent Ovarian Clear Cell Carcinoma | January 2013 | January 2016 |
NCT01445418 | Completed | Phase 1 | AZD2281 Plus Carboplatin to Treat Breast and Ovarian Cancer | May 12, 2008 | October 18, 2019 |
NCT00692900 | Completed | Phase 1 | Safety Study Involving Oxaliplatin With Docetaxel for Recurrent Ovarian,Primary Peritoneal, and Fallopian Tube Cancer | December 2008 | October 2013 |
NCT00004066 | Completed | Phase 2 | Gemcitabine, Docetaxel, and Filgrastim in Treating Patients With Recurrent or Persistent Leiomyosarcoma or Soft Tissue Sarcoma | June 1999 | October 2003 |
NCT00103545 | Completed | Phase 1/Phase 2 | Use of ACA 125 in Patients With Ovarian Cancer: Safety and Immune Response | July 2003 | August 2004 |
NCT01905163 | Completed | Phase 2 | Feasibility of Interval Debulking Surgery by Laparoscopy for Peritoneal Carcinosis in Chemosensitive Patients | August 2013 | July 2017 |
NCT04417192 | Completed | Phase 2 | Olaparib Monotherapy and Olaparib + Pembrolizumab Combination Therapy for Ovarian Cancer | December 1, 2020 | June 30, 2023 |
NCT00003103 | Completed | Phase 1/Phase 2 | Chemotherapy in Treating Patients With Solid Tumors | August 1997 | August 2002 |
NCT00444054 | Completed | N/A | The RECHARGE Low Carbohydrate Diet Trial for Metastatic Cancer | February 2006 | May 2012 |
NCT00959647 | Completed | Phase 2 | A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study | September 2009 | January 2014 |
NCT00091377 | Completed | Phase 1/Phase 2 | Phenoxodiol Combined With Either Cisplatin or Paclitaxel in Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | August 2004 | March 2008 |
NCT00410657 | Completed | Phase 2 | Alemtuzumab and Glucocorticoids in Treating Newly Diagnosed Acute Graft-Versus-Host Disease in Patients Who Have Undergone a Donor Stem Cell Transplant | July 2006 | |
NCT00782145 | Completed | Phase 3 | A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families | June 2008 | June 2011 |
NCT05529303 | Completed | N/A | Prolonged Grief and Perception of Femininity in Gynecological Cancer Patients | February 26, 2023 | September 18, 2023 |
NCT00946140 | Completed | Motion Correction in Dynamic Contrast Enhanced Magnetic Resonance Imaging (MRI) in Ovarian Cancer: A Pilot Study | July 2009 | October 2013 | |
NCT00826150 | Completed | Phase 1/Phase 2 | Phase 1/2a Study of DTA-H19 in Advanced Stage Ovarian Cancer | June 2009 | February 2012 |
NCT00004895 | Completed | Phase 2 | Octreotide as Palliative Therapy for Cancer-Related Bowel Obstruction That Cannot Be Removed by Surgery | October 1999 | October 2002 |
NCT00002928 | Completed | Phase 2 | Paclitaxel in Treating Patients With Recurrent or Progressive Advanced Ovarian Cancer | January 1997 | August 2001 |
NCT00237627 | Completed | Phase 1/Phase 2 | Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer | May 2001 | January 2010 |
NCT02465892 | Completed | N/A | Pillars4Life Trial | May 2015 | October 2016 |
NCT03759600 | Completed | Phase 2 | Japan Phase 2 Study of Niraparib in Participants With Advanced, Relapsed Ovarian Cancer | December 26, 2018 | December 28, 2022 |
NCT00066729 | Completed | Phase 1 | Vaccine Therapy in Treating Patients With Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer | June 23, 2003 | August 1, 2013 |
NCT02374827 | Completed | N/A | Salpingectomy at Cesarean Delivery for Ovarian Cancer Reduction (SCORE) | April 2015 | September 2017 |
NCT00390611 | Completed | Phase 2 | Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer | October 2006 | April 2014 |
NCT00004083 | Completed | Phase 2 | Liposomal Cisplatin in Treating Patients With Recurrent Ovarian Cancer | February 1999 | |
NCT00003939 | Completed | Phase 2 | Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma | ||
NCT00604994 | Completed | Prospective Evaluation of Lymphoedema Among Patients With Gynaecological Cancer | June 2008 | April 2013 | |
NCT00684801 | Completed | Disease Management Program or Usual Care in Patients With Stage III or Stage IV Lung Cancer, Pancreatic Cancer, Ovarian Cancer, or Colorectal Cancer, and Their Caregivers | August 2007 | December 2011 | |
NCT00400348 | Completed | Phase 2 | Safety and Efficacy Study of Panzem® Nanocrystal Colloidal Dispersion in Patients With Ovarian Cancer | October 2006 | November 2008 |
NCT01172028 | Completed | Phase 1 | Pemetrexed Disodium and Docetaxel in Treating Patients With Advanced Solid Tumors | September 2005 | July 2014 |
NCT02237690 | Completed | Phase 1 | Assess Bioequivalence of Two Formulations of Doxorubicin Hydrochloride Liposome in Female Patients With Ovarian Cancer | September 2014 | August 2016 |
NCT04626895 | Completed | N/A | Efficacy of Paxman Scalp Cooling to Prevent Chemo Induced Alopecia in Black Patients With Breast or GYN Cancers | June 4, 2019 | October 1, 2020 |
NCT00004921 | Completed | Phase 3 | High-Dose Chemotherapy Compared With Standard Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer That Has Been Removed During Surgery | September 1998 | September 2007 |
NCT00471432 | Completed | Phase 1 | OGX-011 and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Solid Tumors | April 4, 2003 | December 21, 2009 |
NCT00003136 | Completed | Phase 1/Phase 2 | Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Epithelial Ovarian Cancer or Primary Peritoneal Cancer | December 1996 | October 2001 |
NCT05300828 | Completed | Safety of Genexol PM and Carboplatin as First-line Therapy in Ovarian Cancer | October 19, 2015 | December 31, 2022 | |
NCT04676334 | Completed | Phase 3 | CATCH-R: A Rollover Study to Provide Continued Access to Rucaparib | March 22, 2021 | March 8, 2023 |
NCT00003080 | Completed | Phase 1 | Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Persistent or Platinum Refractory Stage III or IV Ovarian Cancer | September 1996 | May 2001 |
NCT03367260 | Completed | The Treatment Preferences of Women Diagnosed With Ovarian Cancer | October 19, 2017 | January 4, 2019 | |
NCT00005046 | Completed | Phase 1 | Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian or Primary Peritoneal Cancer | April 2000 | |
NCT00562640 | Completed | Phase 1 | Autologous T Cells With or Without Cyclophosphamide and Fludarabine in Treating Patients With Recurrent or Persistent Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer (Fludarabine Treatment Closed as of 12/01/2009) | October 16, 2007 | August 3, 2021 |
NCT00003887 | Completed | Phase 2 | Lymphocyte Infusion in Treating Patients With Relapsed Cancer After Bone Marrow or Peripheral Stem Cell Transplantation | August 1998 | February 2003 |
NCT00879840 | Completed | Assessment of Screening Modalities for Gynecologic Cancers | April 9, 2009 | November 16, 2020 | |
NCT00006028 | Completed | Phase 2 | Gemcitabine Plus Cisplatin in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Is Recurrent or Has Not Responded to Platinum-based Chemotherapy | January 2001 | |
NCT01567891 | Completed | Phase 1/Phase 2 | CT Antigen TCR-redirected T Cells for Ovarian Cancer. | July 9, 2013 | June 6, 2017 |
NCT00097019 | Completed | Phase 2 | A Study of Bevacizumab in Ovarian Cancer or Primary Peritoneal Cancer Where Doxil or Topotecan Therapy Has Failed | February 2005 | May 2006 |
NCT01163552 | Completed | Phase 2 | Heated Chemotherapy for Cancers That Have Spread to the Chest Cavity | June 2010 | May 2014 |
NCT03038100 | Completed | Phase 3 | A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | March 8, 2017 | August 12, 2022 |
NCT00453310 | Completed | Phase 2 | Sunitinib in Treating Patients With Metastatic Germ Cell Tumors That Have Relapsed or Not Responded to Treatment | March 2007 | November 2008 |
NCT03266185 | Completed | N/A | Shorter Scalp Cooling Time in Paclitaxel | December 20, 2017 | August 28, 2020 |
NCT00003322 | Completed | Phase 3 | Combination Chemotherapy in Treating Patients With Primary Peritoneal or Stage III Epithelial Ovarian Cancer | March 1998 | |
NCT03639246 | Completed | Phase 1 | Efficacy and Safety Study of AVB-S6-500 in Patients With Platinum-Resistant Recurrent Ovarian Cancer | December 6, 2018 | December 30, 2022 |
NCT00003173 | Completed | Phase 2 | High-Dose Thiotepa Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory Solid Tumors | September 1997 | May 2003 |
NCT00064311 | Completed | Phase 1/Phase 2 | Ravuconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Stem Cell Transplantation | June 2003 | September 2004 |
NCT00033605 | Completed | Phase 3 | Octreotide in Preventing Diarrhea in Patients Who Are Undergoing Radiation Therapy to the Pelvis | April 2002 | July 2006 |
NCT02759588 | Completed | Phase 1/Phase 2 | GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer | May 2016 | December 31, 2022 |
NCT00831636 | Completed | Phase 1/Phase 2 | A Phase I/II Study of CP-4055 in Patients With Platinum Resistant Ovarian Cancer | April 2008 | April 2010 |
NCT00993655 | Completed | Phase 2 | Intraperitoneal vs Intravenous Chemotherapy Following Neoadjuvant Chemotherapy in Ovarian Cancer | March 3, 2010 | July 11, 2016 |
NCT00315861 | Completed | Phase 1 | Topotecan in Combination With Pemetrexed in Patients With Advanced Malignancies | March 2006 | January 2009 |
NCT01505829 | Completed | Diffusion-weighted Imaging Study in Cancer of the Ovary | August 2012 | October 13, 2018 | |
NCT00005952 | Completed | Phase 1/Phase 2 | Temozolomide Plus Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Malignant Glioma or Recurrent CNS or Other Solid Tumors | August 2000 | November 2005 |
NCT03837327 | Completed | Clinical Validation of the InterVenn Ovarian CAncer Liquid Biopsy | April 16, 2019 | January 22, 2024 | |
NCT02792959 | Completed | N/A | Evaluation of Response to the Neoadjuvant Chemotherapy for Advanced Ovarian Cancer by Multimodal Functional Imaging | August 2014 | August 2017 |
NCT02033551 | Completed | Phase 1 | A Study Evaluating Veliparib as a Single Agent or in Combination With Chemotherapy in Subjects With Solid Tumors | December 2013 | September 2016 |
NCT00408590 | Completed | Phase 1 | Recombinant Measles Virus Vaccine Therapy and Oncolytic Virus Therapy in Treating Patients With Progressive, Recurrent, or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer | April 19, 2004 | November 7, 2017 |
NCT00003892 | Completed | Phase 2 | ISIS 5132 in Treating Patients With Metastatic or Recurrent Ovarian Cancer | February 1, 1999 | September 22, 2008 |
NCT03508011 | Completed | Phase 1 | A Study of IMP4297 in Patients With Advanced Solid Tumors | August 23, 2017 | December 16, 2020 |
NCT03551171 | Completed | Phase 1 | The Clinical Trial to Evaluate the Pharmacokinetics, Safety and Tolerability of ZL-2306 (Niraparib) in Patients With Ovarian Cancer | December 19, 2017 | July 10, 2018 |
NCT00574678 | Completed | Phase 1/Phase 2 | Analyzing the Composition of Tears to Identify Cancer | December 2006 | February 2016 |
NCT00284427 | Completed | Phase 2 | Safety of Antioxidants During GYN Cancer Care | September 2005 | December 2006 |
NCT01065441 | Completed | Phase 1/Phase 2 | Experimental Therapeutic Cancer Vaccine Created In-situ in Patients With Stage II-Stage IV Cancer | December 2010 | July 2013 |
NCT00655447 | Completed | Examining the Long-Term Risks of Oophorectomy | January 1980 | June 2004 | |
NCT04330716 | Completed | N/A | Genetic Testing for Breast, Ovarian, Pancreatic, and Prostate Cancers | December 1, 2020 | December 31, 2023 |
NCT01041235 | Completed | Phase 1 | Safety Study of a Liposomal Docetaxel Formulation in Patients With Solid Tumors Who Have Failed Previous Therapies | December 2009 | December 2011 |
NCT02354586 | Completed | Phase 2 | A Study of Niraparib in Patients With Ovarian Cancer Who Have Received Three or Four Previous Chemotherapy Regimens | March 23, 2015 | August 23, 2021 |
NCT01262040 | Completed | N/A | Narrow Band Imaging (NBI): A Novel Imaging Modality in Minimally Invasive | December 14, 2010 | October 29, 2018 |
NCT03779399 | Completed | Treg, Th17 Cells, NKT in Epithelial Ovarian Tumor | December 1, 2011 | December 31, 2016 | |
NCT01216813 | Completed | Study of Physical and Psychosocial Rehabilitation Needs of Patients After Diagnosis and Treatment of Upper Gastrointestinal Cancer or Gynecological Cancer | August 2010 | December 2010 | |
NCT02785887 | Completed | N/A | Impact of Geriatrician Interventions on Chemotherapy Delivery in Vulnerable Elderly Oncology Patients | August 1, 2014 | September 25, 2018 |
NCT00102375 | Completed | Phase 3 | Paclitaxel, Carboplatin, and Topotecan in Patients With Ovarian Cancer | December 1999 | October 2004 |
NCT00381173 | Completed | Phase 1 | A Study of ZYC300 Administered With Cyclophosphamide Pre-Dosing | November 2006 | October 2008 |
NCT00189345 | Completed | Phase 2 | Randomized, Multicenter, 2-Dose Level. Open-Label, Phase IIa Study With the Intraperitoneally Infused Trifunctional Bispecific Antibody Removab(TM) (Anti-EpCAM x Anti-CD3) to Select the Better Dose Level in Platinum Refractory Epithelial Ovarian Cancer Patients | May 2004 | October 2005 |
NCT04284631 | Completed | Prognostic Value of Her2neu and EGFR in Primary Ovarian High Grade Serous Carcinoma. | January 1, 2012 | December 30, 2019 | |
NCT00052468 | Completed | Phase 3 | Carboplatin/Paclitaxel +/-Gemcitabine in Treating Patients With Ovarian Epithelial or Fallopian Tube Cancer | August 2002 | January 2011 |
NCT00021034 | Completed | Phase 1 | Taurolidine in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | March 2001 | August 2001 |
NCT00610740 | Completed | Phase 2 | CerviPrep for Applying Topical Gemcitabine to the Cervix in Treating Patients With Primary Endometrial, Cervical, or Ovarian Epithelial Cancer | July 2006 | April 2008 |
NCT00157560 | Completed | Phase 2 | Phase II Study of Modified Triple Doublet Therapy in Women With Newly Diagnosed Mullerian Carcinoma | December 2000 | July 2005 |
NCT00317772 | Completed | Phase 1/Phase 2 | Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube Cancer | September 2, 2004 | November 4, 2020 |
NCT02766582 | Completed | Phase 2 | Phase II: Pembrolizumab/Carboplatin/Taxol in Epithelial Ovary Cancer | October 2016 | December 30, 2023 |
NCT00066651 | Completed | Phase 1 | Immunotoxin Therapy in Treating Patients With Advanced Solid Tumors | July 2003 | |
NCT04461457 | Completed | Early Phase 1 | Targeted Radiation Therapy for Ovarian Cancer: Intraperitoneal Treatment With 211-astatine-MX35 F(ab')2 | February 5, 2005 | January 19, 2012 |
NCT01422265 | Completed | Patient Reported Symptoms in Ovarian Cancer (PRECISION) | June 2011 | April 2015 | |
NCT00002764 | Completed | Phase 3 | Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma | April 1996 | |
NCT01997190 | Completed | Phase 1 | Intrapleural AdV-tk Therapy in Patients With Malignant Pleural Effusion | October 2013 | February 2018 |
NCT03470402 | Completed | N/A | Decision Support for BRCA Testing in Ethnically Diverse Women | December 13, 2017 | August 17, 2020 |
NCT03881683 | Completed | N/A | Determination of the Feasibility of Tumoural Somatic Mutations Detection in Blood of Patients With Ovarian Cancer | February 21, 2020 | February 19, 2021 |
NCT01696032 | Completed | Phase 2 | SGI-110 in Combination With Carboplatin in Ovarian Cancer | September 2012 | August 2016 |
NCT00001383 | Completed | Phase 1 | A Phase I Study of Infusional Paclitaxel With the P-Glycoprotein Antagonist PSC 833 | March 1994 | January 2001 |
NCT03219268 | Completed | Phase 1 | A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms | August 18, 2017 | February 8, 2023 |
NCT00019019 | Completed | Phase 1 | Carboxyamidotriazole and Paclitaxel in Treating Patients With Advanced Solid Tumors or Refractory Lymphomas | October 1994 | July 2006 |
NCT02973750 | Completed | Determinants of Age-Related Treatment Effectiveness in Ovarian Cancer | October 20, 2016 | July 18, 2020 | |
NCT00804258 | Completed | Palliative Care During Intraperitoneal Chemotherapy in Patients With Ovarian Cancer | August 2007 | January 2012 | |
NCT03345485 | Completed | Phase 1/Phase 2 | Study of the Safety, Pharmacokinetics and Efficacy of EDO-S101, in Patients With Advanced Solid Tumors | October 6, 2017 | March 29, 2023 |
NCT06145295 | Completed | N/A | The Effectiveness of an Online Support Group in Enhancing Recovery Identity and Health-Related Quality of Life | June 1, 2023 | November 1, 2023 |
NCT00316173 | Completed | Phase 2 | Second-Line Therapy Study For Potentially Platinum-Sensitive Relapsed Ovarian Cancer | March 2005 | March 2009 |
NCT04927013 | Completed | N/A | Connecting Families to Overcome Ovarian Cancer | July 24, 2021 | February 21, 2023 |
NCT00563836 | Completed | Phase 2 | Phase II Study of the Trifunctional Antibody Catumaxomab Administered Intra- and Postoperatively in Patients With Ovarian Cancer | November 2007 | August 2010 |
NCT02179515 | Completed | Phase 1 | Safety and Tolerability of a Modified Vaccinia Ankara (MVA)-Based Vaccine Modified to Express Brachyury and T-cell Costimulatory Molecules (MVA-Brachyury-TRICOM) | June 28, 2014 | February 28, 2018 |
NCT04298827 | Completed | N/A | Gyn Onc Prehab Study | July 21, 2020 | March 1, 2024 |
NCT00003358 | Completed | Phase 1 | Cisplatin and Gemcitabine in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | January 1998 | |
NCT03742713 | Completed | Phase 2 | Efficacy Study of CPC634 (CriPec® Docetaxel) in Platinum Resistant Ovarian Cancer | October 1, 2018 | December 1, 2020 |
NCT03538028 | Completed | Phase 1 | A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies | June 18, 2018 | October 7, 2020 |
NCT01705158 | Completed | Phase 1/Phase 2 | Myocet ® - Carboplatine in Ovarian Cancer in Relapse, Sensitive to the Platinum | October 2012 | April 2017 |
NCT00005858 | Completed | Phase 1 | LMB-9 Immunotoxin in Treating Patients With Advanced Colon, Breast, Non-small Cell Lung, Bladder, Pancreatic, or Ovarian Cancer | April 2000 | December 2003 |
NCT00003518 | Completed | Phase 2 | Paclitaxel Plus Gemcitabine in Treating Patients With Refractory Metastatic Germ Cell Tumors | January 25, 1999 | |
NCT02567253 | Completed | Phase 2 | Intraoperative Intraperitoneal Chemoperfusion to Treat Peritoneal Minimal Residual Disease in Stage III Ovarian Cancer | March 2016 | August 25, 2021 |
NCT00421889 | Completed | Phase 1/Phase 2 | A Study of Belinostat + Carboplatin or Paclitaxel or Both in Patients With Ovarian Cancer in Need of Relapse Treatment | August 2005 | February 2009 |
NCT00003811 | Completed | Phase 2 | Combination Chemotherapy Plus Amifostine in Treating Children With Malignant Germ Cell Tumors | April 2000 | September 2007 |
NCT01459653 | Completed | Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor | March 2010 | August 2013 | |
NCT04817501 | Completed | Phenotypic Spectrum of CTCs in Tumors of the Female Reproductive System | February 14, 2014 | December 1, 2022 | |
NCT00023699 | Completed | Phase 2 | Gefitinib in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer or Primary Peritoneal Cancer | August 2001 | May 2006 |
NCT00003772 | Completed | Quality-of-Life Assessment in Patients With Ovarian Cancer | January 1999 | February 2003 | |
NCT00295945 | Completed | Epidural Analgesia or Patient-Controlled Analgesia in Treating Patients Who Have Undergone Surgery for Gynecologic Cancer | March 2005 | December 2009 | |
NCT02560337 | Completed | Phase 2 | Cabazitaxel in Patients With Recurrent Ovarian Cancer After Failure of Standard Therapy. | September 2015 | June 1, 2019 |
NCT00002671 | Completed | Phase 2 | Aminocamptothecin in Treating Patients With Recurrent or Unresectable Epithelial Ovarian Cancer | December 1995 | |
NCT01012336 | Completed | Phase 2 | Safety and Efficacy of Aprepitant, Ramosetron, and Dexamethasone for Chemotherapy-Induced Nausea and Vomiting in Patients With Ovarian Cancer Treated With Taxane/Carboplatin | May 2010 | April 2012 |
NCT00112957 | Completed | Phase 2 | Vaccine Therapy in Patients With Stage II, III, or IV Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer | December 2004 | May 2009 |
NCT01104675 | Completed | Phase 2 | Study of Oral ENMD-2076 Administered to Patients With Ovarian Cancer | April 2010 | December 2012 |
NCT06385912 | Completed | Systematic Lymphadenectomy During Interval Debulking Surgery in Advanced Epithelial Ovarian Cancer | July 1, 2006 | February 10, 2021 | |
NCT02877862 | Completed | N/A | Mobile Phone Technology to Increase Genetic Counseling | February 2016 | February 2018 |
NCT00158379 | Completed | Phase 2 | Taxol Carboplatin and Erythropoetin | July 2003 | June 2008 |
NCT03840200 | Completed | Phase 1 | A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer. | June 12, 2019 | January 4, 2022 |
NCT00620243 | Completed | Early Phase 1 | Pilot Study to Evaluate 18F-fluorodeoxyglucose (FDG) Positron Emission Tomography /Computed Tomography (PET/CT) in Prediction of Early Response to Chemotherapy in Ovarian Cancer. | June 2004 | November 2008 |
NCT00082654 | Completed | N/A | Study of the Emotional Needs of Caregivers of Stem Cell Transplantation Patients | March 2002 | October 2004 |
NCT04406623 | Completed | Phase 1 | Phase 1 Study of SL-172154 (SIRPα-Fc-CD40L) in Subjects With Ovarian Cancer | June 29, 2020 | February 2, 2023 |
NCT00001302 | Completed | Phase 1 | A Phase I Study of Infusional Chemotherapy With the P-Glycoprotein Antagonist PSC 833 | September 1992 | June 2002 |
NCT00842452 | Completed | Phase 1 | Topotecan in Treating Patients With Gynecologic Cancer That Cannot Be Removed by Surgery | February 2009 | April 2011 |
NCT01376505 | Completed | Phase 1 | Vaccine Therapy in Treating Patients With Metastatic Solid Tumors | June 21, 2011 | November 28, 2022 |
NCT00928642 | Completed | Phase 2 | Gleevec and Gemzar in Patients With Epithelial Ovarian Cancer | June 2009 | November 2010 |
NCT03166891 | Completed | Phase 1/Phase 2 | Phase Ib Study of Chiauranib in Patients With Ovarian Cancer | December 15, 2017 | March 20, 2019 |
NCT00562003 | Completed | Phase 1 | Safety Study of a Genetically Modified Adenovirus in Ovarian Cancer Patients | June 2007 | June 2010 |
NCT02526017 | Completed | Phase 1 | Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers | September 8, 2015 | November 18, 2019 |
NCT00002515 | Completed | Phase 2 | Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Rare Cancer | October 1992 | April 2005 |
NCT00581815 | Completed | Phase 1 | Spectroscopy With Surface Coils and Decoupling | February 1997 | February 2014 |
NCT00488202 | Completed | Advanced Ovarian Cancer and Sexuality Phase 1 | May 2007 | August 2011 | |
NCT02063464 | Completed | Blood Collection From People With Ovarian Cancer | March 10, 2014 | November 16, 2016 | |
NCT00073541 | Completed | Phase 2 | A Study of the Safety and Effects of EMD 72000 in Subjects With Recurrent Ovarian Cancer | April 2003 | August 2004 |
NCT00102414 | Completed | Phase 3 | Gemcitabine Plus Carboplatin Versus Carboplatin Monotherapy in Patients With Advanced Ovarian Cancer | September 1999 | November 2004 |
NCT06328491 | Completed | N/A | Erdafitinib in Metastatic Steroid-cell Ovarian Cancer | May 30, 2022 | August 22, 2022 |
NCT01237067 | Completed | Phase 1 | Olaparib in Combination With Carboplatin for Refractory or Recurrent Women s Cancers | February 7, 2011 | December 12, 2019 |
NCT00391118 | Completed | Phase 2 | Comparing Two Treatments for Ovarian Cancer: Standard Chemotherapy Plus Enzastaurin, or Placebo ("Sugar Pill") | November 2006 | July 2012 |
NCT02988817 | Completed | Phase 1/Phase 2 | Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors | November 23, 2016 | November 12, 2021 |
NCT00507741 | Completed | Phase 2 | Study of Vintafolide (MK-8109, EC145) in Participants With Advanced Ovarian and Endometrial Cancers (MK-8109-007, EC-FV-02) | August 2007 | April 2009 |
NCT04672460 | Completed | Phase 1 | A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors | December 21, 2020 | July 22, 2022 |
NCT03752216 | Completed | Phase 4 | NIraparib and Quality Of LifE is a Longitudinal Study Evaluating in Real Life the Tolerability of Niraparib. | April 3, 2019 | December 13, 2022 |
NCT00342446 | Completed | A Follow-up Study of Women Evaluated and Treated for Infertility | October 1, 1995 | January 11, 2023 | |
NCT00987649 | Completed | Ovarian Cancer Risk Estimation in Patients With Pelvic Mass | October 2009 | September 2010 | |
NCT03593681 | Completed | Compare Fallopian Tube Cells Collected by Cytuity With Removed Ovarian/Tubal Tissue to Determine Presence of Malignancy | August 27, 2018 | February 14, 2020 | |
NCT03759587 | Completed | Phase 2 | Japan Phase 2 Study of Niraparib (Maintenance Therapy) in Participants With Relapsed Ovarian Cancer | December 28, 2018 | December 28, 2022 |
NCT02610075 | Completed | Phase 1 | Phase Ib Study to Determine MTD of AZD1775 Monotherapy in Patients With Locally Advanced or Metastatic Solid Tumours. | December 1, 2015 | April 26, 2018 |
NCT00003732 | Completed | Phase 2 | Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Cancer | September 1998 | September 2005 |
NCT01419210 | Completed | N/A | Pilot Program to Personalize Care & Improve Quality of Life for Women With Ovarian Cancer | January 2010 | September 2015 |
NCT01370122 | Completed | Pelvic Floor Disorders in Survivors of Gynecologic Malignancies | May 2011 | September 2017 | |
NCT00045175 | Completed | Phase 1 | UCN-01 and Topotecan in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer | June 2002 | |
NCT00617188 | Completed | Phase 2 | Fulvestrant in Treating Patients With Recurrent Ovarian Epithelial Cancer | June 2007 | July 2008 |
NCT00055614 | Completed | Phase 1 | Topotecan in Treating Patients With Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | May 2002 | October 2007 |
NCT00437307 | Completed | Phase 3 | Hycamtin Plus Carboplatin Versus Established Regimens for the Treatment of Ovarian Cancer Relapse | March 2007 | June 2015 |
NCT00019084 | Completed | Phase 2 | Vaccine Therapy and Biological Therapy in Treating Patients With Advanced Cancer | February 1996 | May 2003 |
NCT00005836 | Completed | Phase 2 | Oxaliplatin in Treating Patients With Recurrent or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Has Not Responded to Platinum- Based Chemotherapy | February 2000 | July 2004 |
NCT00003297 | Completed | Phase 1/Phase 2 | Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian Cancer | December 1997 | January 2001 |
NCT01433224 | Completed | Studying Biomarkers in Samples From Younger Patients With Malignant Germ Cell Tumor Progression | October 2011 | May 2016 | |
NCT01570218 | Completed | N/A | Musicotherapy in the Reduction of Fatigue in Women With Breast or Gynecological Cancer Under Radiotherapy | February 2010 | February 2011 |
NCT05001347 | Completed | Phase 2 | A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ®) in Patients With Ovarian Cancer and Selected Solid Tumors | November 2, 2021 | February 8, 2023 |
NCT00270166 | Completed | Phase 3 | The Effect of Epoetin Alfa on the Anemia of Patients With Selected Cancers Receiving Chemotherapy | February 1995 | May 1998 |
NCT01239732 | Completed | Phase 3 | A Study of the Addition of Avastin (Bevacizumab) to Carboplatin and Paclitaxel Therapy in Patients With Ovarian Cancer | December 2010 | March 2015 |
NCT03069872 | Completed | N/A | A Trial of Fast Access to Transvaginal Ultrasound Through General Practice for Earlier Diagnosis of Ovarian Cancer | April 5, 2017 | April 30, 2018 |
NCT00377429 | Completed | Phase 2 | Safety and Efficacy Study of Catumaxomab to Treat Ovarian Cancer After a Complete Response to Chemotherapy | September 2006 | February 2008 |
NCT01444456 | Completed | Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia | October 2011 | ||
NCT00291837 | Completed | Phase 2 | CT-2106 for the Second Line Treatment of Ovarian Cancer | November 2004 | December 2007 |
NCT00293384 | Completed | N/A | Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant | October 2004 | February 2012 |
NCT02878122 | Completed | Study of Predictive Factors of Chemoresistance in Ovarian Cancer | March 2015 | March 2020 | |
NCT00608452 | Completed | Prevalence+Significance of Paraneoplastic Autoantibodies in Many Cancers | July 1995 | November 2009 | |
NCT00520013 | Completed | Phase 2 | Avastin +/- Erlotinib Consolidation Chemotherapy After Carboplatin, Paclitaxel, and Avastin (CTA) Induction Therapy for Advanced Ovarian, Fallopian Tube, Primary Peritoneal Cancer & Papillary Serous or Clear Cell Mullerian Tumors | August 2007 | November 2013 |
NCT00477282 | Completed | Phase 3 | Karenitecin Versus Topotecan in Patients With Advanced Epithelial Ovarian Cancer | August 2007 | June 2013 |
NCT00291473 | Completed | Phase 1 | Safety and Immunogenicity of CHP-HER2 and CHP-NY-ESO-1 Protein With OK-432 in Antigen-Expressing Cancers | July 2005 | August 2008 |
NCT00337233 | Completed | N/A | Yoga in Controlling Symptoms and Reducing Stress in Women With Ovarian Cancer or Breast Cancer | January 2004 | November 2016 |
NCT06342934 | Completed | Radiomics and Machine Learning in the Diagnosis of Ovarian Masses | July 22, 2020 | December 31, 2023 | |
NCT00003967 | Completed | Phase 1 | Topotecan Plus Etoposide in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer | September 1999 | |
NCT00075712 | Completed | Phase 2/Phase 3 | Timing of Surgery and Chemotherapy in Treating Patients With Newly Diagnosed Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer | September 2003 | |
NCT00129727 | Completed | Phase 2 | Carboplatin Taxol Avastin in Ovarian Cancer (OVCA) | June 2005 | February 2009 |
NCT05011539 | Completed | Thiol-disulfide Homeostasis in Patients With Ovarian Cancer | April 9, 2021 | May 1, 2022 | |
NCT02483104 | Completed | Phase 1 | Veliparib in Combination With Carboplatin And Weekly Paclitaxel in Japanese Subjects With Ovarian Cancer | July 2015 | July 2016 |
NCT03326713 | Completed | N/A | Genetic Risk Assessment for Cancer Education and Empowerment (GRACE) Project | October 1, 2016 | August 1, 2020 |
NCT00429559 | Completed | Phase 1/Phase 2 | Topotecan in Combination With Gemcitabine in Patients With Platinum-resistant Ovarian Carcinoma | June 2006 | July 2011 |
NCT02249013 | Completed | Phase 2 | Short-course HIPEC in Advanced Epithelial Ovarian Cancer | February 2015 | February 23, 2021 |
NCT04492007 | Completed | N/A | Feasibility Testing of Patient Reported Outcomes - Informed Symptom Management System (PRISMS) | November 2, 2020 | December 20, 2021 |
NCT04041128 | Completed | Early Phase 1 | PARP Inhibition During Pre-surgical Window in Breast/Ovary Cancer | July 23, 2019 | June 15, 2021 |
NCT00101257 | Completed | Phase 1 | Cellular Adoptive Immunotherapy in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal Cancer | October 2004 | March 2010 |
NCT00003413 | Completed | Phase 2 | Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer | September 1998 | February 2001 |
NCT04823065 | Completed | Phase 1/Phase 2 | 4FMFES-PET Imaging of Endometrial and Ovarian Cancers | September 1, 2018 | April 30, 2024 |
NCT00006357 | Completed | Phase 1/Phase 2 | STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma | August 2000 | |
NCT00478387 | Completed | Ovarian Cancer and Immune Response to Flu Vaccine | October 2006 | June 2011 | |
NCT02151370 | Completed | An Observational Study of Avastin (Bevacizumab) in Patients With Ovarian Cancer | March 2013 | September 2013 | |
NCT00027534 | Completed | Phase 1 | Vaccine Therapy in Treating Patients With Advanced or Metastatic Cancer | January 2002 | October 2007 |
NCT00181688 | Completed | Phase 2 | Iressa (ZD1839) Plus Anastrozole (Arimidex) in Patients With Ovarian Cancer | October 2003 | March 2006 |
NCT00849199 | Completed | Cancer Screening and Prevention Program for High Risk Women | July 2001 | January 2018 | |
NCT00787514 | Completed | FR in Stored Plasma | July 2008 | February 2011 | |
NCT00489359 | Completed | Phase 1/Phase 2 | Trial of Pemetrexed and Carboplatin in Patients With Recurrent Ovarian or Primary Peritoneal Cancer | July 2005 | February 2010 |
NCT00801320 | Completed | N/A | Primary Tumor Harvest for the Purpose of Possible Use in a Future Clinical Trial in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer | September 2008 | August 2020 |
NCT01705288 | Completed | Early Phase 1 | Implementation of a Rapid Recovery Program in Gynecologic Oncology Surgery: A Pilot Study | January 1, 2013 | August 24, 2016 |
NCT00803569 | Completed | Phase 1 | Vaccine Therapy in Stage II, III, or IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers | November 14, 2008 | January 24, 2011 |
NCT00006453 | Completed | Phase 3 | Carboplatin With or Without Gemcitabine in Treating Patients With Advanced Ovarian Epithelial Cancer That Has Not Responded to Previous Chemotherapy | September 1999 | October 2006 |
NCT03206645 | Completed | Phase 1 | Unesbulin in Women With Ovarian Cancer Receiving Neoadjuvant Chemotherapy | August 28, 2017 | March 31, 2024 |
NCT03543462 | Completed | Phase 4 | Diaphragmatic Resection And Gynecological Ovarian Neoplasm | March 20, 2018 | January 11, 2020 |
NCT00190697 | Completed | Phase 4 | A Study of LY353381 (Arzoxifene) for Patients Who Benefitted From This Drug in Other Oncology Trials and Wished to Continue Treatment | January 2001 | April 2007 |
NCT00281632 | Completed | Phase 2 | A Phase II, Open-Label Study Evaluating the Effect Of GW786034 In Subjects With Ovarian Cancer | March 2006 | October 2010 |
NCT04823871 | Completed | N/A | Early Detection of High Grade Ovarian Cancer Using Uterine Lavage EHUD Study and Duplex Sequencing | November 1, 2018 | June 30, 2022 |
NCT00434642 | Completed | Phase 3 | A Study of Carboplatin and Gemcitabine Plus Bevacizumab in Patients With Ovary, Peritoneal, or Fallopian Tube Carcinoma | April 2007 | July 2013 |
NCT00626873 | Completed | Phase 1 | Contrast-Enhanced Ultrasonography in Diagnosing Early-Stage Ovarian Cancer in Patients With an Adnexal Mass Undergoing Surgery to Remove the Ovary | January 2007 | February 2012 |
NCT00477386 | Completed | Phase 1/Phase 2 | Trial of Decitabine as a Sensitizer to Carboplatin in Platinum Resistant Recurrent Ovarian Cancer | July 2007 | September 2013 |
NCT00588237 | Completed | Phase 2 | Intravenous and Intraperitoneal Paclitaxel, Intraperitoneal Cisplatin, and Intravenous Bevacizumab for the Initial Treatment of Optimal Stage II or III Ovarian, Primary Peritoneal, and Fallopian Tube Cancer | August 2006 | November 2014 |
NCT02728622 | Completed | Phase 3 | Chemotherapy vs Hormonal Treatment in Platinum-resistant Ovarian Cancer Resistant or Refractory to Platinum and Taxane | March 2002 | January 2009 |
NCT02307500 | Completed | Phase 2 | Regorafenib in Patients With Metastatic Solid Tumors Who Have Progressed After Standard Therapy | December 2014 | August 2020 |
NCT02824328 | Completed | A Pilot Study Investigating the Effect of Chemotherapy on the Tumoral Immunoprofile of Gynecologic Cancers | June 2016 | January 10, 2022 | |
NCT02664389 | Completed | N/A | Targeted Next-generation Sequencing Panel for Identification of Germline Mutations in Early Onset Cancers With Sporadic or Hereditary Presentation | February 1, 2016 | March 15, 2017 |
NCT00217555 | Completed | Phase 2 | Gemcitabine and Topotecan in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer | July 2002 | |
NCT03657043 | Completed | Phase 2 | A Study of Weekly Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With Safety Run-in (innovaTV 208) | March 20, 2019 | February 8, 2022 |
NCT00004081 | Completed | Phase 2 | Docetaxel in Treating Women With Ovarian Epithelial or Primary Peritoneal Cancer | July 1999 | March 2003 |
NCT01166737 | Completed | N/A | Study Comparing Tumor Debulking Surgery Versus Chemotherapy Alone in Recurrent Platinum-Sensitive Ovarian Cancer | July 2010 | December 31, 2020 |
NCT01937104 | Completed | N/A | ONSD According to the Position During Laparoscopy | September 2013 | September 2014 |
NCT03889171 | Completed | Comparison to Psychological, Medical and Emotional Influencing Communication and Achievement Factors to Oncogenetics Tests | August 2012 | September 2018 | |
NCT02490488 | Completed | Phase 2/Phase 3 | Masitinib in Combination With Gemcitabine in Advanced/Metastatic Epithelial Ovarian Cancer Patients | April 2014 | December 2020 |
NCT00216112 | Completed | Phase 2 | Imatinib Mesylate in Combination With Docetaxel for Advanced, Platinum-Refractory Ovarian Cancer | December 2003 | July 2007 |
NCT00113789 | Completed | Phase 2 | Evaluating Pegfilgrastim and a Multi-Day Topotecan Regimen in Subjects With Relapsed or Refractory Ovarian Cancer | October 2003 | April 2005 |
NCT00019461 | Completed | Phase 2 | Carboxyamidotriazole in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | April 1998 | October 2007 |
NCT00003450 | Completed | Phase 1 | Gene Therapy in Treating Patients With Advanced Recurrent or Persistent Ovarian Cancer or Primary Peritoneal Cancer | September 1998 | January 1999 |
NCT00003644 | Completed | Phase 3 | Carboplatin Plus Paclitaxel With or Without Continued Low-Dose Paclitaxel in Treating Patients With Early-Stage Ovarian Cancer | October 1998 | |
NCT01787656 | Completed | A Novel Method of Screening for Ovarian Cancer Using Gynecologic Fluids and Mucus | January 2013 | August 2018 | |
NCT00261027 | Completed | Phase 2 | Aromasin (Exemestane) in Patients With Recurrent or Refractory Stage II - IV Epithelial Ovarian Cancer | January 2003 | September 2007 |
NCT02019524 | Completed | Phase 1 | Phase Ib Trial of Two Folate Binding Protein Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients | September 30, 2013 | December 6, 2016 |
NCT00900679 | Completed | N/A | Effects of a Teaching Intervention With an Advanced Practice Nurse on Quality of Life and Psychosocial and Symptom Distress in Patients With Ovarian Cancer | July 2008 | February 2010 |
NCT04066361 | Completed | N/A | OPTimizing Treatment Focused Genetic Testing IN Cancer | December 19, 2019 | November 30, 2022 |
NCT00721162 | Completed | Phase 2 | Study of Ramucirumab in Ovarian Cancer | August 2008 | August 2015 |
NCT03364673 | Completed | N/A | Stepping Into Survivorship: Harnessing Behavioral Economics to Improve Quality of Life in Ovarian Cancer | July 20, 2018 | December 5, 2020 |
NCT05564234 | Completed | N/A | Role of Laparoscopy in Assessing Resectability of Ovarian Cancer | December 9, 2019 | April 9, 2022 |
NCT00170573 | Completed | Phase 2 | Caelyx Biweekly in Heavily Pretreated Patients With Relapsed Ovarian Cancer | October 2001 | August 2010 |
NCT00001503 | Completed | Follow-up Protocol for Patients With Cancer/AIDS/Skin Disease | September 19, 1996 | June 15, 2023 | |
NCT00964756 | Completed | Phase 1 | A Study of an Infectivity Enhanced Suicide Gene Expressing Adenovirus for Ovarian Cancer in Patients With Recurrent Ovarian and Other Selected Gynecologic Cancers | August 2009 | April 2012 |
NCT02000778 | Completed | Phase 1 | EC17 for Intraoperative Imaging in Occult Ovarian Cancer | November 2013 | November 12, 2014 |
NCT03056833 | Completed | Phase 1 | Ribociclib (Ribociclib (LEE-011)) With Platinum-based Chemotherapy in Recurrent Platinum Sensitive Ovarian Cancer | June 10, 2017 | August 1, 2022 |
NCT03735680 | Completed | Phase 2 | A Study to Evaluate ONM-100, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer | August 9, 2019 | November 18, 2021 |
NCT00030706 | Completed | Phase 2 | Ixabepilone in Treating Patients With Relapsed and/or Refractory Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer | November 2004 | |
NCT00005807 | Completed | Phase 1 | Treating Patients With Advanced Solid Tumors, Breast Cancer or Recurrent Ovarian Cancer | July 2000 | August 2004 |
NCT00517621 | Completed | Phase 2 | Use of FACT-GOG/NTX Questionnaire in Peripheral Neurotoxicity & Validation of a French Version of This Questionnaire | February 2006 | October 2010 |
NCT01582906 | Completed | A Survivorship Care Plan for Gynaecological Cancer Patients | August 2011 | April 2015 | |
NCT00003308 | Completed | Phase 2 | Radiation Therapy in Treating Patients With Newly Diagnosed Brain Metastases From Kidney Cancer, Melanoma, or Sarcoma | February 2, 1999 | |
NCT02477644 | Completed | Phase 3 | Platine, Avastin and OLAparib in 1st Line | May 6, 2015 | March 22, 2022 |
NCT03784378 | Completed | Phase 1 | Continued Access to RXDX-105 | December 14, 2018 | September 30, 2020 |
NCT00735150 | Completed | Awareness and Attitudes Regarding Prenatal and Preimplantation Genetic Diagnosis for Inherited Breast/Ovarian Cancer Risk | March 2008 | October 2010 | |
NCT00002717 | Completed | Phase 3 | Paclitaxel and Cisplatin in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal Cancer | March 1996 | |
NCT01652079 | Completed | Phase 2 | CRLX101 in Combination With Bevacizumab for Recurrent Ovarian/Tubal/Peritoneal Cancer | April 2012 | March 2018 |
NCT01248962 | Completed | Phase 2 | Standard Infusion Carboplatin Versus Prophylactic Extended Infusion Carboplatin in Patients With Patients With Recurrent, Ovary, Fallopian Tube, and Primary Peritoneal Cancer | November 2010 | August 2018 |
NCT00466986 | Completed | Phase 2 | Abraxane Plus Carboplatin for Recurrent Platinum-Sensitive Ovarian Cancer | November 2005 | October 2011 |
NCT00113607 | Completed | Phase 3 | An Efficacy and Safety Study for Yondelis (Trabectedin) in Patients With Advanced Relapsed Ovarian Cancer | April 2005 | November 2010 |
NCT02163720 | Completed | Ovarian Cancer Treatment Platinum-sensitive Relapse - Cohort Study (PROSPECTYON) | July 10, 2014 | September 18, 2018 | |
NCT00844506 | Completed | Phase 2 | p53 Synthetic Long Peptides Vaccine With Cyclophosphamide for Ovarian Cancer | October 2008 | July 2009 |
NCT00002750 | Completed | Phase 1 | Melphalan in Patients With Neoplastic Meningitis | December 1992 | May 2001 |
NCT00002931 | Completed | Phase 2 | Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Relapsed Germ Cell Cancer | February 1997 | December 2014 |
NCT03117933 | Completed | Phase 2 | Olaparib +/- Cediranib or Chemotherapy in Patients With Platinum-resistant Ovarian Cancer | March 9, 2017 | December 31, 2023 |
NCT00607607 | Completed | Phase 2 | A Phase 2 Study of Oral MKC-1 in Patients With Ovarian or Endometrial Cancer | January 2008 | January 2012 |
NCT03656809 | Completed | Feasibility of Multi-gene Panel Testing at the Time of Diagnosis for Patients With Ovarian Cancer | October 15, 2015 | January 29, 2020 | |
NCT04032600 | Completed | N/A | Malignant Ascites in Ovarian Cancer: Impact of Total Paracentesis on Hemodynamics | August 1, 2017 | September 9, 2019 |
NCT00872989 | Completed | Phase 2 | S0904: Docetaxel With or Without Vandetanib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | March 2010 | May 2014 |
NCT01105650 | Completed | Phase 2 | Allogeneic Natural Killer (NK) Cells for Ovarian, Fallopian Tube, Peritoneal and Metastatic Breast Cancer | July 2010 | April 2014 |
NCT02657889 | Completed | Phase 1/Phase 2 | Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer | April 15, 2016 | September 17, 2021 |
NCT00003425 | Completed | Phase 1/Phase 2 | Phase I/II Study of Escalating-Dose Melphalan w/Autologous SCS & Amifostine Cytoprotect | December 1997 | |
NCT02354131 | Completed | Phase 1/Phase 2 | Niraparib Versus Niraparib-bevacizumab Combination in Women With Platinum-sensitive Epithelial Ovarian Cancer | February 15, 2015 | December 15, 2021 |
NCT03470805 | Completed | Phase 2 | Olaparib After Response to Trabectedin-pegylated Liposomal Doxorubicin in Recurrent Ovarian Carcinoma | June 21, 2018 | July 27, 2022 |
NCT00006036 | Completed | Phase 1 | Liposomal Lurtotecan Plus Cisplatin in Treating Patients With Advanced or Metastatic Solid Tumors | March 22, 2000 | December 21, 2009 |
NCT00683241 | Completed | Phase 1 | A Phase I Clinical Trial of Autologous Dendritic Cell Vaccine for Recurrent Ovarian or Primary Peritoneal Cancer | November 2007 | December 2009 |
NCT00005023 | Completed | Phase 1 | Vaccine Therapy Plus Sargramostim in Treating Patients With Stage III or Stage IV Cancer | March 1999 | January 2001 |
NCT02054351 | Completed | Phase 1 | Phase 1 Trial of IMAB027 in Patients With Recurrent Advanced Ovarian Cancer (OVAR) | February 6, 2014 | October 28, 2015 |
NCT00132522 | Completed | Phase 1 | EMD 273066 in Patients With Recurrent EpCAM Positive Ovarian, Prostate, Colorectal or Non-small Cell Lung Cancers When First Given Cyclophosphamide | May 2005 | April 2009 |
NCT00340210 | Completed | Extended Follow-up of Columbia, MO Serum Bank Participants | January 14, 1999 | September 2, 2014 | |
NCT03695380 | Completed | Phase 1 | A Clinical Study of Cobimetinib Administered in Combination With Niraparib, With or Without Atezolizumab to Patients With Advanced Platinum-sensitive Ovarian Cancer | January 9, 2019 | July 12, 2023 |
NCT04234243 | Completed | HIPEC in Ovarian Cancer, Case-Controls Study With 10-years Follow up | August 1, 2007 | August 31, 2019 | |
NCT00003636 | Completed | Phase 3 | Chemotherapy Plus Surgery in Treating Patients With Stage III or Stage IV Ovarian, Peritoneal, or Fallopian Tube Cancer | September 1998 | |
NCT02327078 | Completed | Phase 1/Phase 2 | A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204) | November 26, 2014 | June 16, 2020 |
NCT05868889 | Completed | Retrospective Multicenter Study of Elderly Patients With Ovarian Cancer Treated With Trabectedin and PLD | October 21, 2021 | June 16, 2022 | |
NCT03490669 | Completed | Phase 1 | Study to Evaluate Safety, PK, PD, Immunogenicity & Antitumor Activity of MSC-1 in Patients With Adv Solid Tumors | May 21, 2018 | September 23, 2019 |
NCT00883181 | Completed | A Study of Neutropenia and Anemia Management in Patients With Solid Tumors Receiving Myelotoxic Chemotherapy | November 2006 | September 2014 | |
NCT01891344 | Completed | Phase 2 | A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2) | October 30, 2013 | September 28, 2021 |
NCT00486707 | Completed | Ovarian Cancer Patient Questionnaire on Genetic Testing | June 2007 | October 2008 | |
NCT02269293 | Completed | Phase 1 | Selective Inhibitor of Nuclear Export, Selinexor (KPT-330) in Combination With Paclitaxel and Carboplatin in Patients With Advanced Ovarian or Endometrial Cancers | October 13, 2014 | April 20, 2021 |
NCT00504257 | Completed | Phase 2 | Avastin in Combination With Docetaxel in Ovarian/Fallopian Tube/Peritoneum Carcinoma | March 2007 | October 2012 |
NCT02317705 | Completed | Phase 2 | Phase 2 Study of OTL38 for Intra-operative Imaging of Folate Receptor-alpha Positive Ovarian Cancer | December 2014 | November 2015 |
NCT00267072 | Completed | Ovarian Screening Study | June 2001 | May 2010 | |
NCT00003523 | Completed | Phase 2 | Aminocamptothecin in Treating Patients With Recurrent or Refractory Ovarian Epithelial Cancer or Primary Cancer of the Peritoneum | January 1999 | October 2007 |
NCT00750386 | Completed | Phase 1/Phase 2 | Paclitaxel and Carboplatin Combination as 1st Line Treatment in Ovarian Carcinomas | January 2008 | March 2011 |
NCT00096239 | Completed | Phase 2 | CP-547,632 in Treating Patients With Recurrent or Persistent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | December 2004 | February 2005 |
NCT01556841 | Completed | Phase 2 | The Activity of TroVax® Versus Placebo in Relapsed Asymptomatic Ovarian Cancer | November 2013 | April 19, 2019 |
NCT01523678 | Completed | Phase 2 | Weekly Paclitaxel/Carboplatin With Neupogen in Gynaecological Cancers | February 2012 | August 14, 2018 |
NCT00699907 | Completed | Phase 2 | Effect of Flutamide on Biomarkers in Blood and Tissue Samples From Patients at High Risk of Ovarian Cancer | January 2005 | November 2014 |
NCT00019916 | Completed | Phase 1/Phase 2 | Vaccine Therapy Plus Interleukin-2 in Treating Women With Stage IV, Recurrent, or Progressive Breast or Ovarian Cancer | June 2000 | July 2006 |
NCT00381888 | Completed | Phase 2 | Fondaparinux in Preventing Blood Clots in Patients Undergoing Surgery for Gynecologic Cancer | January 2007 | January 2009 |
NCT00170625 | Completed | Phase 1/Phase 2 | Therapy With Topotecan and Carboplatin by Patients With Relapsed Ovarian Cancer | June 2004 | September 2010 |
NCT03604653 | Completed | Trial of Cytoreductive Surgery and HIPEC in Patients With Primary and Secondary Peritoneal Cancers | May 15, 2018 | May 1, 2021 | |
NCT01033123 | Completed | Phase 2 | A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Sensitive Recurrent Ovarian Cancer | December 2009 | February 2012 |
NCT01272817 | Completed | N/A | Nonmyeloablative Allogeneic Transplant | October 2001 | October 2015 |
NCT02737787 | Completed | Phase 1 | A Phase I Study of WT1 or NY-ESO-1 Vaccine and Nivolumab For Recurrent Ovarian Cancer | April 2016 | April 6, 2023 |
NCT00020696 | Completed | Phase 2 | Tirapazamine Plus Cisplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Primary Peritoneal Cancer | June 2001 | |
NCT03936270 | Completed | Phase 2 | Palbociclib Plus Letrozole Treatment After Progression to Second Line Chemotherapy for Women With ER/PR-positive Ovarian Cancer | March 5, 2020 | May 2, 2023 |
NCT00510653 | Completed | Phase 2 | Gleevec Study for Patients With Ovarian Cancer | March 2002 | February 2012 |
NCT00058435 | Completed | Phase 1 | Monoclonal Antibody Vaccine Therapy in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer | December 2002 | March 2004 |
NCT00523380 | Completed | Phase 2 | Efficacy Study of Recombinant Interleukin-21 in the Treatment of Ovarian Cancer | October 4, 2007 | January 7, 2009 |
NCT00433602 | Completed | Incidence of Blood Clots in Patients Undergoing Chemotherapy for Solid Tumors | November 2006 | ||
NCT01679483 | Completed | N/A | Efficacy Study of FloSeal for Prevention of Lymphocele After Lymphadenectomy for Gynecologic Cancer | September 2012 | November 2015 |
NCT00944944 | Completed | Gynecologic Cancer Lymphedema Questionnaire as a Clinical Care Tool to Identify Lower Extremity Lymphedema | July 2009 | January 2010 | |
NCT00003670 | Completed | Phase 2 | Hormone Therapy With Arzoxifene Hydrochloride in Treating Women With Metastatic Refractory Ovarian Cancer or Primary Peritoneal Cancer | October 1998 | January 2001 |
NCT02039388 | Completed | N/A | Lavage of the Uterine Cavity for the Diagnosis of Serous Tubal Intraepithelial Carcinoma | November 2013 | December 31, 2021 |
NCT02004093 | Completed | Phase 2 | A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer | December 2005 | September 2008 |
NCT00006155 | Completed | Phase 1 | SU5416 and Carboplatin to Treat Ovarian Cancer | August 2000 | April 2001 |
NCT02585362 | Completed | N/A | Whey Protein Supplement in Combination With Physical Exercise and Nutrition Program | March 2016 | October 2018 |
NCT00712218 | Completed | N/A | Lymphadenectomy In Ovarian Neoplasms | December 2008 | December 2017 |
NCT00072410 | Completed | Phase 1 | Radiolabeled Monoclonal Antibody in Treating Patients With Advanced Ovarian Epithelial Cancer | November 2003 | November 15, 2006 |
NCT00004177 | Completed | Phase 1/Phase 2 | Radiolabeled Monoclonal Antibody Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory or Recurrent Ovarian Epithelial Cancer | August 1999 | |
NCT01048814 | Completed | Retrospective Case Study to Validate Existing Chemoresponse Marker Test in Ovarian, Peritoneal or Fallopian Cancer Cases | August 2009 | June 2011 | |
NCT00501644 | Completed | Phase 2 | Chemoimmunotherapy Study for Patients With Epithelial Ovarian Cancer | January 2003 | January 2009 |
NCT00189358 | Completed | Phase 2 | A Phase II Study of ZD1839 and Tamoxifen in Patients With Epithelial Ovarian Carcinoma, Cancer of the Fallopian Tube or the Peritoneum Refractory to Platinum- and Taxane-based Therapy | ||
NCT00474994 | Completed | Phase 2 | Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas | April 2007 | November 2010 |
NCT03075462 | Completed | Phase 1 | A Study of Fluzoparib Given in Combination With Apatinib in Ovarian or Breast Cancer Patients | March 9, 2017 | December 13, 2021 |
NCT00217529 | Completed | Phase 1/Phase 2 | Erlotinib, Docetaxel, and Carboplatin in Treating Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer | June 2004 | |
NCT03267589 | Completed | Phase 2 | Trial in Patients With Relapsed Ovarian Cancer | May 14, 2018 | October 19, 2021 |
NCT00401674 | Completed | Phase 2 | MITO-5: Weekly Carboplatin and Paclitaxel as First Line Chemotherapy for Elderly Patients With Ovarian Cancer | June 2003 | June 2008 |
NCT01276548 | Completed | Phase 2 | A Trial to Evaluate Efficacy and Safety of the Combination Therapy of Genexol®-PM Plus Carboplatin® Compared to Genexol® Plus Carboplatin® as a Firstline Treatment in Subjects With Ovarian Cancer | October 2009 | September 2012 |
NCT00024258 | Completed | Phase 2 | Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors | March 2001 | May 2009 |
NCT01047891 | Completed | Phase 2 | Efficacy and Safety Study of Sorafenib With Topotecan in Patients With Platinum-resistant Recurrent Ovarian Cancer | January 2010 | February 2015 |
NCT00227721 | Completed | Phase 2 | Gemcitabine and Docetaxel in Treating Patients With Relapsed or Refractory Ovarian Epithelial or Peritoneal Cancer | February 2004 | February 2017 |
NCT01931644 | Completed | At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions | July 2013 | April 2024 | |
NCT01709175 | Completed | N/A | Strength Training Study for Survivors of Breast and Gynecologic Cancer | November 2012 | January 2015 |
NCT04939701 | Completed | Phase 1/Phase 2 | Study of ASP0739 Alone and With Pembrolizumab in Advanced Solid Tumors With NY-ESO-1 Expression Participants | January 11, 2022 | June 1, 2023 |
NCT00816764 | Completed | Phase 1 | A Phase 1 Study of the Safety and Pharmacokinetics of AGS-8M4 in Subjects With Advanced Ovarian Cancer | October 2008 | June 2010 |
NCT00716976 | Completed | Phase 3 | Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy | June 23, 2008 | June 30, 2021 |
NCT00003695 | Completed | Phase 3 | Chemotherapy With or Without Surgery in Treating Patients With Stage II or Stage III Ovarian Cancer | May 1998 | January 2001 |
NCT03464201 | Completed | Phase 2 | Enzalutamide in Metastatic or Advanced Non-resectable Granulosa Cell Ovarian Tumors: GREKO III Study | April 13, 2018 | November 11, 2020 |
NCT01350908 | Completed | N/A | Study of Circulating Tumoral DNA in Ovarian Cancer | April 2011 | December 2015 |
NCT02421588 | Completed | Phase 3 | Clinical Trial of Lurbinectedin (PM01183) in Platinum Resistant Ovarian Cancer Patients | May 2015 | October 12, 2018 |
NCT01936363 | Completed | Phase 2 | Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer | September 30, 2013 | November 30, 2017 |
NCT02221076 | Completed | N/A | Probe-based and Needle-based Confocal Laser Endomicroscopy During Gynaecological Procedures. | July 2014 | April 18, 2016 |
NCT00010283 | Completed | Phase 1/Phase 2 | Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Esophagus, Stomach, Small Intestine, or Colon | July 2000 | July 2002 |
NCT02948075 | Completed | Phase 2 | Safety and Efficacy of Quisinostat, a Histone Deacetylase Inhibitor, in Combination With Chemotherapy | September 2015 | June 16, 2017 |
NCT01059643 | Completed | Phase 2 | A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck | April 2011 | December 2012 |
NCT06253559 | Completed | Clinical and Pathological Characteristics of Women With Ovarian Cancers in Syria | January 1, 2017 | December 24, 2023 | |
NCT02144311 | Completed | N/A | Benchmarking Intra-tumor Heterogeneity In Ovarian Cancer: Linking In-vivo Imaging Phenotypes With Histology And Genomics | May 2014 | June 15, 2020 |
NCT00002641 | Completed | Phase 3 | Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma | February 1995 | June 2012 |
NCT00262990 | Completed | Phase 3 | Patupilone Versus Doxorubicin in Patients With Ovarian, Primary Fallopian, or Peritoneal Cancer | November 2005 | |
NCT03314935 | Completed | Phase 1/Phase 2 | A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors | November 21, 2017 | November 28, 2022 |
NCT00340600 | Completed | Continuation of Follow-up of DES-Exposed Cohorts | March 18, 1998 | November 13, 2020 | |
NCT01572467 | Completed | Studying Genes in Samples From Younger Patients With Ovarian or Testicular Sex Cord Stromal Tumors | April 2012 | ||
NCT00900406 | Completed | Collecting and Storing Tissue and DNA Samples From Patients Undergoing a Donor Stem Cell Transplant | January 2007 | March 2010 | |
NCT00002894 | Completed | Phase 3 | Platinum-based Chemotherapy With or Without Paclitaxel in Treating Patients With Relapsed Ovarian Cancer | March 1996 | June 2003 |
NCT00431054 | Completed | Phase 1 | Perifosine and Docetaxel in Patients With Relapsed Epithelial Ovarian Cancer | February 2007 | May 2012 |
NCT02855944 | Completed | Phase 3 | ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients | March 1, 2017 | September 16, 2022 |
NCT01188876 | Completed | Phase 1/Phase 2 | Carboplatin/Pralatrexate in Recurrent Platinum-Sensitive Ovarian, Fallopian or Primary Peritoneal Cancer | August 2010 | July 2017 |
NCT00004065 | Completed | Phase 1 | Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer | July 1999 | March 2005 |
NCT00319748 | Completed | Phase 2 | Study of Immune Response Modifier in the Treatment of Breast, Ovarian, Endometrial and Cervical Cancers | April 2006 | December 2008 |
NCT02963831 | Completed | Phase 1/Phase 2 | A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies | September 7, 2017 | June 25, 2022 |
NCT04122937 | Completed | Defining Inflammation Related to Peritoneal Carcinomatosis in Women With Ovarian or Colon Cancer. | March 1, 2017 | March 30, 2019 | |
NCT01738269 | Completed | Elecsys HE4 Chinese Reference Value Study | November 2012 | May 2013 | |
NCT04458168 | Completed | N/A | Feasibility and Evaluation of a Self-care App to Enhance Purposeful Living | June 28, 2021 | December 10, 2022 |
NCT00002943 | Completed | Phase 2 | Carboplatin, Etoposide, Cyclophosphamide, and Autologous Bone Marrow Transplantation in Patients With Relapsed or Refractory Cancer | February 1993 | August 2007 |
NCT02560818 | Completed | N/A | Transcriptomes Breast, Ovarian and Leukocyte Hereditary Genes Predisposing to Breast and / or Ovarian Cancer | October 2015 | October 2020 |
NCT03229122 | Completed | Characterizing the Cross-sectional Approach to Ovarian Cancer: Genetic Testing of BRCA | December 26, 2016 | July 6, 2018 | |
NCT03719326 | Completed | Phase 1 | A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies | October 15, 2018 | July 2, 2021 |
NCT01031381 | Completed | Phase 2 | Study of RAD001 and Bevacizumab in Recurrent Ovarian, Peritoneal, and Fallopian Tube Cancer | September 2010 | December 2014 |
NCT01851928 | Completed | Validation of a Nutrition Screening Tool | July 2011 | March 2013 | |
NCT00003944 | Completed | Phase 2 | Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | August 1998 | February 2003 |
NCT00164658 | Completed | Phase 1 | Evaluating Tools for Health Promotion and Disease Prevention | September 2005 | October 2007 |
NCT00293293 | Completed | N/A | Outcomes in Ovarian Cancer and Fallopian Tube Cancer Patients Using Complementary Alternative Medicine | May 2005 | January 2010 |
NCT00445965 | Completed | Phase 2 | Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer | January 2006 | February 1, 2023 |
NCT00006391 | Completed | Phase 1 | Oxaliplatin and Topotecan in Treating Patients With Previously Treated Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer | August 2000 | |
NCT04330040 | Completed | Phase 4 | Prospective Multicentre Phase-IV Clinical Trial of Olaparib in Indian Patients With Ovarian and Metastatic Breast Cancer | May 30, 2020 | September 30, 2022 |
NCT00157573 | Completed | Phase 2 | GM-CSF, Sargramostim in Women With Recurrent Ovarian Cancer | December 2004 | April 2010 |
NCT03901118 | Completed | Phase 2 | Chiauranib in Combination With Chemotherapy in Patients With Ovarian Cancer | July 1, 2019 | December 18, 2020 |
NCT00004166 | Completed | Phase 3 | Amifostine in Treating Patients With Ovarian Epithelial Cancer Who Are Receiving Chemotherapy | October 1999 | January 2003 |
NCT00318370 | Completed | Phase 2 | Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based Chemotherapy | May 2006 | June 2010 |
NCT00277160 | Completed | Phase 4 | A Study of Primary Prophylaxis With Neulasta (Pegfilgrastim) Versus Secondary Prophylaxis After Chemotherapy in Elderly Subjects (>/= 65 Years Old) With Cancer | June 2002 | January 2005 |
NCT00001806 | Completed | Phase 3 | Methods in Education for Breast Cancer Genetics | April 6, 1999 | December 6, 2017 |
NCT00433407 | Completed | N/A | T-Cell Response in Patients Receiving Trastuzumab and/or Chemotherapy for HER2-Positive Solid Tumors | August 2005 | |
NCT03378297 | Completed | Early Phase 1 | IMPACT: A Randomized WOO Study of Novel Therapeutic Agents in Women Triaged to Primary Surgery for EOC | May 4, 2018 | January 5, 2023 |
NCT06403072 | Completed | (GI-RADS) in Preoperative Evaluation of Adnexal Masses | June 1, 2021 | January 30, 2023 | |
NCT03790423 | Completed | Phase 1 | 18F-ASIS PET/CT Imaging of Tissue Factor Expression In Patients With Primary and Metastastic Cancer | January 3, 2019 | November 18, 2019 |
NCT00030446 | Completed | Phase 2 | Erlotinib and Carboplatin in Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | January 10, 2002 | December 21, 2009 |
NCT00003795 | Completed | Quality of Life in Survivors of Gynecologic Cancer | April 1999 | ||
NCT01033292 | Completed | Phase 2 | A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Resistant Recurrent Ovarian Cancer | December 2009 | December 2012 |
NCT02475772 | Completed | Phase 1 | A Study With Intraperitoneal Cisplatin and Doxorubicin in Recurrent Ovarian Cancer and Peritoneal Carcinomatosis | November 2016 | May 2018 |
NCT05504174 | Completed | Detection of Circulating Tumor DNA Through Liquid Biopsies in Ovarian Cancer Patients and Evaluation of Prognostic and Predictive Values of Circulating Tumor DNA Assay. | September 10, 2019 | June 30, 2022 | |
NCT00419510 | Completed | N/A | Genetic Counseling in African American Women | February 2003 | September 2012 |
NCT06063343 | Completed | Phase 1 | Evaluation of Safety, Tolerability, Pharmacokinetics, Food Effect and Interaction With Midazolam in Healthy Volunteers After Oral Single and Multiple Ascending Dosing of KAND145 | November 9, 2023 | April 8, 2024 |
NCT00003408 | Completed | Phase 2 | Biological Therapy Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Cancer | April 1998 | March 2000 |
NCT00751205 | Completed | Phase 2 | Prevention of Sagopilone-induced Neurotoxicity With Acetyl-L-Carnitine (ALC) | August 2008 | August 2010 |
NCT00098800 | Completed | N/A | Fenretinide in Preventing Ovarian Cancer in Participants Who Are at High Risk for Developing Ovarian Cancer and Planning to Undergo Surgery to Remove the Ovaries | October 2004 | November 2006 |
NCT00739661 | Completed | Phase 2 | A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) As Maintenance Therapy in Patients With Ovarian Cancer in a Second or Third Complete Remission | December 2008 | November 2010 |
NCT00002895 | Completed | Phase 3 | Early Chemotherapy Based on CA 125 Level Alone Compared With Delayed Chemotherapy in Treating Patients With Recurrent Ovarian Epithelial , Fallopian Tube, or Primary Peritoneal Cancer | June 1996 | October 2010 |
NCT03028519 | Completed | Early Phase 1 | Vitamin D, Leptin, Vitamin D Receptor Polymorphism, and Treatment-Related Morbidity in Ovarian Cancer | January 31, 2017 | December 30, 2020 |
NCT00976911 | Completed | Phase 3 | AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer | October 29, 2009 | July 9, 2014 |
NCT00648102 | Completed | Phase 1 | Phase I Study of CDX-1307, hCG-B Vaccine, for Patients With Incurable, Locally Advanced or Metastatic Breast, Colorectal, Pancreatic, Bladder or Ovarian Cancer | January 2006 | December 2009 |
NCT00003120 | Completed | Phase 3 | S9701 Paclitaxel in Treating Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission | November 1997 | November 2012 |
NCT00189553 | Completed | Phase 3 | Caelyx Plus Carboplatin Versus Paclitaxel Plus Carboplatin in Patients With Epithelial Ovarian Cancer in Late Relapse | April 2005 | June 2012 |
NCT03519165 | Completed | N/A | Restrictive or Individualized Goal-Directed Fluid Replacement Strategy in Ovarian Cancer Cytoreductive Surgery | June 2016 | September 2019 |
NCT06436248 | Enrolling by invitation | Polygenic Risk Scores and Multi-cancer Early Detection for Ovarian Cancer | July 2024 | October 2027 | |
NCT03762733 | Enrolling by invitation | Tissue Acquisition and Genomics Analysis of Breast Cancer and Other Gynecologic Malignancies | January 4, 2022 | December 29, 2028 | |
NCT05721326 | Enrolling by invitation | N/A | Sequential EHR Based Interventions to Increase Genetic Testing for Breast and Ovarian Cancer Predisposition | May 1, 2023 | December 1, 2024 |
NCT04421963 | Enrolling by invitation | Phase 3 | Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib | August 4, 2020 | December 10, 2024 |
NCT04699006 | Enrolling by invitation | Efficacy and Adverse Effects of Olaparib in Ovarian Cancer. | January 21, 2021 | January 1, 2026 | |
NCT05904730 | Enrolling by invitation | Phase 1 | Phase I Clinical Trials Investigating the Potential Efficacy of Axitinib in Patients With a BRCA 1/2 Mutations | July 11, 2023 | November 9, 2024 |
NCT05318625 | Enrolling by invitation | N/A | A Prospective Study to Evaluate the Clinical Performance and Safety of the SIRIUS Endoscope System in Laparoscopic Gynecological Surgery. | January 10, 2023 | July 2024 |
NCT06386653 | Enrolling by invitation | Phase 1 | Molecular Imaging of EpCAM Receptors Using [123I]I-DARPIN-Ec1 | April 14, 2024 | December 31, 2024 |
NCT06120309 | Enrolling by invitation | New Prognostic Index for Neoadjuvant Chemotherapy Outcome in Patients With Advanced High-grade Serous Ovarian Cancer | November 1, 2023 | December 31, 2024 | |
NCT05223218 | Enrolling by invitation | Investigating the Diagnostic Potential of Tear Proteins in Cancer - A Pilot Study | August 25, 2021 | December 2023 | |
NCT03554434 | No longer available | An Expanded Access Program for AM0010 (Pegilodecakin) | |||
NCT06188455 | Not yet recruiting | Phase 3 | Maintenance Therapy After Platinum-containing Chemotherapy in Patients With Recurrent Ovarian Cancer | December 1, 2024 | December 1, 2026 |
NCT05583799 | Not yet recruiting | Efficacy and Adverse Effects of Niraparib in Ovarian Cancer. | October 15, 2022 | September 30, 2025 | |
NCT06180356 | Not yet recruiting | Phase 2 | Niraparib Rechallenge After Surgery in Ovarian Cancer Patients With Oligometastatic Progression | August 2024 | November 2025 |
NCT06412120 | Not yet recruiting | Phase 4 | Study Evaluating Safety, Tolerability, and Metabolism of Niraparib | September 1, 2024 | September 1, 2029 |
NCT06018935 | Not yet recruiting | A Cohort Establishment Study of Total Management of Ovarian Cancer | January 1, 2024 | September 1, 2025 | |
NCT05976932 | Not yet recruiting | Circulating Tumor DNA Monitoring in Platinum-resistant Ovarian Cancer | August 2023 | October 2024 | |
NCT05475184 | Not yet recruiting | Phase 2 | A Study to Evaluate the Efficacy and Safety of JPI-547 in Platinum-resistant, Advanced/Relapsed Ovarian Cancer Subjects Previously Treated With a PARP Inhibitor | August 1, 2022 | June 2025 |
NCT06392997 | Not yet recruiting | Evaluation of Salivary RNA in Subjects Scheduled for Surgery for a Gynecologic Pathology | June 2024 | June 2026 | |
NCT06376253 | Not yet recruiting | Phase 1 | A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers | September 6, 2024 | August 30, 2030 |
NCT06465069 | Not yet recruiting | Phase 1 | A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors | June 2024 | May 2027 |
NCT06304922 | Not yet recruiting | BRCA 1/2 Status as a Predictive Factor to Response to Platinum Based Chemotherapy in Cancer Ovary | April 1, 2024 | April 1, 2026 | |
NCT05805358 | Not yet recruiting | Phase 2 | Hyperpolarized 13C MRI for Cancer Immunotherapy | November 1, 2023 | July 31, 2026 |
NCT05921149 | Not yet recruiting | N/A | Fasting Mimicking Diet (FMD) in Conjunction With Chemotherapy in Advanced Ovarian Cancer | May 25, 2024 | June 1, 2031 |
NCT06383507 | Not yet recruiting | Phase 1 | A Clinical Study of Anti-CD70 UCAR-T in Relapsed or Refractory Solid Tumors | April 22, 2024 | April 21, 2029 |
NCT05749211 | Not yet recruiting | N/A | Huaier Granule in Combination With Nilaparil in Therapy Patients With Stage III/IV BRCA Wild-type Ovarian Cancer | May 2023 | December 2025 |
NCT06430541 | Not yet recruiting | Phase 1 | A Phase 1b Study of Psilocybin Assisted Psychotherapy to Address Fear of Recurrence | December 2024 | December 2028 |
NCT05375526 | Not yet recruiting | N/A | Magtrial: Magtrace® as Tracer for Sentinel Lymph Node Detection in Early Stage Epithelial Ovarian Cancer | June 1, 2022 | October 1, 2024 |
NCT05641506 | Not yet recruiting | Phase 2 | A Chinese Patent Medicine Yangzhengxiaoji Capsule to Improve the Nausea of Niraparib in the Maintenance Treatment in Ovarian Cancer | December 2022 | May 2025 |
NCT05801796 | Not yet recruiting | Appraising Medical Trial Experiences of Ovarian Cancer Patients | April 2024 | April 2026 | |
NCT06063070 | Not yet recruiting | Phase 2 | First-line Maintenance Treatment With Fluzoparib Plus Bevacizumab in Advanced BRCA Wild Type Ovarian Cancer | October 18, 2023 | October 30, 2027 |
NCT06440018 | Not yet recruiting | INSPIRE: A Multi-Cancer Early Detection Study | June 20, 2024 | February 28, 2025 | |
NCT06305299 | Not yet recruiting | Phase 1 | Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells | July 2024 | March 2026 |
NCT04640480 | Not yet recruiting | Phase 1 | Dose-finding Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SNB-101(SN-38) in Patients With Tumors | June 21, 2024 | June 30, 2025 |
NCT05200260 | Not yet recruiting | Phase 2 | Surgery Combined With Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer | February 2022 | February 2027 |
NCT06268665 | Not yet recruiting | Phase 2 | Tart Cherry Juice as a Dietary Supplement for the Prevention of Paclitaxel-Induced Neuropathy | February 28, 2024 | June 2027 |
NCT04520139 | Not yet recruiting | Phase 1/Phase 2 | Effect of NAC on Preventing Chemo-Related Cognitive Impairments in Ovarian Ca Pts Treated W/ PBT | December 2024 | December 2026 |
NCT06321484 | Not yet recruiting | Phase 1 | Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer | May 2024 | October 31, 2031 |
NCT05187208 | Not yet recruiting | Phase 4 | PARP Inhibitor Oral Maintenance in Low-Risk Ovarian Cancer | January 2022 | December 2025 |
NCT06161272 | Not yet recruiting | Phase 2 | Fluzoparib With or Without Apatinib in Platinum-sensitive Relapsed Ovarian Cancer Previously Treated With PARPi | December 10, 2023 | January 10, 2026 |
NCT05460000 | Not yet recruiting | Phase 2 | A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy | June 1, 2024 | May 1, 2032 |
NCT05931055 | Not yet recruiting | The Effectiveness of Liquid Biopsy in Differential Diagnosis and Early Screening of Epithelial Ovarian Cancer | January 1, 2024 | January 1, 2032 | |
NCT05669768 | Not yet recruiting | Phase 2 | Study on the Efficacy and Toxicity of Pamiparib Combined With Tamoxifen in the Treatment of Epithelial Ovarian Cancer Patients With Biochemical Recurrence During First-line PARPi Maintenance Therapy | January 1, 2023 | December 1, 2024 |
NCT04214782 | Not yet recruiting | N/A | Detection of Ovarian Cancer Using an Artificial Intelligence Enabled Transvaginal Ultrasound Imaging Algorithm | October 1, 2022 | October 1, 2024 |
NCT04451369 | Not yet recruiting | N/A | Connected Prehabilitation Program During Neo Adjuvant Chemotherapy | May 2021 | September 2027 |
NCT05965141 | Not yet recruiting | Phase 1/Phase 2 | Aribulin Combined With Carboplatin and Bevacizumab in the Treatment of Ovarian Cancer | August 1, 2023 | June 1, 2025 |
NCT05044871 | Not yet recruiting | Phase 2 | Biomarker-driven Targeted Therapy in Patients With Recurrent Platinum-resistant Epithelial Ovarian Cancer | January 1, 2023 | December 1, 2027 |
NCT06127446 | Not yet recruiting | The Registry of Genetic Alterations of Taiwan Ovarian Cancer | November 15, 2023 | December 31, 2028 | |
NCT05052632 | Not yet recruiting | Evaluating a New Gonadotoxic Risk Stratification System | April 2024 | May 2028 | |
NCT05952453 | Not yet recruiting | Phase 2 | Newly Diagnosed Stage III/IV Ovarian Cancer, Neoadjuvant Carbo/Taxol/Pembro, Maintenance Olaparib/Pembro | May 26, 2024 | September 30, 2025 |
NCT06412510 | Not yet recruiting | Phase 1/Phase 2 | Prehabilitation for EOC, Fallopian Tube, Primary Peritoneal Carcinoma and Pancreatic Cancer w/ NACT | June 1, 2024 | February 10, 2025 |
NCT06211023 | Not yet recruiting | Phase 2/Phase 3 | A Study of SHR-A1921 With or Without Carboplatin in Subjects With Ovarian Cancer | February 15, 2024 | June 15, 2026 |
NCT05567601 | Not yet recruiting | Phase 1 | Doxil/Caelyx BE Study | November 30, 2023 | April 1, 2024 |
NCT06238284 | Not yet recruiting | HER2 Expression in Gynecological Malignant Tumors in Chongqing Area of China | January 26, 2024 | May 31, 2024 | |
NCT06366490 | Not yet recruiting | Phase 1 | Safety and Immunogenicity of Innocell Autologous Cellular Immunotherapy in Recurrent Epithelial Ovarian Cancer | June 1, 2024 | March 1, 2025 |
NCT05597527 | Not yet recruiting | Phase 2 | Fluzopari Combined With Apatinib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer | November 1, 2022 | May 31, 2025 |
NCT06283875 | Not yet recruiting | The Exploration of Personalized ctDNA Based MRD in the Clinical Significance of Cervical Cancer | March 1, 2024 | January 30, 2029 | |
NCT03818282 | Not yet recruiting | Phase 2 | Efficacy and Safety of Paclitaxel for Injection (Albumin-bound) for First-line Chemotherapy of Ovarian Cancer | March 1, 2019 | December 31, 2024 |
NCT06342986 | Not yet recruiting | Phase 1 | Intraperitoneal FT536 in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer | August 1, 2024 | June 30, 2029 |
NCT06040970 | Not yet recruiting | Phase 1/Phase 2 | Sacituzumab Govitecan in Combination With Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial Cancer | October 2024 | September 7, 2026 |
NCT05684731 | Not yet recruiting | Phase 1 | Safety and Efficacy of KM1 in Subjects With Recurrent or Refractory Ovarian Cancer | February 1, 2023 | June 1, 2026 |
NCT06399757 | Not yet recruiting | Phase 1/Phase 2 | A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors | May 2024 | May 2027 |
NCT06433219 | Not yet recruiting | Phase 2 | Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302) | July 26, 2024 | January 25, 2028 |
NCT05043402 | Not yet recruiting | Phase 3 | A Study of Navicixizumab in Patients With Platinum Resistant Ovarian Cancer | November 30, 2022 | August 15, 2024 |
NCT06329323 | Not yet recruiting | SerUm and Plasma MicroRNAs in Malignant Ovarian gERm Cell Tumours | April 14, 2024 | April 2028 | |
NCT05496517 | Not yet recruiting | Ovarian Cancer Individualized Scoring System Scoring System | November 11, 2022 | November 22, 2023 | |
NCT06394492 | Not yet recruiting | Phase 3 | SHR-A1921 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer | May 31, 2024 | December 31, 2026 |
NCT06457997 | Not yet recruiting | Phase 1 | A Study of PHN-010 in Patients With Advanced Solid Tumors | July 2024 | July 2027 |
NCT05450055 | Not yet recruiting | N/A | Intraperitoneal Lidocaine in Ovarian Cancer Surgery | July 18, 2022 | July 30, 2029 |
NCT04828616 | Not yet recruiting | Phase 2 | Study of DP303c Injection in Patients With Advanced Ovarian Cancer | July 2021 | July 2024 |
NCT06284343 | Not yet recruiting | Development and Validation of a Risk Prediction Model for Venous Thromboembolism in Gynecological Cancer Patients Undergoing Systemic Antineoplastic Treatment: The Gynecological Cancer Associated Thrombosis (GynCAT) Study | April 1, 2024 | September 30, 2026 | |
NCT05316376 | Not yet recruiting | Phase 2 | Effect of Albumin-bound Paclitaxel Plus Carboplatin Compared With Paclitaxel Plus Carboplatin in Patients Receiving Neoadjuvant Chemotherapy for Advanced Ovarian, Fallopian Tube or Peritoneal Cancer: A Phase 2 Single Center Clinical Trial | May 1, 2022 | April 30, 2025 |
NCT06139783 | Not yet recruiting | N/A | Combined Program of Supervised Physical Exercise and Nutritional Counseling in Ovarian Cancer Patients on Frontline Maintenance Treatment With PARP Inhibitors | September 2024 | August 2025 |
NCT06377267 | Recruiting | Phase 2 | Status of HRD That Lead to a Benefit From Olaparib in Combination With Bevacizumab (STROBE Trial) | February 6, 2024 | September 2025 |
NCT06458361 | Recruiting | Identification of Risk Factors and Construction of Prediction Model for Postoperative Intestinal Anastomotic Leakage in Ovarian Cancer | January 1, 2018 | November 1, 2024 | |
NCT04294927 | Recruiting | N/A | TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention | March 1, 2020 | February 17, 2040 |
NCT06253520 | Recruiting | Phase 1 | Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer | May 16, 2024 | June 15, 2033 |
NCT05827614 | Recruiting | Phase 1 | Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), in Subjects With Tumors With Oncogene Amplifications | March 24, 2023 | September 30, 2027 |
NCT06037213 | Recruiting | A Real-World Patient-Reported Outcomes Study in Patients With Long-Term Use of Niraparib | August 23, 2023 | January 31, 2024 | |
NCT05048407 | Recruiting | N/A | Sirius in Gynaecological Laparoscopic Surgery | May 30, 2023 | June 30, 2024 |
NCT05704621 | Recruiting | Phase 2 | Secondary Cytoreductive Surgery (CRS) in Patients With Relapsed Ovarian Cancer Who Have Progressed on PARP Inhibitor Maintenance | December 1, 2023 | December 28, 2028 |
NCT06182917 | Recruiting | Prognostic Value of MRD Detection in CA125 Non-sensitive Ovarian Cancer Patients | October 1, 2023 | June 30, 2026 | |
NCT01977274 | Recruiting | N/A | Predictive Clinical and Biological Parameters in Gynecological Cancer | December 2013 | December 2033 |
NCT04657068 | Recruiting | Phase 1/Phase 2 | A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors | December 13, 2020 | June 2025 |
NCT05129969 | Recruiting | Registry Platform Ovarian and Endometrial Cancer | November 25, 2021 | December 2027 | |
NCT06103916 | Recruiting | Prospective RegIstration Of the peRformance of the IoTa ADNEX Model in Dutch gYnaecological Practice | July 15, 2022 | May 2028 | |
NCT05226507 | Recruiting | Phase 1 | A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer | December 31, 2021 | June 2025 |
NCT06250686 | Recruiting | N/A | Exercise and Nutrition Intervention in Ovarian Cancer | January 10, 2024 | December 31, 2025 |
NCT04188652 | Recruiting | Diagnosing Ovarian Cysts - the DOC Study | January 1, 2020 | December 2025 | |
NCT05059782 | Recruiting | N/A | Efficacy and Safety of Involving Field Radiotherapy in the Oligo-lesions(Metastasis/Recurrent/Refractory) of Ovarian Cancer | October 10, 2021 | September 1, 2024 |
NCT05259696 | Recruiting | Phase 1/Phase 2 | Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01) | February 11, 2022 | June 2025 |
NCT04751435 | Recruiting | N/A | Developing New Educational Materials About Genetic Testing for a Diverse Group of Cancer Patients | November 16, 2021 | August 31, 2026 |
NCT05922930 | Recruiting | Phase 1/Phase 2 | Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer | October 11, 2023 | July 1, 2028 |
NCT05099978 | Recruiting | Asian Multicenter Prospective Study of ctDNA Sequencing | November 1, 2021 | December 31, 2024 | |
NCT06257264 | Recruiting | Phase 1 | A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors | February 28, 2024 | December 31, 2026 |
NCT05605535 | Recruiting | Phase 2 | Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer | February 7, 2023 | May 15, 2026 |
NCT04473833 | Recruiting | N/A | Transvaginal Ultrasonography as a Screening Method for Ovarian Cancer | December 19, 1988 | December 31, 2025 |
NCT05649072 | Recruiting | N/A | Identifying Underserved Individuals inTexas With Hereditary Cancer Risk Using Mobile Mammography Units and Telegenetics. | November 18, 2022 | February 2, 2027 |
NCT02632448 | Recruiting | Phase 1/Phase 2 | A Study of LY2880070 in Participants With Advanced or Metastatic Cancer | May 16, 2016 | September 30, 2025 |
NCT05239143 | Recruiting | Phase 1 | P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors | February 15, 2022 | April 2039 |
NCT04945187 | Recruiting | N/A | Patient-Reported Outcomes Among Women Wtih Gynecological Cancer (The CONNECT Study) | May 17, 2021 | February 1, 2024 |
NCT06249308 | Recruiting | Liquid Biopsy-based Early Detection of Ovarian Cancer: a Proof-of-concept Study ( PROFOUND-OC ) | December 18, 2023 | December 31, 2026 | |
NCT04282356 | Recruiting | Phase 2 | Intensive Intraperitoneal Therapy in Advanced Ovarian Cancer | September 15, 2020 | December 2030 |
NCT05056077 | Recruiting | N/A | Improving Nutrition and Physical Activity for Cancer Survivors (Tools To Be Fit) | October 21, 2021 | December 31, 2027 |
NCT05494580 | Recruiting | Phase 1/Phase 2 | Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer | September 22, 2022 | August 10, 2025 |
NCT05429970 | Recruiting | N/A | A Study Comparing Perioperative Stress Reduction vs. Standard of Care in Ovarian Cancer (PRESERVE) | June 17, 2022 | June 17, 2025 |
NCT04981119 | Recruiting | Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing | October 29, 2021 | December 2026 | |
NCT05574673 | Recruiting | Characterization of Epithelial Ovarian Cancer Patients in Terms of Homologous Recombination Phenotype | December 1, 2022 | December 1, 2028 | |
NCT06240598 | Recruiting | Phase 2 | A Study of Second Look Laparoscopy (SLL) in People With Ovarian Cancer Who Have Completed Their First Course of Chemotherapy | January 26, 2024 | January 2026 |
NCT04414683 | Recruiting | Factors Affecting the Prognosis of Early Ovarian Cancer | April 13, 2020 | December 31, 2024 | |
NCT03787056 | Recruiting | N/A | Predictive Value of Progastrin Titer at Diagnosis and of Progastrin Kinetics During Treatment in Cancer Patients | December 4, 2018 | January 4, 2028 |
NCT05646680 | Recruiting | N/A | A Performance Study of (Opportunistic) Salpingectomy | December 9, 2022 | January 30, 2026 |
NCT05640024 | Recruiting | Prospective Cohort Study for Validation of Predictive Immune Biomarkers of Response to PAPR Inhibitors | November 6, 2022 | October 30, 2025 | |
NCT05467670 | Recruiting | Phase 2 | Safety and Efficacy of Anti-CD47, ALX148 in Combination With Liposomal Doxorubicin and Pembrolizumab in Recurrent Platinum-resistant Ovarian Cancer | December 16, 2022 | December 2027 |
NCT05498597 | Recruiting | Phase 1 | AMT-151 in Patients With Selected Advanced Solid Tumours | January 25, 2023 | October 30, 2024 |
NCT03150121 | Recruiting | N/A | Biomarkers for Early Detection of Ovarian Cancer Using Uterine Lavage | June 29, 2014 | December 31, 2024 |
NCT03958240 | Recruiting | N/A | Deciphering Mechanisms Underlying Cancer Immunogenicity | January 17, 2020 | September 2029 |
NCT05446545 | Recruiting | Bespoke ctDNA Assay for Recurrence and Treatment Response Monitoring in Advanced Epithelial Ovarian Cancer | September 1, 2021 | December 31, 2026 | |
NCT05000294 | Recruiting | Phase 1/Phase 2 | Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types | December 7, 2021 | December 2025 |
NCT04560452 | Recruiting | Drug Intensive Monitoring Study of Olaparib in Clinical Practice Among Chinese Patients | March 15, 2021 | December 31, 2025 | |
NCT05974150 | Recruiting | Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring | July 19, 2023 | December 31, 2024 | |
NCT05316129 | Recruiting | Phase 1 | Infusion of Autologous T Cells Engineered to Target FSH Receptor in Recurrent Ovarian Cancer | April 28, 2022 | March 2029 |
NCT05030805 | Recruiting | Transcriptional Map of Ovarian Cancer at the Single Cell Level | May 1, 2022 | April 2030 | |
NCT06264921 | Recruiting | Phase 1 | A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors | February 23, 2024 | May 2025 |
NCT06118307 | Recruiting | Shanghai Ovarian Cancer and Family Care Project | January 1, 2013 | October 13, 2028 | |
NCT06085404 | Recruiting | N/A | Patients Derived Organoids in Ovarian Cancer | December 20, 2021 | December 20, 2023 |
NCT05693987 | Recruiting | Early Detection of Ovarian Cancer Using Plasma Cell-free DNA Fragmentomics (Prospective Study) | November 1, 2022 | April 30, 2023 | |
NCT05829057 | Recruiting | Phase 1 | The IIT Study of Evaluation of P-IL-2 Single Agent and With Anti-PD-1 | May 23, 2023 | June 21, 2025 |
NCT02917798 | Recruiting | Evaluating an Alternative Clinical Genetics Cancer Care Delivery Model: A Pilot Study of Patient Outcomes | July 12, 2016 | September 2025 | |
NCT05903807 | Recruiting | Phase 2 | [68Ga]Ga-FAPI-46 PET/CT in Ovarian Cancer | November 17, 2023 | January 1, 2035 |
NCT05633836 | Recruiting | N/A | MicroFluO: FLUorescence-guided Surgery for Ovarian Cancer | May 2023 | February 2024 |
NCT05156892 | Recruiting | Phase 1 | Tamoxifen and SUBA-Itraconzole Combination Testing in Ovarian Cancer | September 4, 2022 | January 1, 2025 |
NCT04742075 | Recruiting | Phase 2 | Olaparib, Durvalumab and UV1 in Relapsed Ovarian Cancer | December 15, 2021 | December 15, 2026 |
NCT03287271 | Recruiting | Phase 1/Phase 2 | ROCKIF Trial: Re-sensitization of Carboplatin-resistant Ovarian Cancer With Kinase Inhibition of FAK | February 6, 2018 | October 2024 |
NCT03842982 | Recruiting | Phase 3 | Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer (CHIPPI) | April 1, 2019 | August 1, 2028 |
NCT05065021 | Recruiting | Phase 2 | Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor | February 23, 2023 | June 6, 2025 |
NCT04122235 | Recruiting | N/A | The Lifestyle and Empowerment Techniques in Survivorship of Gynecologic Oncology Study | November 18, 2019 | December 31, 2030 |
NCT05523700 | Recruiting | N/A | Value-based Integrated Recommendation Software Guiding Ovarian Cancer Treatment (VIRGO2) | October 17, 2023 | October 1, 2028 |
NCT05864144 | Recruiting | Phase 1/Phase 2 | A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors | May 31, 2023 | June 2027 |
NCT06238479 | Recruiting | Phase 1 | A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors | March 5, 2024 | March 4, 2027 |
NCT05739981 | Recruiting | Phase 1/Phase 2 | Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer | February 10, 2023 | January 30, 2028 |
NCT05113368 | Recruiting | Phase 2 | Regorafenib Combined With Fulvestrant in Recurrent Low-Grade Serous Ovarian Cancer | June 28, 2022 | December 1, 2024 |
NCT05518253 | Recruiting | Phase 1 | A Clinical Study of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors | May 30, 2022 | May 30, 2025 |
NCT04520074 | Recruiting | Phase 3 | Adjuvant Chemotherapy of Three-step Regimen in BRCA1/2 Wide Type Ovarian Cancer (ACTS-2) | October 8, 2021 | September 2030 |
NCT06363123 | Recruiting | Plasma Metabolic Biomarkers for Multi-Cancer Diagnosis | March 29, 2024 | April 2025 | |
NCT05431530 | Recruiting | Assessment of Quality of Life After Low Anterior Resection During Cytoreductive Surgery for Advanced Ovarian Cancer | June 22, 2022 | May 31, 2027 | |
NCT05211557 | Recruiting | Phase 1/Phase 2 | Study of Fully Human B7H3 CAR-T in Treating Recurrent Malignant Ovarian Cancer | November 16, 2021 | August 31, 2026 |
NCT05287451 | Recruiting | N/A | Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study | May 10, 2022 | December 26, 2026 |
NCT05606692 | Recruiting | Phase 4 | Influences of Propofol and Sevoflurane Anesthesia in Ovarian Cancer (Anesthetics) | November 23, 2022 | September 30, 2027 |
NCT05427214 | Recruiting | N/A | Imaging Study on Halcyon 4.0 System for Patients Receiving Radiation Therapy | August 19, 2022 | October 2, 2024 |
NCT03010124 | Recruiting | N/A | Prognostic and Predictive Biomarkers in Ovarian Cancers | September 26, 2016 | September 2032 |
NCT03410784 | Recruiting | Phase 2 | Pembrolizumab With Chemotherapy in Front Line Advanced Ovarian, Primary Peritoneal and Fallopian Tube Cancer | April 1, 2018 | December 2024 |
NCT05738902 | Recruiting | Adherence and Compliance to ERAS in Gynecological Surgery | May 30, 2023 | March 31, 2025 | |
NCT05427487 | Recruiting | Phase 1 | Study of Intratumoral IVX037 in Patients With Advanced or Metastatic Solid Tumours | February 17, 2023 | September 1, 2024 |
NCT04969835 | Recruiting | Phase 1 | A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours | July 16, 2021 | June 30, 2023 |
NCT04575961 | Recruiting | Phase 2 | Study of Pembrolizumab Combination With Chemotherapy in Platinum-sensitive Recurrent Low-grade Serous Ovarian Cancer | February 22, 2022 | November 1, 2026 |
NCT06317610 | Recruiting | Artificial Intelligence Model for Growth Prediction of Ovarian Cancer Organoids | January 1, 2022 | May 30, 2024 | |
NCT04884360 | Recruiting | Phase 3 | D9319C00001- 1L OC Mono Global RCT | May 31, 2021 | July 2, 2025 |
NCT05092763 | Recruiting | N/A | Prehabilitation During the Neoadjuvant Window of Opportunity in Older Women With Ovarian Cancer | December 10, 2021 | August 31, 2024 |
NCT04606914 | Recruiting | Phase 2 | Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer | May 27, 2021 | May 31, 2028 |
NCT06395519 | Recruiting | Phase 1 | A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies | May 2024 | December 2026 |
NCT05086692 | Recruiting | Phase 1/Phase 2 | A Beta-only IL-2 ImmunoTherapY Study | August 27, 2021 | December 30, 2026 |
NCT06184867 | Recruiting | Early Phase 1 | Choices About Genetic Testing And Learning Your Risk With Smart Technology | October 26, 2023 | January 31, 2025 |
NCT04180371 | Recruiting | Phase 1/Phase 2 | Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression | November 7, 2019 | December 31, 2024 |
NCT04830709 | Recruiting | Non-interventional Study to Collect Real-world Clinical and Patient-reported Outcomes in Ovarian Cancer | June 15, 2021 | December 31, 2031 | |
NCT05788484 | Recruiting | Phase 1 | A Study of CDX-585 in Patients With Advanced Malignancies | May 11, 2023 | February 2026 |
NCT03412877 | Recruiting | Phase 2 | Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer | September 6, 2018 | March 23, 2028 |
NCT06324175 | Recruiting | Spatial Radiogenomics of Ovarian Cancer: Implementation of a Lesion-specific 3D-printed Mould Pipeline in the Clinical Workflow for Image-guided Tissue Multi-sampling of Ovarian Tumours | February 1, 2024 | December 31, 2026 | |
NCT05051722 | Recruiting | Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer | August 3, 2021 | December 30, 2025 | |
NCT06459271 | Recruiting | N/A | Feasibility of CALM in Patients With Ovarian Cancer | June 10, 2024 | August 10, 2025 |
NCT05349227 | Recruiting | N/A | Comprehensive Outcomes for After Cancer Health | June 23, 2022 | December 2025 |
NCT06071286 | Recruiting | N/A | SEQUENTIAL PROFILING OF TUMOR-DERIVED CIRCULATING CELL-FREE DNA (ctDNA) IN ADVANCED OVARIAN CANCER PATIENTS | November 1, 2023 | November 1, 2025 |
NCT06215950 | Recruiting | Phase 1 | A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Gynecologic Cancer | January 10, 2024 | December 31, 2027 |
NCT03872947 | Recruiting | Phase 1 | A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors | April 26, 2019 | March 2025 |
NCT05886075 | Recruiting | Early Phase 1 | A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Advanced Solid Tumors | March 30, 2023 | March 2025 |
NCT06229522 | Recruiting | Patients Derived Organoids as a Promising Tool to Tailor Ovarian Cancer Therapies (PANDORA). | November 16, 2023 | December 31, 2037 | |
NCT05866679 | Recruiting | Phase 1 | Early Assessment of Ovarian Cancer Aggressiveness by Metabolic Imaging | April 12, 2024 | August 31, 2028 |
NCT06437353 | Recruiting | Phase 2 | Surufatinib Combined With Carboplatin/Paclitaxel and Surufatinib Combined With Olaparib as First-line and Maintenance Therapy for Newly Diagnosed High-risk Ovarian Cancer | May 25, 2024 | October 30, 2027 |
NCT04140526 | Recruiting | Phase 1/Phase 2 | Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC | September 16, 2020 | December 31, 2027 |
NCT03540017 | Recruiting | Phase 1 | HIPEC After Initial CRS in Patients Who Have Received NACT | March 12, 2019 | July 5, 2025 |
NCT01034033 | Recruiting | Genetic & Pathological Studies of BRCA1/BRCA2: Associated Tumors & Blood Samples | August 2001 | January 2099 | |
NCT05071937 | Recruiting | Phase 2 | ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer | April 13, 2023 | March 1, 2031 |
NCT02884648 | Recruiting | Phase 2 | Bevacizumab in Ovarian Cancer Patients With Disease at Second-Look Surgery | November 15, 2016 | February 1, 2025 |
NCT05215574 | Recruiting | Phase 1 | Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors | March 31, 2022 | March 2026 |
NCT05272462 | Recruiting | Phase 2 | Oral Minoxidil for the Treatment of Recurrent Platinum Resistant Epithelial Ovarian Cancer | December 13, 2021 | December 31, 2024 |
NCT06048367 | Recruiting | Phase 1 | Carbon Nanoparticle-Loaded Iron [CNSI-Fe(II)] in the Treatment of Advanced Solid Tumor | October 14, 2022 | February 29, 2024 |
NCT06014190 | Recruiting | Phase 2 | HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer | December 18, 2023 | December 31, 2027 |
NCT04644068 | Recruiting | Phase 1/Phase 2 | Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies | November 12, 2020 | December 15, 2026 |
NCT04997096 | Recruiting | N/A | Exercise as a Preventive Agent to Combat Immobility in Patients With Ovarian or Endometrial Cancers Receiving Chemotherapy | April 2, 2022 | April 30, 2025 |
NCT05989724 | Recruiting | Phase 1 | A First-in-Human Study of SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors | September 19, 2023 | March 2026 |
NCT06152731 | Recruiting | Phase 2 | HRD Tests for Ovarian cancER | February 15, 2024 | June 2031 |
NCT02288676 | Recruiting | DOvEEgene: Diagnosing Ovarian and Endometrial Cancer Early Using Genomics | January 2014 | October 2026 | |
NCT04066335 | Recruiting | Study to Evaluate the Safety of Nanoxel M Inj. | September 18, 2019 | August 2024 | |
NCT05955105 | Recruiting | Phase 1/Phase 2 | A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies | July 25, 2023 | July 24, 2026 |
NCT06303505 | Recruiting | Phase 1/Phase 2 | FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC | May 2024 | January 2027 |
NCT05206890 | Recruiting | A Non-interventional Registry Study of Fluzoparib in the Treatment of Ovarian Cancer | January 14, 2022 | December 31, 2032 | |
NCT03556228 | Recruiting | Phase 1 | Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma | June 8, 2018 | June 2026 |
NCT05961124 | Recruiting | Phase 2 | Alternative Dosing Of Niraparib To Decrease Dose Interruption In First Line Maintenance Treatment For Ovarian Cancer | August 21, 2023 | September 2027 |
NCT06447064 | Recruiting | Cancer Loyalty Card Study 2 (CLOCS-2) | April 29, 2024 | March 31, 2027 | |
NCT05572684 | Recruiting | Phase 1/Phase 2 | A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors | October 6, 2022 | November 2025 |
NCT05983276 | Recruiting | Phase 2 | Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer | November 16, 2023 | August 28, 2031 |
NCT04710797 | Recruiting | N/A | Lymphadenectomy in Early Ovarian Cancer | January 31, 2021 | December 31, 2028 |
NCT01441089 | Recruiting | Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis | May 21, 2012 | ||
NCT05080556 | Recruiting | Phase 2 | Adaptive ChemoTherapy for Ovarian Cancer in Patients With Replased Platinum-sensitive High Grade Serous or High Grade Endometrioid Ovarian Cancer | May 24, 2023 | November 1, 2027 |
NCT06380660 | Recruiting | Phase 1/Phase 2 | Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors | March 22, 2024 | March 21, 2029 |
NCT06051695 | Recruiting | Phase 1/Phase 2 | A Study to Evaluate the Safety and Efficacy of A2B694, a Logic-gated CAR T, in Subjects With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression | April 3, 2024 | June 2029 |
NCT04770376 | Recruiting | Evaluation of the Predictive Value of Blood Levels of Angiopoietin 1 and Endothelial Internal Tunica Cell Kinase 2 in Patients With Ovarian Cancer Treated With Chemotherapy Associated to Bevacizumab | October 12, 2020 | December 2023 | |
NCT05697198 | Recruiting | PRospective rEgistry OF Advanced Stage cancER (PREFER) Patients to Assess Prevalence of Actionable Biomarkers and Driver Mutations to Address Disparities in Precision Medicine | April 19, 2021 | September 2024 | |
NCT05472532 | Recruiting | N/A | Evaluation of an Automated System to Culture Metastatic Patient Circulating Tumor Cells in Embryonated Chicken Eggs (in Ovo Culture) | February 14, 2023 | December 14, 2024 |
NCT04511871 | Recruiting | Phase 1 | A Phase I Trial of CCT303-406 in Patients With Relapsed or Refractory HER2 Positive Solid Tumors | July 9, 2020 | March 29, 2025 |
NCT03746431 | Recruiting | Phase 1/Phase 2 | A Phase 1/2 Study of [225Ac]-FPI-1434 Injection | January 17, 2019 | June 2026 |
NCT06307249 | Recruiting | Phase 1 | Precision Therapy for Solid Tumors: Synergistic CDK4/6 Inhibition and Anti-VEGF Targeting LncRNA | February 15, 2023 | December 2027 |
NCT04284969 | Recruiting | N/A | PROADAPT-ovary/EWOC-2 | June 3, 2021 | March 3, 2026 |
NCT05468190 | Recruiting | Phase 1 | A Clinical Research About CD70-positive Advanced/Metastatic Solid Tumors Treated by CD70-targeted CAR-T | July 17, 2022 | July 17, 2025 |
NCT05142033 | Recruiting | Avera Cancer Sequencing and Analytics Protocol (ASAP) | November 1, 2021 | December 31, 2026 | |
NCT02830724 | Recruiting | Phase 1/Phase 2 | Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers | April 6, 2017 | January 1, 2028 |
NCT05857397 | Recruiting | A Collaborative Trial of Niraparib to Evaluate Patients With Ovarian Cancer in the Expanded Access Program in Latin America | July 21, 2023 | April 30, 2025 | |
NCT04847063 | Recruiting | Phase 1 | Individualized Response Assessment to Heated Intraperitoneal Chemotherapy (HIPEC) for the Treatment of Peritoneal Carcinomatosis From Ovarian, Colorectal, Appendiceal, or Peritoneal Mesothelioma Histologies | October 19, 2021 | December 30, 2031 |
NCT05198804 | Recruiting | Phase 1/Phase 2 | A Study of ZN-c3 and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer | January 27, 2022 | November 2023 |
NCT05032040 | Recruiting | Phase 2 | A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies | July 21, 2022 | May 30, 2025 |
NCT05458973 | Recruiting | Circulating Tumor DNA and BRCA Reversion Mutation in Advanced or Recurrent Ovarian Cancer Patients With Germline Mutation. | October 31, 2017 | October 2024 | |
NCT05360680 | Recruiting | Phase 1 | A Phase 1 in Patients With HLA-A*0201+ and WT1+ Recurrent/Metastatic Cancers | June 14, 2022 | December 2026 |
NCT03917043 | Recruiting | Phase 1 | APG-2449 in Patients With Advanced Solid Tumors | May 27, 2019 | February 2025 |
NCT05715216 | Recruiting | Phase 2 | EON: A Single-arm Phase II Study of Etigilimab (OMP-313M32) in Combination With Checkpoint Inhibition (Nivolumab) in Patients With Platinum-resistant, Recurrent Epithelial Ovarian Cancer | March 24, 2023 | April 30, 2025 |
NCT05813509 | Recruiting | N/A | Individualized Precision Treatment Based on Ovarian Cancer Organoid Model | December 1, 2022 | February 1, 2025 |
NCT06120972 | Recruiting | Phase 2 | Upfront Maintenance Olaparib in Advanced Ovarian Cancer BRCAwt Patients With Known Homologous Recombination Deficiency | January 17, 2024 | December 31, 2029 |
NCT04768270 | Recruiting | The Culture of Ovarian Cancer Organoids and Drug Screening | April 12, 2022 | December 31, 2024 | |
NCT05856409 | Recruiting | Clinical Application of 68Ga-FAPI PET Imaging in Detection of Ovarian Cancer Recurrence | May 10, 2023 | December 31, 2025 | |
NCT05848739 | Recruiting | Phase 1 | A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors | June 5, 2023 | May 31, 2027 |
NCT05420545 | Recruiting | Phase 1 | A Clinical Study of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors | December 31, 2021 | December 31, 2024 |
NCT05801783 | Recruiting | Early Phase 1 | A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Ovarian Cancer | December 2, 2022 | December 2, 2025 |
NCT06251947 | Recruiting | Phase 2 | Efbemalenograstim Alfa Injection for Ovarian or Cervical Cancer Receiving Chemotherapy Regimen | April 15, 2024 | December 2026 |
NCT05636111 | Recruiting | Phase 1 | Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian Cancer | July 12, 2023 | July 31, 2026 |
NCT05001282 | Recruiting | Phase 1/Phase 2 | A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα) | September 13, 2021 | June 15, 2025 |
NCT06222008 | Recruiting | Study on Symptom Clusters During Chemotherapy in Ovarian Cancer Patients With Different Chinese Medicine Constitution | January 30, 2022 | June 30, 2024 | |
NCT05708950 | Recruiting | Phase 1/Phase 2 | A Clinical Trial of KVA12123 Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101) | March 3, 2023 | December 31, 2024 |
NCT04585750 | Recruiting | Phase 1/Phase 2 | The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) | October 29, 2020 | July 14, 2026 |
NCT05123807 | Recruiting | Phase 2 | Secondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Mucinous Ovarian Cancer (HI-MOC Study) | January 7, 2022 | February 2, 2027 |
NCT02012699 | Recruiting | Integrated Cancer Repository for Cancer Research | November 1, 2013 | December 2099 | |
NCT05697601 | Recruiting | Predictors of Ovarian Cancer and Endometrial Cancer for Artificial-Intelligence-Based Screening Tools | February 28, 2023 | June 30, 2024 | |
NCT04502602 | Recruiting | Phase 1 | Niraparib and Neratinib in Advanced Solid Tumors With Expansion Cohort in Advanced Ovarian Cancer | August 24, 2020 | May 31, 2029 |
NCT03702309 | Recruiting | Liquid Biopsy Evaluation and Repository Development at Princess Margaret | August 3, 2017 | July 6, 2024 | |
NCT05953883 | Recruiting | N/A | PROTEOGENOMIC SIGNATURES ANALYSIS IN OVARIAN CANCER | November 17, 2022 | March 17, 2024 |
NCT05812027 | Recruiting | A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors | June 26, 2023 | January 14, 2027 | |
NCT05179824 | Recruiting | Tempus Priority Study: A Pan-tumor Observational Study | October 19, 2020 | October 19, 2030 | |
NCT05445778 | Recruiting | Phase 3 | Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer (GLORIOSA) | December 27, 2022 | April 2029 |
NCT05430906 | Recruiting | Phase 2 | AK104 Combined With Chemotherapy as Neoadjuvant Treatment for Advanced Ovarian Cancer | November 25, 2022 | January 2026 |
NCT05025878 | Recruiting | 13C-Glucose Tracing of Tumour and T Cells in the Ascites of Ovarian Cancer Patients. | October 20, 2021 | August 2023 | |
NCT04918186 | Recruiting | Phase 2 | Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer | May 3, 2022 | June 2025 |
NCT04507841 | Recruiting | Phase 2 | Niraparib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer | July 1, 2020 | July 1, 2023 |
NCT06337084 | Recruiting | Phase 1 | Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid Tumors | April 10, 2024 | June 2025 |
NCT05183984 | Recruiting | Phase 2 | Niraparib With beVAcizumab After Complete cytoreductioN in Patients With ovArian Cancer | February 1, 2022 | February 2030 |
NCT03755739 | Recruiting | Phase 2/Phase 3 | Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors | November 1, 2018 | November 1, 2033 |
NCT04679064 | Recruiting | Phase 3 | Trial on NIraparib-TSR-042 (Dostarlimab) vs Physician's Choice CHEmotherapy in Recurrent, Ovarian, Fallopian Tube or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment | December 1, 2020 | January 1, 2025 |
NCT05489211 | Recruiting | Phase 2 | Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) | September 6, 2022 | August 19, 2026 |
NCT05364879 | Recruiting | N/A | Prehabilitation for Ovarian Cancer Patients | January 3, 2023 | August 31, 2025 |
NCT06216496 | Recruiting | N/A | Evaluation of Amino Acid Metabolism Changes in Ovarian Cancer | March 11, 2024 | December 2026 |
NCT04747717 | Recruiting | N/A | Efficacy of Neoadjuvant Therapy With Cisplatin Plus Mitomycin C in BRCA1-Mutated Ovarian Cancer | October 1, 2020 | October 1, 2025 |
NCT04354246 | Recruiting | Phase 1 | COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies | March 31, 2020 | March 30, 2025 |
NCT04752865 | Recruiting | Effects of Cytotoxic Chemotherapy and PARP Inhibition on the Genomic Contexture of Ovarian Cancer | February 9, 2018 | June 2024 | |
NCT02407509 | Recruiting | Phase 1 | Phase I Trial of VS-6766 Alone and in Combination With Everolimus | June 17, 2013 | May 2024 |
NCT04038619 | Recruiting | Phase 1 | Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients | February 1, 2021 | December 31, 2025 |
NCT06083844 | Recruiting | Phase 2 | Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline Therapy | December 12, 2023 | September 30, 2027 |
NCT05746897 | Recruiting | Phase 1 | A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors | April 13, 2023 | September 30, 2027 |
NCT05410028 | Recruiting | New Serum Biomarkers for Monitoring Early Diagnosis of Ovarian Cancer Recurrence | March 3, 2022 | March 3, 2026 | |
NCT05769517 | Recruiting | PREDICTION OF GERMLINE BRCA 1/2 GENES FROM HEALTHY OVARIES | March 20, 2023 | May 2, 2026 | |
NCT05446298 | Recruiting | Phase 2 | ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer | December 22, 2022 | June 30, 2026 |
NCT05029154 | Recruiting | N/A | Exercise Preconditioning in Ovarian Cancer | October 21, 2021 | October 2024 |
NCT05870748 | Recruiting | Phase 2/Phase 3 | REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1 | July 12, 2023 | February 2026 |
NCT06117384 | Recruiting | Systems Oncology Approach to Optimize Ovarian Cancer Treatment | January 1, 2022 | December 31, 2027 | |
NCT05761561 | Recruiting | N/A | Trial of Exercise and Lifestyle in Women With Ovarian Cancer | April 19, 2023 | June 2027 |
NCT06032975 | Recruiting | PRO for Fighting FT in Ovarian Cancer | October 30, 2023 | September 1, 2027 | |
NCT05053230 | Recruiting | N/A | A Study Evaluating the Integrative Medicine at Home (IM@HOME) Program in People With Cancer | September 20, 2021 | September 20, 2024 |
NCT05358639 | Recruiting | Phase 1 | Combination of Olaparib and Navitoclax in Women With HGSC and TNBC | November 9, 2022 | April 28, 2025 |
NCT05220033 | Recruiting | N/A | Journey Ahead: Enhancing Coping and Communication for Women Diagnosed With Gynecological Cancer | July 14, 2020 | December 1, 2025 |
NCT05708703 | Recruiting | Assessing the Time Demands of Cancer | November 13, 2023 | December 31, 2030 | |
NCT05740956 | Recruiting | Phase 1 | A Study of Hansoh (HS)-10502 in Patients With Advanced Solid Tumors | June 9, 2023 | October 1, 2026 |
NCT03045965 | Recruiting | N/A | Hysterectomy and OPPortunistic SAlpingectomy | June 1, 2017 | December 2053 |
NCT02754115 | Recruiting | An Audit of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy | April 2016 | January 2027 | |
NCT05225428 | Recruiting | N/A | Video Education With Result Dependent dIsclosure | August 4, 2022 | September 1, 2026 |
NCT04787289 | Recruiting | Phase 2 | A Comparison of 2 Standard Doses of Bevacizumab in Combination With Chemotherapy in Epithelial Ovarian Cancer | September 10, 2021 | January 31, 2025 |
NCT05537844 | Recruiting | Longitudinal Sample Collection to Investigate Adaptation and Evolution of Ovarian High-grade Serous Carcinoma | October 27, 2021 | April 27, 2025 | |
NCT05891171 | Recruiting | Phase 1 | Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers | October 13, 2023 | August 2025 |
NCT05601752 | Recruiting | Phase 2 | ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3) | June 26, 2023 | August 12, 2026 |
NCT04921527 | Recruiting | Phase 3 | Chiauranib Plus Weekly Paclitaxel in Patients With Platinum-refractory or Platinum-resistant Recurrent Ovarian Cancer | December 20, 2021 | July 31, 2025 |
NCT05265117 | Recruiting | The Efficacy of Hyperthermic Intraperitoneal Chemotherapy to Ovarian Cancer Patients With Homologous Recombination Repair Defect and Residual: a Prospective Cohort Study | April 1, 2022 | March 30, 2025 | |
NCT06390995 | Recruiting | Phase 1/Phase 2 | A Study of TAK-853 in Adult Participants With Folate Receptor Alpha-Positive Advanced Ovarian Cancer And Other Solid Tumors | May 20, 2024 | September 30, 2026 |
NCT05043922 | Recruiting | Phase 2 | A Study to Evaluate the Efficacy and Safety of CYH33 in Patients With Recurrent/Persistent Ovary Clear Cell Carcinoma | August 13, 2021 | June 30, 2023 |
NCT05633342 | Recruiting | Project CADENCE (CAncer Detected Early caN be CurEd) | July 7, 2022 | May 2025 | |
NCT05251883 | Recruiting | A Study to Analyze Data on Metastatic Ovarian Cancer Using Multi-omics | January 1, 2022 | December 2026 | |
NCT06298877 | Recruiting | N/A | Frailty, Quality Of Life and Early Reversal of Temporary Defunctioning Stoma in Ovarian Cancer | March 11, 2024 | March 28, 2029 |
NCT04339140 | Recruiting | Phase 2 | Zafirlukast in Treatment of Marker Relapsed Ovarian Cancer | June 24, 2020 | December 31, 2024 |
NCT06281860 | Recruiting | Phase 1 | Treatment Pleural Carcinosis of Pressurized IntraThoracic Hyperthermic Aerosol Cisplatin Administration | November 24, 2023 | February 1, 2026 |
NCT02732860 | Recruiting | Personalized Patient Derived Xenograft (pPDX) Modeling to Test Drug Response in Matching Host | December 2015 | January 4, 2025 | |
NCT05103683 | Recruiting | Phase 1 | First in Human Study of TORL-1-23 in Participants With Advanced Cancer | November 17, 2021 | November 15, 2025 |
NCT05810701 | Recruiting | N/A | FRAGINOC Study: Screening and Geriatric Assessment and Intervention in Older Patients With Epithelial Ovarian Cancer | February 1, 2023 | December 31, 2027 |
NCT06234423 | Recruiting | Phase 1 | A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors | February 9, 2024 | August 31, 2027 |
NCT04214210 | Recruiting | N/A | The DIALOGUE Study: Swiss-Korean Billateral Collaboration | April 15, 2022 | December 31, 2024 |
NCT02672098 | Recruiting | Phase 1 | Hyperthermic Intraperitoneal Chemotherapy for Recurrent Ovarian Cancer | July 14, 2016 | April 2025 |
NCT05104515 | Recruiting | Phase 1 | First-in-human Study of OVM-200 as a Therapeutic Cancer Vaccine | November 1, 2021 | December 31, 2024 |
NCT00005095 | Recruiting | Specimen and Data Study for Ovarian Cancer Early Detection and Prevention | March 2000 | December 2040 | |
NCT04878094 | Recruiting | Phase 3 | A Study of Intra-operative Imaging in Women With Ovarian Cancer | May 3, 2021 | May 3, 2025 |
NCT04701645 | Recruiting | Phase 1 | Microdevice In Ovarian, Fallopian Tube, And Peritoneal Cancer | November 1, 2022 | June 2026 |
NCT05842629 | Recruiting | Improved Diagnosis of Ovarian Cancer | May 15, 2021 | December 2028 | |
NCT05973487 | Recruiting | Phase 1 | A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors | May 6, 2024 | December 30, 2026 |
NCT06171789 | Recruiting | Phase 1/Phase 2 | PRO1107 in Patients With Advanced Solid Tumors | January 29, 2024 | February 2027 |
NCT04805333 | Recruiting | Phase 1 | Phase 1 Dose Escalation of ArtemiCoffee | March 26, 2021 | December 2024 |
NCT03772028 | Recruiting | Phase 3 | Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC) | January 1, 2020 | April 1, 2026 |
NCT05797168 | Recruiting | Phase 1/Phase 2 | Phase I/IIa Study for AZD5335 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Solid Tumors | June 5, 2023 | November 1, 2027 |
NCT06052852 | Recruiting | Phase 1/Phase 2 | Study of BDC-3042 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Malignancies | October 11, 2023 | March 2028 |
NCT03275194 | Recruiting | Phase 2 | HIPEC in Ovarian Carcinoma Clinical Stage IIIC and IV During Interval Laparotomy | September 2, 2017 | December 1, 2026 |
NCT05620654 | Recruiting | Phase 1 | A Phase I Dose-finding Trial of Hyperthermic Intraperitoneal Paclitaxel Combined With Cisplatin | December 1, 2022 | May 1, 2023 |
NCT03452774 | Recruiting | SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry | January 1, 2018 | June 2027 | |
NCT05960630 | Recruiting | N/A | MIRRORS-RCT Pilot: Role of Robotic Interval Cytoreductive Surgery for Advanced Ovarian Cancer | October 2, 2023 | December 31, 2024 |
NCT05057013 | Recruiting | Phase 1/Phase 2 | HMBD-001 in Advanced HER3 Positive Solid Tumours | November 10, 2021 | September 2026 |
NCT05824247 | Recruiting | A Prospective Cohort Study of 68ga-FAPI-pet-ct Versus FDG-pet-ct for Ovarian Cancer | April 1, 2022 | June 1, 2025 | |
NCT05514028 | Recruiting | Evaluation of Salivary RNAs in the Presence of an Adnexal Mass of Ovarian Origin | May 4, 2022 | April 2026 | |
NCT06395844 | Recruiting | Phase 1/Phase 2 | Safety and Efficacy of Intraperitoneal Injection of METR-NK Cells as Neoadjuvant Therapy for Advanced Epithelial Ovarian Cancer | May 1, 2024 | December 31, 2026 |
NCT05914974 | Recruiting | Immunotherapy-related CRP Kinetics in Metastatic Gynecological Malignancies | September 11, 2023 | April 2035 | |
NCT05255471 | Recruiting | Phase 3 | MITO 35B: Olaparib Beyond Progression Compared to Platinum Chemotherapy After Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer Patients. | January 21, 2022 | January 21, 2028 |
NCT05964361 | Recruiting | Phase 1/Phase 2 | First-in-human Interleukin-15-transpresenting Wilms' Tumor Protein 1-targeting Autologous Dendritic Cell Vaccination in Cancer Patients | December 6, 2023 | September 1, 2025 |
NCT05796973 | Recruiting | Phase 3 | Measuring Oncological Value of Exercise and Statin | March 31, 2023 | December 31, 2027 |
NCT05787587 | Recruiting | Phase 1 | A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors | April 5, 2023 | September 2025 |
NCT04260802 | Recruiting | Phase 1/Phase 2 | A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers | October 6, 2020 | September 30, 2026 |
NCT05926336 | Recruiting | Phase 4 | The Effects of Using Different Anesthetics on the Prognosis of Primary Tumors and Its Mechanism of Action | May 23, 2023 | July 2026 |
NCT05123482 | Recruiting | Phase 1/Phase 2 | A Phase I/IIa Study of AZD8205 Given Alone or in Combination With Anticancer Drugs, in Participants With Advanced or Metastatic Solid Malignancies | October 18, 2021 | December 30, 2025 |
NCT04044859 | Recruiting | Phase 1 | ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS) | August 20, 2019 | April 30, 2037 |
NCT04590326 | Recruiting | Phase 1/Phase 2 | A Trial to Find Out How Safe REGN5668 is and How Well it Works When Given With Either Cemiplimab or REGN4018 | December 9, 2020 | April 27, 2027 |
NCT05162846 | Recruiting | N/A | Methods for Increasing Genetic Testing Uptake in Michigan | April 21, 2022 | December 31, 2026 |
NCT06019923 | Recruiting | Study on the Dynamic Changes of Metabolic Biomarkers and Their Prognostic Relationship in Ovarian Cancer | October 26, 2023 | September 10, 2027 | |
NCT06203106 | Recruiting | NYSCF Scientific Discovery Biobank | November 10, 2022 | November 10, 2045 | |
NCT04815408 | Recruiting | Phase 2 | PD-1 Antibody Combined Neoadjuvant Chemotherapy for Ovarian Cancer | April 1, 2021 | April 1, 2025 |
NCT06109545 | Recruiting | Doppler Ultrasound and CT Versus Laparoscopy in Assessment of Ovarian Malignancy | June 24, 2023 | June 1, 2025 | |
NCT00539162 | Recruiting | N/A | Use of the CA 125 Algorithm for the Early Detection of Ovarian Cancer in Low Risk Women | July 2, 2001 | November 30, 2028 |
NCT05170594 | Recruiting | Phase 2 | A Study of Bevacizumab Combined With Fluzoparib/Chemotherapy or Fluzoparib in the Treatment of Ovarian Cancer | December 24, 2021 | June 30, 2024 |
NCT05255861 | Recruiting | An Exploratory Study of HRD Score in Chinese Ovarian Cancer Patients Benefiting From PARP Inhibitor Targeted Therapy | March 1, 2022 | December 31, 2024 | |
NCT05394675 | Recruiting | Phase 1 | A Study of DS-9606a in Patients With Advanced Solid Tumors | May 31, 2022 | February 19, 2026 |
NCT06290193 | Recruiting | Phase 2 | Study of Acute Normovolemic Hemodilution (ANH) in People With Ovarian Cancer Who Are Having Primary Cytoreductive Surgery | February 23, 2024 | February 23, 2029 |
NCT03831230 | Recruiting | Constitution of ex Vivo Ovarian Tumor Models for the Validation of the Interest of Innovative Therapies and the Search for Tumor or Circulating Biomarkers Predictive of Treatment Response | March 7, 2019 | August 2029 | |
NCT05776355 | Recruiting | N/A | NKG2D CAR-NK & Ovarian Cancer | March 2023 | September 2024 |
NCT02429700 | Recruiting | Phase 3 | TC or BEP in Treating Patients With Ovarian Malignant Sex Cord-Stromal Tumors | April 2015 | May 2030 |
NCT05233982 | Recruiting | Phase 2 | MITO 35a: Olaparib Maintenance Therapy in Newly Diagnosed BRCA Wild-type Advanced Ovarian, Fallopian Tube and Primitive Peritoneal Cancer | December 9, 2021 | January 2026 |
NCT04714957 | Recruiting | PITCHER (Peritoneal Carcinomatosis Heterogeneity) | September 1, 2020 | September 2027 | |
NCT05410015 | Recruiting | Evaluation of Prognostic Monitoring for Women Who Have Completed Standard Treatment for Ovarian Cancer | February 3, 2022 | February 3, 2026 | |
NCT05912972 | Recruiting | Development and Management of Registry in Patients With Gynecologic Cancer in Korea | October 21, 2022 | October 21, 2027 | |
NCT06010875 | Recruiting | Phase 1 | A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors | November 30, 2023 | September 30, 2026 |
NCT05848648 | Recruiting | PPK Study Based on Quantitative Pharmacology in Patients With Pamipril | May 1, 2023 | June 1, 2026 | |
NCT06276491 | Recruiting | Phase 1 | Phase 1, Safety and Tolerability Study of XmAb®541 in Advanced Solid Tumors | April 4, 2024 | December 2028 |
NCT05862740 | Recruiting | N/A | ULTRA-LAP Trial: Laparoscopic Debulking Surgery (LDS) in Advanced Ovarian Cancer | January 2, 2022 | December 31, 2027 |
NCT05585281 | Recruiting | Phase 2 | A Study of Fluzoparib Combined With QL1101 Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy | July 27, 2023 | December 22, 2025 |
NCT05453825 | Recruiting | Phase 2 | A Study of Navicixizumab Monotherapy or in Combination in Patients With Select Advanced Solid Tumors | August 5, 2022 | December 15, 2024 |
NCT05579366 | Recruiting | Phase 1/Phase 2 | PRO1184 for Advanced Solid Tumors | December 7, 2022 | April 2026 |
NCT06339827 | Recruiting | N/A | ASk Questions in GYnecologic Oncology (ASQ-GYO) | April 4, 2024 | May 2027 |
NCT06293898 | Recruiting | Phase 1 | Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors | February 9, 2024 | August 24, 2027 |
NCT03943316 | Recruiting | Laboratory Study of Cancer & Immune Cells in Ascites Fluid of Ovarian Cancer Patients to Test Alternative Therapies | December 2, 2015 | December 31, 2027 | |
NCT05683418 | Recruiting | Phase 1 | A Study to Evaluate the Safety and Tolerability of TOS-358 in Adults With Select Solid Tumors | February 15, 2023 | December 2025 |
NCT06065358 | Recruiting | N/A | Ovarian Tumor Organotypic Slices Cultures for functionAl Drug Testing and Therapy Response Prediction | September 13, 2021 | December 13, 2023 |
NCT03321188 | Recruiting | Phase 2 | Heated Intraperitoneal Chemotherapy in Primary Ovarian Cancer Patients | December 15, 2017 | December 15, 2024 |
NCT04512209 | Recruiting | N/A | Characterization of Biophysical Stromal Properties in Human Cancer: Towards Personalized Computational Oncology | October 11, 2019 | December 31, 2025 |
NCT03017573 | Recruiting | N/A | Prospective Biobanking Study in Ovarian, Breast, Head and Neck and Cervical Cancer Patients Aiming at Better Understand the Link Between the Molecular Alterations of the Tumor Itself, Its Microenvironment and Immune Response (SCANDARE) | January 6, 2017 | January 6, 2031 |
NCT05401162 | Recruiting | N/A | Chemotherapy Supported by Autologous Hematopoietic Stem Cells | April 15, 2022 | May 2027 |
NCT06445621 | Recruiting | Early Detection of Relapse in Ovarian Cancer Using Capillary Home-sampling and a Protein Biomarker Test | May 30, 2024 | May 2026 | |
NCT04789694 | Recruiting | Phase 3 | Prehabilitation in Gynaecological Cancer Patients | January 25, 2021 | June 30, 2026 |
NCT06161493 | Recruiting | Phase 1 | ZEN003694 Combined With Niraparib in Patients With Metastatic or Recurrent Solid Tumors | January 23, 2024 | December 31, 2029 |
NCT05610501 | Recruiting | Ultrasound-guided Tru-Cut Biopsy in Pelvic Masses. | May 1, 2021 | April 30, 2024 | |
NCT05918042 | Recruiting | A Non-interventional Prospective Study of 1-st Line Treatment Approaches in OVArian Cancer Patients With HRD+ Status in Russian Federation | June 21, 2023 | January 25, 2025 | |
NCT05252390 | Recruiting | Phase 1/Phase 2 | NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors | March 29, 2022 | November 2026 |
NCT06036810 | Recruiting | N/A | Spanish Decision Tool for Ovarian Cancer Maintenance Therapy | August 31, 2023 | October 31, 2027 |
NCT05185947 | Recruiting | Phase 2 | Study of Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis From Colorectal, Appendiceal, Small Bowel, Gastric, Cholangiocarcinoma, Breast, Ovarian, or Other Gynecologic Primary Cancer | October 13, 2022 | December 30, 2031 |
NCT02429687 | Recruiting | Phase 3 | TC or BEP in Treating Patients With Malignant Ovarian Germ Cell Tumors | April 2015 | May 2030 |
NCT05366881 | Recruiting | cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease | May 3, 2022 | December 2026 | |
NCT04553926 | Recruiting | 'OLAP' (OLAparib Regulatory Post-marketing Surveillance) | February 1, 2021 | June 30, 2025 | |
NCT05568680 | Recruiting | Phase 1 | SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma | March 30, 2023 | March 30, 2026 |
NCT05735080 | Recruiting | Phase 1/Phase 2 | Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer | March 28, 2023 | June 2026 |
NCT05344950 | Recruiting | Connecting Audio and Radio Sensing Systems to Improve Care at Home | March 21, 2022 | July 2025 | |
NCT05827523 | Recruiting | Phase 3 | Interval Cytoreductive Surgery With or Without HIPEC for Ovarian Cancer (KOV-HIPEC-04) | May 31, 2023 | December 31, 2030 |
NCT05184140 | Recruiting | N/A | Mapping Sentinel Lymph Node in Initial Stages of Ovarian Cancer | January 1, 2021 | May 1, 2023 |
NCT06129968 | Recruiting | Transforming Ovarian Cancer Diagnostic Pathways | January 23, 2024 | July 31, 2025 | |
NCT05523804 | Recruiting | Patient Outcomes Following Interval and Delayed Cytoreductive Surgery in Advanced Ovarian Cancer | August 26, 2022 | December 31, 2024 | |
NCT05377996 | Recruiting | Phase 1 | A Study of XMT-1660 in Participants With Solid Tumors | August 15, 2022 | May 2027 |
NCT04533763 | Recruiting | N/A | Living WELL: A Web-Based Program for Ovarian Cancer Survivors | September 30, 2020 | January 31, 2026 |
NCT05804370 | Recruiting | Phase 3 | Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302) | May 30, 2024 | May 2026 |
NCT05145569 | Recruiting | Phase 2 | Antitumor Activity of Neoadjuvant Chemotherapy With or Without HCW9218 in Metastatic Advanced Stage Ovarian Cancer | May 10, 2024 | January 31, 2028 |
NCT05591131 | Recruiting | N/A | Genetic Testing in African Americans | April 20, 2023 | November 2027 |
NCT04826198 | Recruiting | Phase 1/Phase 2 | Safety and Efficacy of AsiDNATM, a DNA Repair Inhibitor, Administered Intravenously in Addition to PARP Inhibitors in Patients With Relapsed Platinum Sensitive Ovarian Cancer Already Treated With PARP Inhibitors Since at Least 6 Months | October 5, 2020 | October 2023 |
NCT06028724 | Recruiting | A Study on the Prevalence of Clinically Useful Mutations in Solid Tumor Characterized by Next Generation Sequencing Methods on Liquid Biopsy Analysis (POPCORN) | May 26, 2023 | May 31, 2030 | |
NCT05021562 | Recruiting | A Study of Niraparib in Patients With Ovarian Cancer in Clinical Practice | September 13, 2021 | March 31, 2026 | |
NCT05009082 | Recruiting | Phase 3 | Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer | September 13, 2022 | September 2030 |
NCT06024109 | Recruiting | Performance of SYMMCORA® vs. V-Loc® Suture Material in Patients Undergoing Laparoscopic Total Hysterectomy | March 19, 2024 | January 2026 | |
NCT04028479 | Recruiting | The Registry of Oncology Outcomes Associated With Testing and Treatment | May 5, 2021 | October 1, 2031 | |
NCT05252416 | Recruiting | Phase 1/Phase 2 | (VELA) Study of BLU-222 in Advanced Solid Tumors | April 7, 2022 | September 30, 2026 |
NCT05645510 | Recruiting | LIVInG With chrONic Cancer TrEatments (LONGEVITI) Study | November 24, 2022 | May 30, 2025 | |
NCT05174377 | Recruiting | CADx - Radiomics to Distinguish the Origin of Ovarian Tumors | April 5, 2021 | August 1, 2025 | |
NCT03860272 | Recruiting | Phase 1 | Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer | April 1, 2019 | December 2026 |
NCT06232122 | Recruiting | N/A | Evaluation of 68Ga-FAPI-46 and 18F-FDG PET/CT Imaging for Detecting Recurrent Tumor Lesions in Patients of Ovarian Cancer | August 1, 2022 | July 31, 2028 |
NCT03675893 | Recruiting | Phase 2 | RESOLVE: Abemaciclib + Letrozole +/- Metformin or Zotatifin in Endometrial or Low-Grade Serous Ovarian Cancer | December 24, 2018 | August 1, 2029 |
NCT05080946 | Recruiting | Early Phase 1 | Using Aspirin to Improve Immunological Features of Ovarian Tumors | November 2, 2021 | May 2025 |
NCT04375956 | Recruiting | Phase 2 | Study on Pembrolizumab in Recurrent, Platinum Resistant, CPS >1 Positive Ovarian, Fallopian Tube and Primary Peritoneal Cancer Patients | April 26, 2021 | June 15, 2025 |
NCT05815862 | Recruiting | Phase 2 | Clinical Study of AL2846 Capsules in the Treatment of Advanced Lung Tumor and Advanced Ovarian Cancer | February 15, 2023 | December 2024 |
NCT05551208 | Recruiting | Phase 2 | Fluzoparib Combined With Bevacizumab in PSROC Previously Treated With PARPi | August 15, 2022 | August 30, 2029 |
NCT00753480 | Suspended | Phase 1 | A Study of D4064A Administered to Patients With Recurrent or Persistent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | September 2008 | |
NCT05708924 | Suspended | Phase 1 | MT2021-27 FT538 Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer | April 28, 2023 | September 30, 2028 |
NCT03275298 | Suspended | Evolution of the Therapeutic Care in Ovarian Cancer From 2011 | April 1, 2017 | December 31, 2024 | |
NCT01218490 | Suspended | Phase 3 | Pelvic and Aortic-cava Lymphadenectomy Randomized for Ovarian Cancer | December 9, 2008 | May 2026 |
NCT05506800 | Suspended | Guangzhou Women's Health Cohort Study (GWHCS) | March 3, 2016 | August 21, 2026 | |
NCT02432378 | Suspended | Phase 1/Phase 2 | Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines | September 4, 2015 | June 1, 2026 |
NCT05124743 | Suspended | HLA Typing & Tumor Neoantigen Identification for Phase I/II Study of Autologous TCR-T Cells in Subjects With Solid Tumors | September 24, 2021 | May 28, 2028 | |
NCT03393962 | Suspended | Phase 1/Phase 2 | Intervention of Ovarian Cancer With Antigen-specific Engineered Immune Effectors | December 1, 2017 | December 2020 |
NCT02093871 | Suspended | Phase 1 | A Phase 1 Trial of Perfusion Induced Systemic Hyperthermia (PISH) Over Multiple Cycles for Terminal Ovarian Cancer | August 2013 | June 2018 |
NCT03842865 | Temporarily not available | Expanded Access of Vigil in Solid Tumors | |||
NCT06065059 | Terminated | Phase 1/Phase 2 | Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors | December 8, 2023 | May 22, 2024 |
NCT00085384 | Terminated | Phase 1/Phase 2 | PEG-Interferon Alfa-2b in Treating Patients With Platinum-Resistant Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer | July 2002 | April 2007 |
NCT01485874 | Terminated | Phase 1 | Doxorubicin + BIBF 1120 in Patients for Ovarian Cancer | November 2011 | December 2015 |
NCT01747239 | Terminated | Phase 2 | Cabazitaxel in Platinum Refractory Ovarian Cancer | January 2013 | July 2014 |
NCT00758732 | Terminated | Phase 2 | Docetaxel/Carboplatin Versus Docetaxel/Caelyx in Pretreated Patients With Ovarian Carcinoma | October 2005 | March 2011 |
NCT02346955 | Terminated | Phase 1 | Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001) | February 2015 | February 2017 |
NCT02661815 | Terminated | Phase 1 | A Phase 1b Study of Paclitaxel And Ricolinostat For The Treatment Of Gynecological Cancer | June 15, 2016 | July 28, 2017 |
NCT03641287 | Terminated | N/A | The Effects of Exercise on Distress, Quality of Life, and Biomarkers in Ovarian Cancer Survivors | December 5, 2018 | September 30, 2022 |
NCT00897806 | Terminated | Identifying Genetic Markers That Predict Response to Paclitaxel in Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer | February 2002 | February 2009 | |
NCT01175967 | Terminated | Use of Palliative Performance and Symptom Distress Scales in Older Patients With Advanced Ovarian Cancer | June 2010 | May 2015 | |
NCT00418574 | Terminated | Phase 2/Phase 3 | Efficacy Multicentre Trial of ImmunoTherapy Vaccination With Abagovomab to Treat Ovarian Cancer Patients | December 2006 | June 2011 |
NCT02432690 | Terminated | Phase 2 | A Study of BBI503 in Asymptomatic Recurrent Ovarian Cancer Patients With CA-125 Elevation | June 2015 | January 2, 2017 |
NCT01511055 | Terminated | Phase 2 | Intra-op Detection of Occult Ovarian Carcinoma Using a Folate-Alpha Receptor Specific Fluorescent Ligand | January 2012 | June 2014 |
NCT00102622 | Terminated | Phase 1 | Intraperitoneal tgDCC-E1 and Intravenous Paclitaxel in Women With Platinum-Resistant Ovarian Cancer | December 1, 2004 | July 2012 |
NCT03286062 | Terminated | Phase 1 | VM110 in Detection of Microscopic Tumors: A Phase I Study | October 12, 2017 | April 3, 2020 |
NCT00023907 | Terminated | Phase 2 | Paclitaxel in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer | July 2001 | |
NCT02470585 | Terminated | Phase 3 | Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Adults With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | June 29, 2015 | October 5, 2023 |
NCT00003382 | Terminated | Phase 1 | Combination Chemotherapy Consisting of Gemcitabine And Topotecan in Treating Patients With Refractory or Recurrent Ovarian or Fallopian Tube Cancer | May 1998 | |
NCT01096381 | Terminated | Potential Biomarkers for Bevacizumab-Induced High Blood Pressure in Patients With Solid Tumor | March 2010 | August 2011 | |
NCT00006356 | Terminated | Phase 3 | Chemotherapy With or Without Surgery in Treating Patients With Recurrent Ovarian Cancer | August 2000 | |
NCT01690468 | Terminated | Phase 1/Phase 2 | PTX-200 and Carboplatin in Ovarian Cancer | September 2014 | December 2019 |
NCT00652899 | Terminated | Phase 2 | Allogeneic Natural Killer Cells in Patients With Recurrent Ovarian Cancer, Fallopian Tube, and Primary Peritoneal Cancer | March 2008 | August 2009 |
NCT02110277 | Terminated | N/A | Photoacoustic Imaging of the Ovary | March 2014 | May 2016 |
NCT05061537 | Terminated | Phase 1 | Study of PF-07263689 in Participants With Selected Advanced Solid Tumors | October 20, 2021 | October 14, 2022 |
NCT00866723 | Terminated | Phase 2 | Avastin in Patients With Epithelial Ovarian, Primary Peritoneal Serous or Fallopian Tube Cancer | March 2009 | June 2012 |
NCT00373217 | Terminated | Phase 2 | Vaccine Therapy, Paclitaxel, and Carboplatin in Treating Patients Who Are Undergoing Surgery for Stage III or Stage IV Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | April 13, 2006 | February 7, 2008 |
NCT00086632 | Terminated | Phase 2 | Study of Ovarex® (Oregovomab) MAb With Front-Line Chemotherapy for Ovarian Cancer Treatment | July 2004 | December 2007 |
NCT02933073 | Terminated | Phase 1 | Study of Oncoimmunome for the Treatment of Stage III/IV Ovarian Carcinoma | November 2016 | August 2022 |
NCT04598321 | Terminated | Phase 1 | BrUOG 390: Neoadjuvant Treatment With Talazoparib | March 29, 2021 | December 6, 2022 |
NCT00050375 | Terminated | Phase 3 | Clinical Trial for Ovarian Cancer (OvaRex®) | December 2002 | December 2007 |
NCT01170650 | Terminated | Phase 3 | Study for Women With Platinum Resistant Ovarian Cancer Evaluating EC145 in Combination With Doxil® (PROCEED) | April 22, 2011 | September 8, 2015 |
NCT01284075 | Terminated | N/A | The Effect of Guided Imagery and Music Therapy on Post-Operative Recovery After Gynecological Oncology Surgery | April 2010 | April 2013 |
NCT02452424 | Terminated | Phase 1/Phase 2 | A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors | July 2, 2015 | October 12, 2018 |
NCT04999605 | Terminated | Phase 1/Phase 2 | A Study of AK112 Combined With PARP Inhibitor in the Treatment of Recurrent Ovarian Cancer | June 24, 2021 | June 10, 2022 |
NCT00574951 | Terminated | Phase 2 | AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | December 2007 | |
NCT00322881 | Terminated | Phase 2 | Carboplatin and Paclitaxel in Elderly Women With Newly Diagnosed Ovarian, Peritoneal, or Fallopian Cancer | April 2006 | April 2010 |
NCT00720096 | Terminated | N/A | Genomic Directed Salvage Chemotherapy With Either Liposomal Doxorubicin Or Topotecan | July 2008 | October 2009 |
NCT00003926 | Terminated | Phase 1 | Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors | November 1998 | August 2003 |
NCT03621982 | Terminated | Phase 1 | Study of ADCT-301 in Patients With Selected Advanced Solid Tumors | November 9, 2018 | December 14, 2022 |
NCT00179725 | Terminated | Phase 1/Phase 2 | Phase I/II Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile of Lenalidomide (Revlimid® CC-5013) With Liposomal Doxorubicin In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma | November 2005 | June 2007 |
NCT00926107 | Terminated | Phase 2 | Study of the mTOR Inhibitor Temsirolimus (CCI-779) to Treat Ovarian Cancer With CA125 Only Relapse | June 2009 | October 2011 |
NCT02417753 | Terminated | Phase 2 | AZD9150, a STAT3 Antisense Oligonucleotide, in People With Malignant Ascites | April 3, 2015 | April 7, 2016 |
NCT02469116 | Terminated | Phase 2 | Carboplatin Plus Docetaxel With Day 2 Pegylated G-CSF (Neulasta®) in Patients With Advanced Stage Ovarian Carcinoma | January 2006 | March 2010 |
NCT00053833 | Terminated | Phase 2 | S0025 Irinotecan in Treating Patients With Refractory Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer | April 2003 | July 2004 |
NCT03146663 | Terminated | Phase 2 | NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer | September 28, 2017 | December 31, 2019 |
NCT03134638 | Terminated | Phase 1 | A Study of SY-1365 in Adult Patients With Advanced Solid Tumors | May 12, 2017 | June 24, 2020 |
NCT04731441 | Terminated | N/A | Exercise Intervention Prior to CRS-HIPEC: Feasibility & Impact | March 18, 2021 | December 1, 2023 |
NCT01583686 | Terminated | Phase 1/Phase 2 | CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer | May 4, 2012 | December 17, 2018 |
NCT00418093 | Terminated | Phase 2 | Oxaliplatin, Gemcitabine and Bevacizumab in Women With Recurrent Mullerian Carcinoma | September 2006 | October 2011 |
NCT03858166 | Terminated | Phase 4 | Efficacy and Safety of PEG-rhG-CSF Secondary Prophylaxis vs. Therapeutic Administration in Patients With Ovarian Cancer | December 1, 2017 | December 31, 2020 |
NCT03427073 | Terminated | Phase 1 | A Phase I Dose-escalation Study of Subcutaneous ALM201 in Patients With Advanced Ovarian Cancer and Other Solid Tumours | April 27, 2015 | March 13, 2017 |
NCT00002478 | Terminated | Phase 2 | Etoposide in Treating Patients With Advanced Ovarian or Cervical Cancer | June 1993 | |
NCT00526799 | Terminated | Phase 1/Phase 2 | Sorafenib + Topotecan for Platinum-Resistant Recurrent Ovarian Cancer | September 2007 | August 2010 |
NCT01296035 | Terminated | Phase 2 | Panitumumab and Gemcitabine in Relapsed Ovarian Cancer | February 2011 | November 2013 |
NCT01991210 | Terminated | Phase 2 | A Study of DNIB0600A in Comparison With Pegylated Liposomal Doxorubicin (PLD) in Participants With Platinum-Resistant Ovarian Cancer (PROC) | February 6, 2014 | August 17, 2016 |
NCT03149549 | Terminated | Phase 1/Phase 2 | PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors | June 1, 2017 | September 10, 2020 |
NCT00522301 | Terminated | Phase 2 | Sorafenib in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in at Least the Second Remission | July 2007 | March 2008 |
NCT02218502 | Terminated | N/A | Study Into a New Diagnostic Tool (Simple Ultrasound-based Rules) in Patients With Adnexal Masses | September 2014 | October 1, 2015 |
NCT00505661 | Terminated | Phase 2 | Letrozole in Patients With Ovarian Tumors | September 2003 | May 2010 |
NCT00253461 | Terminated | Early Phase 1 | 11C Topotecan PET Imaging | December 2004 | November 2009 |
NCT01133756 | Terminated | Phase 1/Phase 2 | E7080 in Combination With Carboplatin + Gemcitabine Versus Carboplatin + Gemcitabine Alone as Second Line Therapy in Patients With Platinum-Sensitive Recurrent Ovarian Cancer by CA125 | March 2010 | September 2012 |
NCT03323398 | Terminated | Phase 1/Phase 2 | Dose Escalation and Efficacy Study of mRNA-2416 for Intratumoral Injection Alone and in Combination With Durvalumab for Participants With Advanced Malignancies | August 15, 2017 | August 18, 2021 |
NCT03587129 | Terminated | Phase 2 | Clinical Study of Apatinib in the Treatment of Platinum Resistant Recurrent Ovarian Cancer | July 10, 2018 | June 14, 2020 |
NCT03300843 | Terminated | Phase 2 | Ability of a Dendritic Cell Vaccine to Immunize Melanoma or Epithelial Cancer Patients Against Defined Mutated Neoantigens Expressed by the Autologous Cancer | April 11, 2018 | September 16, 2019 |
NCT02718417 | Terminated | Phase 3 | Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN 100) | May 19, 2016 | May 16, 2019 |
NCT01035658 | Terminated | Phase 1/Phase 2 | Pazopanib/Doxil in Adv Relapsed Plat Sensitive or Resistant Ovarian, Fallopian or Primary Peritoneal Adenocarcinoma | January 2010 | March 2014 |
NCT04586335 | Terminated | Phase 1 | Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors. | September 28, 2020 | February 15, 2023 |
NCT00550654 | Terminated | Phase 2 | Conformal Radiation Therapy in Treating Patients With Metastatic Cancer Outside the Brain | October 2007 | May 2010 |
NCT01821859 | Terminated | Phase 2 | Abraxane/Bevacizumab | January 2010 | November 2011 |
NCT01743547 | Terminated | N/A | The Effects Of Yoga On Quality Of Life Among A Population Of Ovarian/ Fallopian Tube/ Primary Peritoneal Cancer Patients Receiving Chemotherapy: A Feasibility Study | November 2012 | November 2013 |
NCT01212887 | Terminated | Phase 1 | Treated Blood Cells, Cyclophosphamide, Fludarabine Phosphate, and Aldesleukin in Treating Patients With Cancer | August 2007 | April 2010 |
NCT01202890 | Terminated | Phase 1 | Study of Revlimid With Doxil and Avastin for Patients With Platinum Resistant Ovarian Cancer | September 2010 | May 2012 |
NCT00900068 | Terminated | Blood Samples From Patients on a Clinical Trial to CINV During HSCT | August 2008 | October 2009 | |
NCT00748527 | Terminated | Phase 2 | Carboplatin With or Without Decitabine in Treating Patients With Progressive, Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | July 2007 | November 2010 |
NCT02411565 | Terminated | Early Phase 1 | Fermented Wheat Germ Extract in Women With Ovarian Cancer | March 1, 2016 | January 8, 2018 |
NCT00023634 | Terminated | Phase 1 | S0114 Vaccine Therapy in Treating Patients With Gastric, Prostate, or Ovarian Cancer | June 2001 | November 2008 |
NCT00331422 | Terminated | Phase 2 | Carboplatin, Paclitaxel, and Surgery in Treating Patients With Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer | October 2005 | March 2009 |
NCT01149434 | Terminated | Phase 1/Phase 2 | Study of JI-101 in Patients With Advanced Low Grade Endocrine Tumors, Ovarian Cancers or K-RAS Mutant Colon Cancers | September 2010 | August 2012 |
NCT00903630 | Terminated | Phase 1/Phase 2 | Lenalidomide and Doxorubicin Hydrochloride Liposome in Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | April 2009 | August 2011 |
NCT02558348 | Terminated | Phase 1/Phase 2 | Phase 1/2a Evaluation of AL3818 in Subjects With Recurrent or Metastatic Endometrial, Ovarian or Cervical Cancer (AL3818-US-001) | November 2015 | May 30, 2017 |
NCT04267939 | Terminated | Phase 1 | ATR Inhibitor Elimusertib (BAY1895344) Plus Niraparib Phase 1b Study in Advanced Solid Tumors and Ovarian Cancer | February 26, 2020 | December 1, 2023 |
NCT02978222 | Terminated | Phase 2 | Folate Receptor Alpha Peptide Vaccine With GM-CSF Versus GM-CSF Alone in Patients With Platinum Sensitive Ovarian Cancer | July 20, 2017 | January 15, 2020 |
NCT02669914 | Terminated | Phase 2 | MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors | September 12, 2016 | January 11, 2018 |
NCT03944902 | Terminated | Phase 1 | CB-839 in Combination With Niraparib in Platinum Resistant BRCA -Wild-type Ovarian Cancer Patients | September 1, 2021 | January 5, 2022 |
NCT01281254 | Terminated | Phase 3 | AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2) | April 18, 2011 | April 19, 2017 |
NCT02326844 | Terminated | Phase 2 | BMN 673 (Talazoparib), an Oral PARP Inhibitor, in People With Deleterious BRCA1/2 Mutation-Associated Ovarian Cancer Who Have Had Prior PARP Inhibitor Treatment | March 2, 2015 | April 14, 2016 |
NCT00288275 | Terminated | Correlation of the Chemoresponse Assay With PFS in Patients With Recurrent Epithelial Ovarian, Peritoneal, or Fallopian Tube Cancer | July 2004 | October 2012 | |
NCT02769546 | Terminated | Physician-Patient Communication and Expectations Regarding Ovarian Cancer Prognosis | January 2016 | January 2018 | |
NCT04244552 | Terminated | Phase 1 | A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies | February 11, 2020 | November 1, 2023 |
NCT00539968 | Terminated | Phase 1/Phase 2 | A Study to Evaluate the Safety, Tolerability, and Activity of Lonafarnib and Docetaxel (Study P04467AM1)(TERMINATED) | June 2007 | December 2009 |
NCT02203513 | Terminated | Phase 2 | A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate Cancer | January 20, 2015 | August 27, 2021 |
NCT01010334 | Terminated | N/A | Comparison of Standard of Care or Treatment on Protocol | March 2009 | July 2011 |
NCT02367352 | Terminated | Phase 1 | Alisertib (MLN8237) in Combination With Weekly Paclitaxel in East Asian Patients With Advanced Solid Tumors | March 19, 2015 | May 23, 2017 |
NCT01972516 | Terminated | Phase 2 | Tivozanib As Maintenance Therapy In GYN | November 2013 | January 2016 |
NCT03549000 | Terminated | Phase 1 | A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies. | July 18, 2018 | October 17, 2022 |
NCT00287482 | Terminated | N/A | Essiac (ESIAK) Versus Placebo to Improve Quality of Life in Transition in Women With Breast or Ovarian Cancer. | October 2005 | July 2007 |
NCT00055432 | Terminated | Phase 2 | Gemzar (Gemcitabine) and Alimta (Pemetrexed) in the Treatment of Patients With Recurrent Platinum-Sensitive and Platinum-Resistant Ovarian or Peritoneal Cancer | ||
NCT00669422 | Terminated | ChemoFx® PRO - A Post-Market Data Collection Study | October 2006 | October 2012 | |
NCT04691375 | Terminated | Phase 1 | A Study of PY314 in Subjects With Advanced Solid Tumors | October 29, 2020 | September 22, 2023 |
NCT03128294 | Terminated | Long Term Survivors in Ovarian Cancer | January 2017 | December 31, 2018 | |
NCT00738699 | Terminated | Phase 2 | An Efficacy and Safety Study of MORAb-003 in Platinum-Resistant or Refractory Relapsed Ovarian Cancer | September 2008 | January 2012 |
NCT00819169 | Terminated | Phase 1/Phase 2 | QUILT-3.026: AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors | January 2009 | October 2011 |
NCT02539719 | Terminated | Phase 1 | Study of SC-003 Alone and in Combination With ABBV-181 in Subjects With Platinum-Resistant/Refractory Ovarian Cancer | August 2015 | January 2, 2019 |
NCT00637390 | Terminated | Phase 1 | A Phase I Study of Alemtuzumab in Patients With Relapsed Ovarian/Primary Peritoneal Cancer. | March 2008 | October 2010 |
NCT04367467 | Terminated | Effect of PARP Inhibitors on Glomerular Filtration Rate | February 3, 2020 | July 1, 2021 | |
NCT00516841 | Terminated | Phase 2 | A Phase 2, Single-Arm Study of Volociximab Monotherapy in Subjects With Platinum-Resistant Advanced Epithelial Ovarian Cancer or Primary Peritoneal Cancer | August 2007 | April 2008 |
NCT04891185 | Terminated | Phase 2 | Visualisation of Indocyanine Green in Primary and Interval Debulking for Ovarian Cancer | October 1, 2021 | October 1, 2023 |
NCT04814875 | Terminated | Phase 1/Phase 2 | A Study to Evaluate the Combination of ATX-101 and Platinum-based Chemotherapy | September 1, 2021 | November 30, 2023 |
NCT00408070 | Terminated | Phase 2 | Bevacizumab Study With Carboplatin & Paclitaxel in Ovarian, Fallopian Tube or Primary Peritoneal Cancer | October 2006 | October 2009 |
NCT05261490 | Terminated | Phase 1/Phase 2 | Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer | August 1, 2022 | February 15, 2024 |
NCT00194935 | Terminated | Phase 2 | Weekly Topotecan Therapy in Patients With Ovarian Cancer | February 2003 | August 2006 |
NCT01016054 | Terminated | Phase 1 | A Study of the Safety and Pharmacokinetics of AGS-8M4 Given in Combination With Chemotherapy in Women With Ovarian Cancer | October 2009 | April 2010 |
NCT02042885 | Terminated | Phase 1/Phase 2 | A Clinical Trial to Determine the Most Suitable Dose of OPB-111001 in Patients With Advanced Cancer | January 2014 | February 2015 |
NCT01003938 | Terminated | Phase 2 | Topotecan With Erlotinib for Topotecan Pretreated Ovarian Cancer | August 2009 | December 2012 |
NCT00862836 | Terminated | Phase 1/Phase 2 | Addition of Vandetanib to Standard Therapy Pegliposomal Doxorubicin (PLD) | April 2009 | September 2010 |
NCT01227941 | Terminated | Phase 1 | MK-4827 in Combination With Pegylated Liposomal Doxorubicin in Participants With Advanced Solid Tumors and Ovarian Cancer (MK-4827-011) | November 2010 | September 2011 |
NCT00317434 | Terminated | Phase 1 | Maximum Tolerated Dose of Lapatinib When Given With Carboplatin for Recurrent Ovarian Cancer | November 2005 | April 2007 |
NCT00003852 | Terminated | Phase 2 | Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Germ Cell Tumors | March 1998 | March 2000 |
NCT01744821 | Terminated | N/A | Vitamin D for Women at Increased Risk of Developing Ovarian, Fallopian, or Primary Peritoneal Cancer | October 2012 | April 2015 |
NCT02278783 | Terminated | Phase 2 | Phase 2 Trial of Regorafenib in Patients With Recurrent Ovarian, Primary Peritoneal and Fallopian Tube Cancer | March 2015 | January 2017 |
NCT00354601 | Terminated | Phase 2 | Docetaxel and Capecitabine in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cavity Cancer | January 2006 | July 2008 |
NCT04460807 | Terminated | Phase 3 | Exemestane in Hormone Receptor Positive High Grade Ovarian Cancer | February 13, 2020 | April 27, 2023 |
NCT00003880 | Terminated | Phase 2/Phase 3 | Paclitaxel Plus Carboplatin With or Without SCH-58500 in Treating Patients With Newly Diagnosed Stage III Ovarian or Stage III Primary Peritoneal Cancer | February 1999 | August 2001 |
NCT02948426 | Terminated | Phase 1 | Intraperitoneal Infusion of Autologous Monocytes With Sylatron (Peginterferon Alfa-2b) and Actimmune (Interferon Gamma-1b) in Women With Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer | February 8, 2017 | September 29, 2020 |
NCT01144442 | Terminated | N/A | WCC# 59 Hyperthermic Intraperitoneal Chemotherapy Utilizing Carboplatin in First Recurrence Ovarian Cancer | July 27, 2010 | May 1, 2015 |
NCT00585052 | Terminated | Phase 2 | A Phase II Study of Interaction of Lovastatin and Paclitaxel For Patients With Refractory or Relapsed Ovarian Cancer | August 2003 | June 2013 |
NCT05363605 | Terminated | Phase 1/Phase 2 | A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours | April 20, 2022 | September 8, 2023 |
NCT02649673 | Terminated | Phase 1 | LCL161 Plus Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies | March 23, 2016 | July 30, 2021 |
NCT00651716 | Terminated | T Cells in Predicting Acute Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant | December 2006 | October 2019 | |
NCT00003378 | Terminated | Phase 1 | Combination Chemotherapy in Treating Patients With Previously Untreated Stage III or Stage IV Ovarian or Primary Peritoneal Cancer | August 1998 | |
NCT00523809 | Terminated | Phase 2 | Allogeneic Hematopoietic Stem Cell Transplantation With Bevacizumab for Advanced Solid Tumor | August 2007 | October 2011 |
NCT00006262 | Terminated | Phase 2 | Rebeccamycin Analogue in Treating Patients With Refractory Stage III or Stage IV Ovarian Epithelial Cancer | July 2000 | September 2001 |
NCT03144661 | Terminated | Phase 1 | An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies | May 25, 2017 | June 10, 2020 |
NCT00596544 | Terminated | Sexual Functioning After Primary Treatment of Ovarian Cancer | November 2004 | November 2015 | |
NCT00898781 | Terminated | Study of Circulating Cancer Cells in Patients With Metastatic Breast, Ovarian, Colon, or Pancreatic Cancer | November 2007 | April 2010 | |
NCT01312389 | Terminated | Phase 1/Phase 2 | A Clinical Trial of Autologous Oxidized Tumor Cell Lysate Vaccine For Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer | April 2011 | August 17, 2012 |
NCT00946283 | Terminated | N/A | Lactobacillus in Preventing Infection in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer or Myelodysplastic Syndrome | March 2010 | October 14, 2015 |
NCT00287859 | Terminated | Phase 1 | Topotecan in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer | August 2004 | December 2006 |
NCT02476955 | Terminated | Phase 1 | Open-label Phase 1b Study of ARQ 092 in Combination With Anastrozole | June 9, 2015 | May 7, 2019 |
NCT02628535 | Terminated | Phase 1 | Safety Study of MGD009 in B7-H3-expressing Tumors | September 2015 | November 25, 2019 |
NCT04614051 | Terminated | Phase 1 | Safety Evaluation of Autologous Dendritic Cell Anticancer Immune Cell Therapy (Cellgram-DC) | March 30, 2021 | May 10, 2022 |
NCT03992131 | Terminated | Phase 1/Phase 2 | A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR) | June 28, 2019 | April 22, 2022 |
NCT03203993 | Terminated | China Ovarian Cancer BRCA Testing Study | January 31, 2018 | March 31, 2020 | |
NCT04163094 | Terminated | Phase 1 | Ovarian Cancer Treatment With a Liposome Formulated mRNA Vaccine in Combination With (Neo-)Adjuvant Chemotherapy | November 25, 2019 | June 26, 2023 |
NCT00324324 | Terminated | Phase 3 | Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant | May 2006 | December 2012 |
NCT00006812 | Terminated | Phase 2 | Capecitabine in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cavity Cancer | March 2001 | |
NCT00189579 | Terminated | Phase 2 | Addition of Herceptin to a Carboplatin-Paclitaxel Regimen in Patients With Ovarian Cancer | January 2007 | |
NCT00840450 | Terminated | Phase 2 | Imatinib Mesylate (Gleevec) and Paclitaxel in Recurrent Patients of Ovarian and Other Cancers of Mullerian Origin | April 2007 | October 2012 |
NCT03585764 | Terminated | Phase 1 | MOv19-BBz CAR T Cells in aFR Expressing Recurrent High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | October 24, 2018 | March 26, 2024 |
NCT00788125 | Terminated | Phase 1/Phase 2 | Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors | September 3, 2008 | July 30, 2022 |
NCT02576665 | Terminated | Phase 1 | A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6) | July 2016 | December 20, 2019 |
NCT00003794 | Terminated | Quality-of-Life Study of Patients With Previously Treated Ovarian Cancer | April 1999 | ||
NCT00006099 | Terminated | Phase 1 | Monoclonal Antibody Therapy in Treating Patients Scheduled for Surgery to Remove Ovarian Cancer | August 2, 2000 | August 12, 2002 |
NCT01881451 | Terminated | Imaging Tumor Hypoxia With 18F-EF5 PET in Recurrent or Metastatic Clear Cell Ovarian Cancer | August 2013 | May 2020 | |
NCT02055690 | Terminated | Phase 1/Phase 2 | PAZOFOS: Phase Ib and Phase II Trial of Pazopanib +/- Fosbretabulin in Advanced Recurrent Ovarian Cancer | September 2014 | November 24, 2017 |
NCT01392352 | Terminated | Phase 2 | HYPAZ: Hypertension Induced by Pazopanib | April 2011 | September 2015 |
NCT01535157 | Terminated | Phase 1/Phase 2 | Fenretinide/LXS Oral Powder Plus Ketoconazole in Recurrent Ovarian Cancer | February 2012 | June 2017 |
NCT00442598 | Terminated | Phase 2 | Safety and Efficacy Study of Glufosfamide in Ovarian Cancer | January 2007 | April 2008 |
NCT00536523 | Terminated | Effect of Serotonin Level on Constipation Caused by Chemotherapy in Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | April 2007 | December 2009 | |
NCT00856453 | Terminated | N/A | Yoga in Relieving Fatigue in Patients Undergoing Chemotherapy for Ovarian Cancer | May 2009 | October 2009 |
NCT01177501 | Terminated | Phase 1 | Trial of High Dose Topotecan With Carboplatin in Patients With Relapsed Ovarian Carcinoma | April 2009 | March 2012 |
NCT01383408 | Terminated | Phase 2 | Distinction Between Lung Cancer and Gynecological Cancers by Canine Scent Detection | March 2011 | March 2013 |
NCT02389985 | Terminated | Phase 1/Phase 2 | A Study of CRLX101(NLG207) in Combination With Weekly Paclitaxel in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer | July 2015 | October 18, 2018 |
NCT00003380 | Terminated | Phase 1 | Liposomal Doxorubicin and Etoposide in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Peritoneal Cancer | May 1998 | |
NCT00005612 | Terminated | Phase 1/Phase 2 | Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Ovarian Epithelial Cancer | August 1999 | February 2004 |
NCT01493505 | Terminated | Phase 3 | TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer | January 2012 | December 2016 |
NCT04025216 | Terminated | Phase 1 | A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers | October 10, 2019 | December 2, 2022 |
NCT00582205 | Terminated | Phase 2 | Feasibility Trial of Intraperitoneal Chemotherapy for Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma | January 2006 | December 2011 |
NCT00082212 | Terminated | Phase 2 | A Study in Patients With Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma | November 2004 | June 2007 |
NCT00017134 | Terminated | N/A | Fenretinide Followed by Surgery Compared With Surgery Alone in Preventing Ovarian Cancer in Patients at Increased Risk | September 2002 | |
NCT00602446 | Terminated | Phase 2 | Deferasirox in Treating Patients With Iron Overload After Undergoing a Donor Stem Cell Transplant | August 2007 | December 2009 |
NCT00910000 | Terminated | Phase 1/Phase 2 | Vorinostat, Carboplatin and Gemcitabine in Women With Recurrent, Platinum-Sensitive Ovarian Cancer | June 2009 | October 2015 |
NCT04408599 | Terminated | Phase 1/Phase 2 | A Safety and Tolerability Study of NC410 in Subjects With Advanced or Metastatic Solid Tumors | June 10, 2020 | July 7, 2023 |
NCT00004037 | Terminated | Phase 2 | Docetaxel in Treating Patients With Recurrent or Refractory Ovarian or Primary Peritoneal Cancer | June 1998 | |
NCT01685255 | Terminated | Phase 2 | A Phase 2 Study of the IDO Inhibitor Epacadostat Versus Tamoxifen for Subjects With Biochemical-recurrent-only EOC, PPC or FTC Following Complete Remission With First-line Chemotherapy | August 2012 | October 23, 2014 |
NCT02387125 | Terminated | Phase 1 | Phase 1b Safety Study of CMB305 in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1 | February 28, 2015 | March 29, 2019 |
NCT01083537 | Terminated | Phase 1/Phase 2 | Trial of Best Supportive Care and Either Cisplatin or Paclitaxel to Treat Patients With Primary Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer and Inoperable Malignant Bowel Obstruction | February 2010 | June 2012 |
NCT00531778 | Terminated | NYU Ovarian Cancer Early Detection Program Blood and Genetics | June 2004 | November 2010 | |
NCT00084448 | Terminated | Phase 2 | Paclitaxel and Celecoxib in Treating Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epithelial or Primary Peritoneal Cancer | April 2004 | |
NCT00303888 | Terminated | Phase 1 | Docetaxel With or Without Phenoxodiol in Treating Patients With Recurrent Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer | May 2006 | October 2009 |
NCT03622931 | Terminated | Phase 2 | Patients With Relapsed Ovarian Cancer (2nd and 3rd Line) Treated With Chemotherapy According to AGO Guidelines | February 1, 2014 | January 17, 2019 |
NCT00003624 | Terminated | Phase 2 | Amifostine in Treating Women With Ovarian, Peritoneal, Cervical, Fallopian Tube, Uterine, or Endometrial Cancer | December 1998 | |
NCT02341118 | Terminated | Capturing BRCA1/2 Mutational Status in Women With High Grade Serous Ovarian Cancer and Impact on Clinical Outcome. | May 2014 | May 8, 2023 | |
NCT03642132 | Terminated | Phase 3 | Avelumab and Talazoparib in Untreated Advanced Ovarian Cancer (JAVELIN OVARIAN PARP 100) | July 19, 2018 | December 22, 2021 |
NCT02607813 | Terminated | Phase 1 | Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway Alterations | January 18, 2016 | February 19, 2022 |
NCT00005029 | Terminated | Phase 2 | Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer | February 2000 | |
NCT00653328 | Terminated | Phase 2 | Ph II Atrasentan + DOXIL in Recurrent Ovarian/Fallopian/Peritoneal Serous Papillary Adenocarcinoma | May 2003 | March 2009 |
NCT03342417 | Terminated | Phase 2 | Combination of Nivolumab and Ipilimumab in Breast, Ovarian and Gastric Cancer Patients | February 14, 2018 | May 29, 2019 |
NCT00002819 | Terminated | Phase 3 | Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Persistent Ovarian Epithelial Cancer | November 1996 | |
NCT04396340 | Terminated | Phase 1 | First-in-Human Study of XMT-1592 in Patients With Ovarian Cancer and NSCLC Likely to Express NaPi2b | May 11, 2020 | September 30, 2022 |
NCT01137071 | Terminated | Phase 2 | Consolidation Therapy With Hu3S193 for Women With Ovarian, Primary Peritoneal or Fallopian Tube Cancer | April 2011 | June 2015 |
NCT00003386 | Terminated | Phase 2 | Vaccine Therapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer | July 1999 | |
NCT04254107 | Terminated | Phase 1 | A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer | May 29, 2020 | December 1, 2023 |
NCT05395052 | Terminated | Phase 1 | FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors | May 31, 2022 | August 11, 2023 |
NCT00849667 | Terminated | Phase 3 | Efficacy and Safety of Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Participants With Platinum-sensitive Ovarian Cancer in First Relapse | April 16, 2009 | April 12, 2013 |
NCT00277290 | Terminated | Phase 2 | Study of XL999 in Patients With Previously Treated Ovarian Cancer | January 2006 | November 2006 |
NCT04377087 | Terminated | Phase 2 | Delayed Initiation of Olaparib Maintenance Therapy in Platinum Sensitive Recurrent Ovarian Cancer | June 29, 2020 | May 31, 2023 |
NCT04875806 | Terminated | Phase 1/Phase 2 | A Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastatic Solid Tumors | June 30, 2021 | January 30, 2024 |
NCT00583622 | Terminated | Phase 2 | Bevacizumab Plus Gemcitabine, Docetaxel, Melphalan, and Carboplatin in Ovarian Cancer Patients | December 2007 | January 2012 |
NCT03799913 | Unknown status | Early Phase 1 | MESO-CAR T Cells Therapy for Relapsed and Refractory Ovarian Cancer | April 10, 2019 | April 2022 |
NCT03846856 | Unknown status | The IGF Axis Involvement in Immune Tumor Microenvironment in Ovarian Cancer and Its Clinical Significance | April 2019 | March 2021 | |
NCT03916679 | Unknown status | Phase 1/Phase 2 | MESO-CAR T Cells Therapy for Relapsed and Refractory Epithelial Ovarian Cancer | April 20, 2019 | April 20, 2023 |
NCT03648489 | Unknown status | Phase 2 | Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma) | September 21, 2018 | December 2022 |
NCT04089189 | Unknown status | Phase 2 | Study of IMP4297 in Patients With BRCA1/2 Mutation Ovarian Cancer | September 11, 2019 | August 2022 |
NCT03863860 | Unknown status | Phase 3 | A Trial of Maintenance Treatment With Fluzoparib Versus Placebo in Relapsed Ovarian Cancer Patients | April 30, 2019 | December 31, 2022 |
NCT02719041 | Unknown status | Predictive Biomarkers for IGF1R Targeted Therapy in Ovarian Cancer: a Retrospective Study | April 2016 | April 2018 | |
NCT00155896 | Unknown status | Establishing the Incidences of BRCA1 and BRCA2 Mutation by Combining DHPLC and Direct Sequencing in Ovarian Cancer | January 2003 | December 2008 | |
NCT00327925 | Unknown status | Blood Test for Ovarian Cancer Associated Antibodies (CAAb) | July 2006 | June 2008 | |
NCT01187706 | Unknown status | A Controlled Study of Quality of Life and it's Related Factors Among Gynecological Cancer Survivors | August 2010 | ||
NCT00722228 | Unknown status | Phase 1/Phase 2 | Autologous and Allogeneic Whole Cell Cancer Vaccine for Metastatic Tumors | July 2008 | January 2022 |
NCT00003733 | Unknown status | Phase 2 | Sequential Chemotherapy in Treating Patients With Residual Disease Following Surgery for Stage IIB, Stage III, or Stage IV Ovarian Cancer | December 1997 | |
NCT00039559 | Unknown status | N/A | Clinical Trial to Screen Participants Who Are at High Genetic Risk for Ovarian Cancer | May 2002 | December 2014 |
NCT04503980 | Unknown status | Early Phase 1 | αPD1-MSLN-CAR T Cells for the Treatment of MSLN-positive Advanced Solid Tumors | March 26, 2020 | June 2022 |
NCT00419627 | Unknown status | Proteomic Analysis of HLA Complex in Solid Cancers: Breast, Ovary, Colon, Rectum, Stomach, and Pancreas | February 2007 | ||
NCT02188550 | Unknown status | Phase 2 | Single Arm Trial With Combination of Everolimus and Letrozole in Treatment of Platinum Resistant Relapse or Refractory or Persistent Ovarian Cancer/Endometrial Cancer | June 2014 | |
NCT00703105 | Unknown status | Phase 2 | Ovarian Dendritic Cell Vaccine Trial | October 2008 | July 2021 |
NCT01242072 | Unknown status | Phase 1 | Intravenous Palifosfamide-tris in Combination With Etoposide and Carboplatin in Patients With Malignancies | November 2010 | December 2012 |
NCT00238342 | Unknown status | N/A | Proteomic Profiling in Diagnosing Ovarian Cancer in Patients Who Are Undergoing Surgery for an Abnormal Pelvic Mass | October 2005 | |
NCT02952183 | Unknown status | N/A | Efficacy of Pelvic Autonomic Nerve Monitoring System (PAMS I) in Female Patients With Pelvic Tumors | July 2015 | |
NCT00004206 | Unknown status | Phase 2 | Oxaliplatin and Fluorouracil in Treating Patients With Recurrent Ovarian Cancer | September 1999 | |
NCT01220154 | Unknown status | Phase 1 | Study of Intraperitoneal Carboplatin With IV Paclitaxel and Bevacizumab in Untreated Ovarian Cancer | October 2010 | |
NCT04849858 | Unknown status | Phase 3 | Pilot Study of Liposomal Bupivacaine Redosing in Patients Undergoing Major Gynecologic Procedures | May 20, 2019 | June 2022 |
NCT03076372 | Unknown status | Phase 1 | A Study Evaluating MM-310 in Patients With Solid Tumors | February 22, 2017 | December 2018 |
NCT00003718 | Unknown status | Phase 2 | Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma | September 1998 | |
NCT00005025 | Unknown status | Phase 2 | Gene Therapy in Treating Women With Refractory or Relapsed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer | June 2000 | |
NCT02178462 | Unknown status | Biomarkers for Gynecologic Cancer | June 2014 | March 2018 | |
NCT04176484 | Unknown status | Feasibility of Opportunistic Salpingectomy During Non-Gynecologic Surgery | December 1, 2019 | December 1, 2022 | |
NCT00017303 | Unknown status | Phase 2 | Combination Chemotherapy Plus IM-862 in Treating Patients With Resected Stage III Ovarian Cancer or Primary Peritoneal Cancer | January 2001 | |
NCT04383977 | Unknown status | Phase 2 | Apatinib and Etoposide Capsule Versus Apatinib in Patients With Platinum Resistant Ovarian Cancer | May 2020 | June 2021 |
NCT03709316 | Unknown status | Phase 3 | A Study of ZL-2306 (Niraparib) as Maintenance Treatment Following First-line Chemotherapy in Patients With Advanced Ovarian Cancer | June 30, 2018 | December 30, 2023 |
NCT00155935 | Unknown status | N/A | The Development of Human Immunologic Assays Specific to Folate Receptor Antigen | January 2004 | December 2008 |
NCT00886717 | Unknown status | Phase 1/Phase 2 | Paclitaxel-Loaded Polymeric Micelle and Carboplatin as First-Line Therapy in Treating Patients With Advanced Ovarian Cancer | May 2008 | |
NCT02821793 | Unknown status | Expectations and Priorities of Elderly Patients for a First Medical Treatment for Cancer | January 2016 | July 2020 | |
NCT03184753 | Unknown status | Phase 1/Phase 2 | Genetically Modified T Cells Against Ovarian Cancer | May 15, 2017 | December 31, 2020 |
NCT01187602 | Unknown status | Short Non-coding RNA Biomarkers of Predisposition to Ovarian Cancer | August 2010 | June 2015 | |
NCT05273944 | Unknown status | Phase 1 | Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection (Lipodox®) in Chinese Patients | July 28, 2021 | April 30, 2022 |
NCT05371301 | Unknown status | Phase 3 | Efficacy of Primary Debulking Surgery Versus Neoadjuvant Chemotherapy in Stage IV Ovarian Cancer | July 16, 2021 | December 2023 |
NCT01268956 | Unknown status | Circulating Lymphatic Progenitor Cell and Lymph Node Metastasis | January 2011 | September 2011 | |
NCT03210298 | Unknown status | International Registry of Patients Treated With Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) | January 2016 | September 2022 | |
NCT03154281 | Unknown status | Phase 1 | Evaluation of the Safety and Tolerability of Niraparib With Everolimus in Advanced Gynecologic Malignancies and Breast | July 17, 2017 | June 2024 |
NCT04812938 | Unknown status | Exploiting Pathogenic Tp53 Mutation for Early Diagnosis of Ovarian Cancer by Mean of Papanicolau Test | April 12, 2021 | October 1, 2022 | |
NCT04582552 | Unknown status | The Clinical Markers for PARP Inhibitors-related Efficacy in Ovarian Cancer | December 15, 2020 | November 2023 | |
NCT04229615 | Unknown status | Phase 3 | A Study of Fluzoparib±Apatinib Versus Placebo Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on First-Line Platinum-Based Chemotherapy | June 2, 2020 | April 1, 2024 |
NCT00036712 | Unknown status | Phase 2 | Light-Emitting Diode Therapy in Preventing Mucositis in Children Receiving Chemotherapy With or Without Radiation Therapy Before Bone Marrow Transplantation | January 2002 | |
NCT03219242 | Unknown status | N/A | Primary Debulking Surgery Including Bowel Resection in Advanced Stage Ovarian Cancer Using Caiman® Technology | June 30, 2016 | January 30, 2018 |
NCT01100372 | Unknown status | Phase 2 | Liposome-Encapsulated Doxorubicin Citrate With or Without Gemcitabine Hydrochloride in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer | July 2009 | |
NCT04528940 | Unknown status | Tumor Grade Determines PD-1/PDL-1 Expression | August 25, 2020 | September 30, 2021 | |
NCT00002477 | Unknown status | Phase 3 | Adjuvant Chemotherapy Compared With Observation in Treating Patients With Resected Early Stage Ovarian Epithelial Cancer | April 1991 | |
NCT02349958 | Unknown status | Phase 2 | Clinical Trial of Intraperitoneal Hyperthermic Chemotherapy | September 2006 | January 2022 |
NCT02534922 | Unknown status | Phase 1 | Study of Prolanta™ in Recurrent or Persistent Epithelial Ovarian Cancer | February 2016 | February 2019 |
NCT04337632 | Unknown status | Phase 3 | Evaluation of the Sensitivity to Different Chemotherapy Regimens in Platinum-Partial Sensitive Recurrent Ovarian Cancer | August 1, 2017 | June 2021 |
NCT03019315 | Unknown status | The Analyses of Treatment Efficacy and Cost-effectiveness in Early-staged Ovarian Cancer Patients | January 2015 | December 2020 | |
NCT03547375 | Unknown status | Phase 2 | Clinical Study of Apatinib in the Treatment of Advanced Ovarian Cancer After the Failure of Standard Chemotherapy | June 1, 2018 | June 1, 2020 |
NCT01387399 | Unknown status | Phase 1 | Safety and Pharmacokinetics of Intraoperative Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) With Cisplatin to Treat Platinum-sensitive Recurrent Ovarian Cancer | June 2011 | July 2013 |
NCT03448354 | Unknown status | N/A | Comparative Effectiveness of HIPEC Following Interval Debulking Surgery in Patients With Advanced-stage Ovarian Cancer | October 26, 2017 | July 1, 2022 |
NCT01470235 | Unknown status | Hypodontia and Ovarian Cancer | September 2011 | August 2015 | |
NCT01715168 | Unknown status | Phase 1 | A Crossover Bioequivalence Study of Intravenously Administered ATI0918 and DOXIL/CAELYX in Patients With Ovarian Cancer | October 2012 | December 2015 |
NCT03362606 | Unknown status | Phase 1/Phase 2 | Engineered Immune Effectors Against Ovarian Cancer | November 15, 2017 | December 2020 |
NCT01465750 | Unknown status | Epidemiology of Ovarian Cancer in Taiwan | April 2011 | April 2014 | |
NCT02686463 | Unknown status | N/A | Treatment for Malignant Ovarian Cancer: Laparoscopy vs Laparotomy | April 2016 | June 2023 |
NCT01600573 | Unknown status | Phase 1/Phase 2 | Pazopanib and Weekly Topotecan in Patients Recurrent Ovarian Cancer (TOPAZ) | May 2012 | March 2017 |
NCT04300699 | Unknown status | N/A | Feasibility of Frailty Assessment and Implementation of Interventions in Women Over 70 With Epithelial Ovarian Cancer | June 1, 2020 | December 1, 2022 |
NCT00726635 | Unknown status | Phase 3 | The Assessment of Preoperative Psychological Intervention on Stress in Women With Gynecological Malignancies | August 2008 | August 2009 |
NCT04489706 | Unknown status | N/A | Arsenic Trioxide in Recurrent and Metastatic Ovarian Cancer and Endometrial Cancer With P53 Mutation | June 28, 2020 | November 2022 |
NCT04566952 | Unknown status | Phase 2 | Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian Cancer | October 28, 2020 | October 1, 2023 |
NCT05342506 | Unknown status | Phase 2 | Clinical Study on the Safety, Pharmacokinetics, and Efficacy of ScTIL (Genetically Modified Tumor Infiltrating Lymphocytes) in the Treatment of Gynecological Malignancies | April 18, 2022 | May 31, 2024 |
NCT01770535 | Unknown status | Oxford Ovarian Cancer Predict Chemotherapy Response 01 | November 2012 | June 2015 | |
NCT00757263 | Unknown status | Study of Genes and the Environment in Patients With Ovarian Cancer in the East Anglia, Oxford, Trent, or West Midlands Regions of the United Kingdom | February 2008 | ||
NCT04055038 | Unknown status | Phase 2/Phase 3 | Efficacy of Platinum-based Chemotherapy in Platinum-resistant Ovarian Cancer) (EPITOC) | September 1, 2019 | January 1, 2022 |
NCT00003634 | Unknown status | Phase 2 | Monoclonal Antibody Therapy in Treating Patients With Residual Disease From Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer Following Surgery and Chemotherapy | April 1998 | |
NCT04714931 | Unknown status | N/A | Sentinel Lymph Node Assessment in Ovarian Cancer (TRSGO-SLN-OO5) | January 1, 2021 | April 1, 2022 |
NCT01367353 | Unknown status | N/A | Characterization of Ovarian Cancer Stem Cell | January 2010 | December 2013 |
NCT03979339 | Unknown status | N/A | Feasibility of a New Technology for Isolating Circulating Tumour Cells | March 11, 2020 | December 2023 |
NCT03539328 | Unknown status | Phase 2 | Study on MK-3475 Plus Chemotherapy Versus Chemotherapy Alone in Recurrent, Platinum-resistant Ovarian Cancer | June 2018 | April 2022 |
NCT03556566 | Unknown status | Phase 2 | Open Label Immunotherapy Trial for Ovarian Cancer | July 1, 2018 | December 31, 2019 |
NCT03638206 | Unknown status | Phase 1/Phase 2 | Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies | March 1, 2018 | March 1, 2023 |
NCT00905658 | Unknown status | Phase 2 | Nutritional Supplements in Improving Quality of Life During First-Line Chemotherapy in Patients With Metastatic Gynecological Cancer | June 2008 | |
NCT00533299 | Unknown status | Phase 3 | Hydralazine Valproate for Ovarian Cancer | August 2007 | December 2009 |
NCT03399344 | Unknown status | N/A | Clinical Impact of Dedicated MR Staging of Ovarian Cancer | April 13, 2018 | July 1, 2022 |
NCT02457650 | Unknown status | Phase 1 | T Cell Receptor-transduced T Cells Targeting NY-ESO-1 for Treatment of Patients With NY-ESO-1- Expressing Malignancies | April 2015 | December 2019 |
NCT05069818 | Unknown status | Variance of HRD From Paired Ovarian Cancer | October 2021 | December 2022 | |
NCT00897039 | Unknown status | Laboratory Study in Predicting Tumor Response to Chemotherapy in Patients With Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | March 2006 | ||
NCT01334437 | Unknown status | Blood Test for Ovarian Cancer Associated Auto Antibodies | June 2012 | January 2015 | |
NCT01258881 | Unknown status | Retrospective Study of Ovarian Cancer Patients With Brain Metastasis | April 2010 | December 2011 | |
NCT00173394 | Unknown status | The Assessment of Mesothelin Antigen Specific Immunologic Assays in Ovarian Cancer Patients | August 2005 | December 2008 | |
NCT04170712 | Unknown status | Data and Specimen Bank of Patients Diagnosed With, and at High-risk for, Gynecologic Cancers | June 10, 2016 | June 10, 2022 | |
NCT03942068 | Unknown status | Phase 2 | Apatinib With Albumin-bound Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer | September 1, 2019 | December 30, 2020 |
NCT03278717 | Unknown status | Phase 3 | Study Evaluating the Efficacy of Maintenance Olaparib and Cediranib or Olaparib Alone in Ovarian Cancer Patients | June 15, 2018 | December 2023 |
NCT03895788 | Unknown status | Phase 1 | A Study of Niraparib in Combination With Brivanib in Recurrent Ovarian Cancer | January 14, 2019 | March 2020 |
NCT00499512 | Unknown status | Role of Spirituality in Coping and Surviving With Ovarian Cancer, Primary Peritoneal or Fallopian Tube Cancer | August 10, 2005 | August 31, 2020 | |
NCT04627740 | Unknown status | Phase 1/Phase 2 | Anti-ALPP CAR-T Cells Immunotherapy for Ovarian and Endometrial Cancer | December 1, 2020 | December 31, 2023 |
NCT04000295 | Unknown status | Phase 3 | Apatinib and Etoposide Capsule Versus Weekly Paclitaxel in Patients With Platinum Resistant Ovarian Cancer | August 16, 2019 | July 2022 |
NCT02704832 | Unknown status | Phase 3 | Role of Geriatric Intervention in Treatment of Older Patients With Cancer (PREPARE) | March 2016 | February 2021 |
NCT03763123 | Unknown status | Phase 1 | A Phase 1b Study of Sevacizumab in Combination With Chemotherapy in Chinese Patients With Platinum-Resistant Recurrent Ovarian Cancer. | April 24, 2018 | December 31, 2020 |
NCT02458001 | Unknown status | N/A | Developing a Stepped Approach to Improving Sexual Function aFteR Treatment fOr gyNaecological Cancer | July 2015 | March 2017 |
NCT01388621 | Unknown status | Phase 2 | Carboplatin-based Chemotherapy With or Without Panitumumab in Platinum-sensitive Recurrent Ovarian Cancer | October 2011 | July 2015 |
NCT00002487 | Unknown status | Phase 2 | Methotrexate Plus Dipyridamole in Treating Patients With Advanced Ovarian Cancer | July 1991 | |
NCT00410462 | Unknown status | Phase 2 | Brostallicin or Doxorubicin as First-Line Therapy in Treating Patients With Relapsed, Refractory, or Metastatic Soft Tissue Sarcoma | October 2006 | |
NCT02970786 | Unknown status | Phase 1 | Phase I Trial: 68Ga-NODAGA-E(c[RGDyK])2 Positron Emission Tomography for Imaging Angiogenesis in Primary and Metastatic Tumor Lesions in Humans | November 2016 | |
NCT00004064 | Unknown status | Phase 2 | Monoclonal Antibody Therapy in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer | November 1998 | |
NCT04590625 | Unknown status | Phase 2 | Apatinib Combined With Abraxane and Carboplatin or Cisplatinum as First-line Treatment for Epithelial Ovarian Cancer | October 2020 | December 2023 |
NCT05274867 | Unknown status | Development of a Patient Reported Outcome Measure for Advanced Ovarian Cancer Patients Receiving Surgical and Chemotherapy Treatment | March 7, 2022 | June 7, 2022 | |
NCT04696276 | Unknown status | N/A | Implementing Enhanced Recovery After Surgery (ERAS) Pathways In Major Gynecologic Oncology Operations In Greece | January 6, 2020 | December 30, 2021 |
NCT01570582 | Unknown status | Phase 2 | A Phase IIclinical Trial of Carboplatin and Paclitaxel or Carboplatin and Gemcitabine in Platinum-sensitive, Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer | March 2010 | March 2014 |
NCT03283943 | Unknown status | Phase 1 | PDL-1 Inhibition and Focal Sensitizing Radiotherapy in Recurrent Ovarian/Primary Peritoneal/Fallopian Tube Cancers. | April 1, 2018 | December 16, 2020 |
NCT04295577 | Unknown status | Multi-Centre Observational Study of Maintenance Niraparib in Treatment of Ovarian CanceR | February 3, 2020 | February 3, 2024 | |
NCT00982631 | Unknown status | Phase 1 | A Study of Combination of Temsirolimus (Torisel®) and Pegylated Liposomal Doxorubicin (PLD, Doxil®/Caelyx®) in Advanced or Recurrent Breast, Endometrial and Ovarian Cancer | June 2009 | August 2012 |
NCT00003160 | Unknown status | Phase 2 | Weekly Infusions of Paclitaxel in Treating Women With Stage III or Stage IV Ovarian Cancer Refractory to Paclitaxel and Platinum | September 1997 | |
NCT00003560 | Unknown status | Phase 2 | Docetaxel Plus Carboplatin in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | May 1998 | |
NCT03959761 | Unknown status | Phase 1/Phase 2 | Tolerance of Intraperitoneal (IP) Nivolumab After Extensive Debulking Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Ovarian Carcinoma | July 31, 2019 | November 30, 2021 |
NCT04402333 | Unknown status | Minimally Invasive Robotic Surgery, Role in Optimal Debulking Ovarian Cancer, Recovery & Survival | June 26, 2020 | October 3, 2021 | |
NCT02480790 | Unknown status | Venous Thromboembolic Complications in Ovarian Cancer | November 2014 | September 2019 | |
NCT02132988 | Unknown status | Phase 2 | Trial of Active Immunotherapy With Globo H-KLH (OPT-822/821) in Women Who Have Non-Progressive Ovarian Cancer | November 2013 | November 2018 |
NCT00155740 | Unknown status | Mesothelin as a New Tumor Marker for Ovarian Cancer | January 2002 | December 2006 | |
NCT05175326 | Unknown status | Study on the Consistency Evaluation of Organoids Used in the Clinical Treatment of Ovarian Cancer With Anti-tumor Drugs | November 1, 2021 | November 1, 2022 | |
NCT03235648 | Unknown status | N/A | Evaluation of Surgical Excision of Cardiophrenic Lymph Nodes in Patients With Advanced Ovarian Cancer | June 1, 2017 | June 1, 2023 |
NCT00045461 | Unknown status | Phase 2/Phase 3 | Combination Chemotherapy With or Without Whole-Body Hyperthermia in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer | June 2000 | |
NCT03371693 | Unknown status | Phase 3 | Cytoreductive Surgery(CRS) Plus Hyperthermic Intraperitoneal Chemotherapy(HIPEC) With Lobaplatin in Advanced and Recurrent Epithelial Ovarian Cancer | September 30, 2017 | March 30, 2023 |
NCT02247323 | Unknown status | Ovarian Malignancy Incidence in Moderate Risk Women With Low CA 125 | January 2016 | December 2021 | |
NCT00854399 | Unknown status | N/A | Screening and Identification of Ovarian Cancers | January 2006 | December 2011 |
NCT03446495 | Unknown status | An Observational Study of Combination of Pegylated Liposomal Doxorubicin and Trabectedin in Routine Practice in Patients With Recurrent Partial-platinum Sensitive Ovarian Cancer | March 28, 2017 | May 20, 2019 | |
NCT00511641 | Unknown status | Quality of Life Associated With a Low-Risk Screening Program for Ovarian Cancer | February 12, 2002 | February 2021 | |
NCT02545010 | Unknown status | Phase 1 | Phase I Low Dose WART in Combination With Weekly Paclitaxel for Platinum Resistant Ovarian Cancer | September 2015 | August 2018 |
NCT00021385 | Unknown status | Phase 2 | Squalamine Lactate Plus Carboplatin in Treating Patients With Recurrent or Refractory Stage III or Stage IV Ovarian Cancer | May 2001 | |
NCT01889615 | Unknown status | Dual PETOvac - Dual Time PET/CT in the Preoperative Assessment of Ovarian Cancer | August 2013 | January 2017 | |
NCT03808792 | Unknown status | Imaging Study in Advanced Ovarian Cancer | January 2020 | December 31, 2022 | |
NCT00436774 | Unknown status | Treatment Outcome and Quality of Life in Patients With Pediatric Extra-Cranial Germ Cell Tumors Previously Treated on Clinical Trial CCLG-GC-1979-01 or CCLG-GC-1989-01 | June 2006 | ||
NCT00652119 | Unknown status | Phase 1 | Intraperitoneal Paclitaxel and Carboplatin With IV Avastin Therapy in Patients With Carcinomas of Mullerian Origin | February 2008 | August 2021 |
NCT00003064 | Unknown status | Phase 1/Phase 2 | Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Persistent Epithelial Ovarian Cancer, Fallopian Tube, or Primary Peritoneal Cancer | January 1997 | |
NCT00595348 | Unknown status | Korean Hereditary Breast Cancer Study | November 2007 | May 2017 | |
NCT01180504 | Unknown status | Phase 2 | Consolidation Whole Abdominal Intensity-Modulated Radiation Therapy (IMRT) in Advanced Ovarian Cancer | August 2010 | August 2016 |
NCT04911114 | Unknown status | N/A | Targeted Physical Activity to Improve Mobility and Falls Risk in Women Living With Ovarian Cancer | June 15, 2021 | December 31, 2022 |
NCT01654146 | Unknown status | Phase 3 | ICON8: Weekly Chemotherapy in Ovarian Cancer | June 2011 | |
NCT04473339 | Unknown status | Phase 3 | A Randomized Prospective Trail of HIPEC in Recurrent Ovarian Cancer Patients With HRR Mutation | August 1, 2020 | December 30, 2023 |
NCT05044091 | Unknown status | Homologous Recombination Deficiency in Chinese Ovarian Cancer Patients | September 15, 2021 | September 2023 | |
NCT03298074 | Unknown status | Phase 2 | Apatinib Plus Etoposide Versus Etoposide Alone for Platinum-resistant Recurrent Ovarian Cancer | October 2017 | April 2019 |
NCT00075543 | Unknown status | Phase 1/Phase 2 | Docetaxel and Oxaliplatin in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer | July 2003 | |
NCT03000192 | Unknown status | HORIZONS: Understanding the Impact of Cancer Diagnosis and Treatment on Everyday Life | August 2016 | September 2021 | |
NCT02684318 | Unknown status | Phase 1/Phase 2 | Study to Evaluate PM01183 in Combination With Olaparib in Advanced Solid Tumors | July 2015 | October 2019 |
NCT04217798 | Unknown status | Phase 2 | Efficacy and Safety of Niraparib Combined With Oral Etoposide in Platinum Resistant/Refractory Recurrent Ovarian Cancer | May 21, 2020 | June 1, 2022 |
NCT00003135 | Unknown status | Phase 2 | Whole Body Hyperthermia Combined With Chemotherapy in Treating Patients With Metastatic Breast, Ovarian, Endometrial, or Cervical Cancer | November 1997 | |
NCT01888159 | Unknown status | N/A | Salpingectomy vs Tubal Sterilisation in Low Risk for Ovarian Cancer Women and Its Effect on Ovarian Reserve | September 2013 | |
NCT01267851 | Unknown status | Clinical Database and Biobank of Patients With Gynecologic Neoplasms | January 1, 2010 | December 30, 2020 | |
NCT00551122 | Unknown status | Phase 1/Phase 2 | Gemcitabine, Paclitaxel, Ifosfamide, and Cisplatin in Treating Patients With Progressive or Relapsed Metastatic Germ Cell Tumors | November 2006 | |
NCT02711865 | Unknown status | Predictive Biomarkers for IGF1R Targeted Therapy in Ovarian Cancer | May 2016 | May 2019 | |
NCT00305838 | Unknown status | Phase 2 | CA 125 Levels in Treating Patients With Relapsed Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Who Are Receiving Tamoxifen | March 2004 | |
NCT00855998 | Unknown status | Thymidine Kinase 1 in Risk Assessment for Hereditary Breast /Ovarian Cancer | March 2009 | March 2011 | |
NCT03393507 | Unknown status | Phase 2 | A Study of Apatinib Treatment in for Advanced Ovarian Cancer | August 1, 2017 | December 1, 2019 |
NCT02433626 | Unknown status | Phase 1 | Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Malignancies | December 2015 | June 2020 |
NCT01074398 | Unknown status | Biomarkers in Predicting Response in Patients With Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Treated on GOG-0172 or GOG-0182 | February 2010 | ||
NCT00463996 | Unknown status | MRI in Staging Ovarian Cancer Using MRI Contrast Agent | April 2007 | April 2008 | |
NCT00527631 | Unknown status | Phase 1 | Adjuvant Whole Abdominal Intensity Modulated Radiotherapy (IMRT) for High Risk Stage FIGO III Patients With Ovarian Cancer | July 2006 | November 2012 |
NCT02321735 | Unknown status | N/A | DOD Long-Term Survivors of Ovarian Cancer | September 2014 | September 2019 |
NCT03335241 | Unknown status | Phase 2 | Study of Fludarabine With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer | March 1, 2017 | December 2022 |
NCT03188159 | Unknown status | Phase 2 | Vinorelbine in Relapsed Platinum Resistant or Refractory C5 High Grade Serous, Endometrioid, or Undifferentiated Primary Peritoneum, Fallopian Tube or Ovarian Cancer | July 1, 2017 | July 1, 2022 |
NCT03814447 | Unknown status | Early Phase 1 | The Fourth Generation CART-cell Therapy for Refractory-Relapsed Ovarian Cancer | August 16, 2019 | January 2023 |
NCT04053114 | Unknown status | MOLecular Characterization and Treatment of THYroid Carcinoma on Struma Ovarii | September 2019 | May 2020 | |
NCT00004115 | Unknown status | Phase 3 | Monoclonal Antibody Therapy in Treating Patients With Ovarian Cancer or Primary Peritoneal Cancer in Remission Following Surgery and Chemotherapy | December 1998 | |
NCT02638402 | Unknown status | Expression of Altered Glycosyltransferases, Mucins, and RTKs in Human Ovarian and Endometrial Cancers | May 2016 | August 2017 | |
NCT00601406 | Unknown status | N/A | Study of DNA Mutations in Predicting the Effect of External-Beam Radiation Therapy in Patients With Early Breast Cancer, Localized Prostate Cancer, or Gynecological Cancer | March 2006 | |
NCT01779128 | Unknown status | Early Phase 1 | PET-CT vs. Integrated MR-PET Scanning of GYN Cancers | March 2013 | |
NCT00553683 | Unknown status | Phase 1/Phase 2 | Cyclophosphamide, Radiation Therapy, and Poly ICLC in Treating Patients With Unresectable, Recurrent, Primary, or Metastatic Liver Cancer | October 2007 | July 2014 |
NCT02225015 | Unknown status | Phase 1 | Cancer Prevention in Women With a BRCA Mutation | January 2015 | June 2019 |
NCT03517332 | Unknown status | Circulating Tumor DNA Exposure in Peripheral Blood | January 1, 2015 | December 31, 2019 | |
NCT00274950 | Unknown status | Phase 3 | Observation and/or Combination Chemotherapy After Surgery or Biopsy in Treating Young Patients With Extracranial Germ Cell Tumors | May 2005 | |
NCT00838656 | Unknown status | Phase 2 | Two Different Schedules of Carboplatin, Paclitaxel, Gemcitabine, and Surgery in Treating Patients With Newly Diagnosed Stage IIIC or Stage IV Primary Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | October 2007 | |
NCT00964626 | Unknown status | Phase 2 | Paclitaxel and Cisplatin as First-Line Treatment for Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer | April 2009 | |
NCT03738319 | Unknown status | Non-coding RNA in the Exosome of the Epithelia Ovarian Cancer | November 10, 2018 | November 23, 2019 | |
NCT00854282 | Unknown status | N/A | The Role of Regulatory T Cell in Ovarian Cancer: Focus on Relationship Between Clinical Prognosis and Regulatory T Cell Expression | January 2009 | December 2012 |
NCT00276718 | Unknown status | N/A | Etoposide, Carboplatin, and Bleomycin in Treating Young Patients Undergoing Surgery For Malignant Germ Cell Tumors | April 1989 | |
NCT03924882 | Unknown status | Phase 2 | Anlotinib for Patients With Platinum Resistant or Refractory Ovarian Cancer | April 25, 2019 | April 25, 2022 |
NCT00772798 | Unknown status | Phase 2 | A Phase I/II Study of Paclitaxel Plus Carboplatin Plus Vorinostat in Recurrent Ovarian Cancer | June 2007 | June 2009 |
NCT04661696 | Unknown status | Phase 2 | Efficacy and Safety of Paclitaxel (Albumin-bound) Combination With Carboplatin in Ovarian Cancer. | December 9, 2020 | February 23, 2024 |
NCT04235556 | Unknown status | Integrated Care Pathway in Oncology (PASSION) | February 21, 2020 | December 31, 2022 | |
NCT04169997 | Unknown status | Phase 3 | A Study of IMP4297 as Maintenance Treatment Following First-line Chemotherapy in Patients With Advanced Ovarian Cancer | December 24, 2019 | December 30, 2022 |
NCT04280185 | Unknown status | N/A | HIPEC in the Treatment of Stage IIc-IV Epithelial Ovarian Cancer After CRS (HIPECOC) | June 1, 2020 | May 1, 2024 |
NCT00532194 | Unknown status | Phase 3 | An RCT of Concurrent and Maintenance Cediranib in Women With Platinum-sensitive Relapsed Ovarian Cancer | July 2007 | December 2016 |
NCT01823731 | Unknown status | A Pilot Test for Newly Developed Synoptic Operative Template for Ovarian Cancer (SOTOC): National Cancer Center - Peritoneal Carcinomatosis Index | January 2013 | December 2013 | |
NCT01087268 | Unknown status | Phase 3 | Hyperbaric Oxygen Therapy in Treating Long-Term Gastrointestinal Adverse Effects Caused by Radiation Therapy in Patients With Pelvic Cancer | January 2009 | |
NCT04617470 | Unknown status | Niraparib as Maintenance Treatment in Platinum Responsive Ovarian Cancer Patients: a Real Life Study | July 8, 2020 | January 1, 2022 | |
NCT03150992 | Unknown status | N/A | EDMONd - Elemental Diet in Bowel Obstruction | July 19, 2017 | December 2019 |
NCT00900289 | Unknown status | Studying DNA in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer | March 2002 | ||
NCT03526809 | Unknown status | Molecular Imaging and Spectroscopy With Stable Isotopes in Oncology and Neurology | June 1, 2016 | December 31, 2019 | |
NCT03634501 | Unknown status | Phase 1/Phase 2 | Clinical Study on Anti-tumor Effect Induced by Activated Primary Natural Killer(NK)Cells | October 26, 2018 | September 30, 2022 |
NCT04368130 | Withdrawn | N/A | SIGNAL:Identifying Behavioral Anomalies Using Smartphones to Improve Cancer Care | September 1, 2022 | September 1, 2023 |
NCT03032614 | Withdrawn | Phase 2 | Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients | September 30, 2017 | April 30, 2020 |
NCT04542603 | Withdrawn | Phase 1 | Neuroinflammation and Age-associated Brain Pathology: Two Potential Mechanisms of Cognitive Impairment in Ovarian Cancer | June 2025 | August 2026 |
NCT04102436 | Withdrawn | Phase 2 | Non-Viral TCR Gene Therapy | March 8, 2024 | March 8, 2024 |
NCT00408967 | Withdrawn | Phase 2 | Determine if Either of 2 Doses of Study Drug Given With a Low-dose of Cyclophosphamide After a Complete or Partial Response to a Platinum-based Second-line Therapy in Women With Recurrent Ovarian Carcinoma Results in a Longer Time to Progression When Compared to the First Time to Progression. | December 31, 2006 | May 31, 2008 |
NCT00017537 | Withdrawn | Phase 1 | Vaccine Therapy in Treating Patients With Metastatic or Recurrent Cancer | March 2000 | March 2005 |
NCT02713984 | Withdrawn | Phase 1/Phase 2 | A Clinical Research of CAR T Cells Targeting HER2 Positive Cancer | March 2016 | July 2019 |
NCT03806049 | Withdrawn | Phase 3 | Trial Comparing Niraparib-bevacizumab-Dostarlimab and Niraparib-bevacizumab to Standard of Care in Recurrent Ovarian Cancer | December 2019 | December 2024 |
NCT04941378 | Withdrawn | Phase 1 | OTL38 Injection (OTL38) for Intra-Operative Imaging of Folate Receptor Positive Ovarian Cancer | May 28, 2022 | May 28, 2022 |
NCT01624493 | Withdrawn | Phase 1/Phase 2 | BNC105P Combination Study in Partially Platinum Sensitive Ovarian Cancer Patients | October 2012 | October 2014 |
NCT00006267 | Withdrawn | Phase 2 | Nitrocamptothecin in Treating Patients With Recurrent or Metastatic Ovarian Epithelial or Primary Peritoneal Cancer | ||
NCT01766622 | Withdrawn | Phase 2 | 18F-CP18 Imaging Studies for Cancer Treatment With Birinapant | November 30, 2012 | July 24, 2013 |
NCT01661868 | Withdrawn | Phase 2 | Olaparib for Patients With Recurrent BRCA Deficient Ovarian Cancer | August 2012 | August 2012 |
NCT00084370 | Withdrawn | N/A | Celecoxib in Preventing Cancer in Patients at High Risk for Ovarian Epithelial Cancer Who Are Undergoing Prophylactic Oophorectomy | June 2002 | March 2005 |
NCT02667925 | Withdrawn | N/A | Study of the Isotopic Distribution of Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis of Ovarian Origin | March 2016 | September 2016 |
NCT00562185 | Withdrawn | Phase 1/Phase 2 | Doxorubicin and Carboplatin in Treating Patients With Recurrent Ovarian Cancer | May 2008 | March 2009 |
NCT03933761 | Withdrawn | Phase 2 | Pamiparib in Fusion Positive, Reversion Negative High Grade Serous Ovarian Cancer or Carcinosarcoma With BRCA1/2 Gene Mutations If Progression on Substrate Poly ADP Ribose Polymerase Inhibitbor (PARPI) or Chemotherapy | July 29, 2019 | August 2, 2021 |
NCT00484666 | Withdrawn | Platinum-Resistant, Recurrent Epithelial Ovarian Cancer | May 2006 | May 2009 | |
NCT00787488 | Withdrawn | N/A | Pilot Study of IV and IP Chemotherapy Plus Abdominal Hyperthermia for Ovarian Ca | April 2009 | April 2009 |
NCT00753740 | Withdrawn | Phase 2 | Efficacy Study of Maintenance IT-101 Therapy for Ovarian Cancer Patients. | September 2008 | May 2010 |
NCT01131039 | Withdrawn | Phase 2 | Safety and Efficacy Study of Gemcitabine Plus Bevacizumab in Patients With Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer | January 2011 | September 2011 |
NCT02117817 | Withdrawn | Phase 1 | Phase I BKM120/Abraxane in Solid Tumors, Expansion Phase Recurrent Endometrial or Ovarian Cancer | February 2015 | February 25, 2015 |
NCT00085527 | Withdrawn | Phase 2 | FR901228 in Treating Patients With Relapsed or Refractory Advanced Ovarian Epithelial Cancer | May 2005 | September 2005 |
NCT00369954 | Withdrawn | Phase 2 | Gemcitabine and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer That Responded to Previous Cisplatin or Carboplatin | April 2006 | |
NCT00842582 | Withdrawn | Phase 1 | Azacitidine With Carboplatin and Paclitaxel for Newly Diagnosed Ovarian Cancer | February 2009 | March 2011 |
NCT00813254 | Withdrawn | Cost Utility Analysis in Recurrent Ovarian Cancer | December 2008 | January 2011 | |
NCT01386502 | Withdrawn | Phase 1 | CT-011 and p53 Genetic Vaccine for Advanced Solid Tumors | June 15, 2011 | October 31, 2011 |
NCT04464967 | Withdrawn | Phase 1/Phase 2 | Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers | March 2021 | February 2023 |
NCT03644459 | Withdrawn | Phase 1 | Safety and Efficacy of the Fully Humanized Anti - VEGF Monoclonal Antibody LYN00101 | April 3, 2019 | August 2020 |
NCT00005645 | Withdrawn | Phase 2 | ILX-295501 in Treating Patients With Stage III or Stage IV Ovarian Cancer That Has Not Responded to Previous Treatment | May 1999 | |
NCT03281681 | Withdrawn | Phase 1/Phase 2 | A Multi-center Study of VAL-083 in Patients With Recurrent Platinum Resistant Ovarian Cancer | March 2021 | September 2022 |
NCT05201001 | Withdrawn | Phase 2 | APX005M in Patients With Recurrent Ovarian Cancer | September 7, 2023 | September 7, 2023 |
NCT01097239 | Withdrawn | Phase 1/Phase 2 | Examining the Role of Transrectal High Intensity Focused Ultrasound (HIFU) in Rectal Pelvic Cancer | November 2009 | September 2018 |
NCT04602117 | Withdrawn | Phase 1 | ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer | July 28, 2021 | November 17, 2021 |
NCT03905902 | Withdrawn | Phase 3 | DCVAC/OvCa and Standard of Care (SoC) in Relapsed Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma | August 2021 | August 16, 2021 |
NCT01606358 | Withdrawn | Influence of Chemotherapy on Gamma-delta T Cells in Patients With Epithelial Ovarian Cancer | |||
NCT00080639 | Withdrawn | CA-125 in Screening Patients at High Risk for Ovarian Cancer | June 2003 | June 2007 | |
NCT02017678 | Withdrawn | Phase 2 | Phase 2 Study of JX-594 in Patients With Peritoneal Carcinomatosis of Ovarian Cancer Origin | January 2014 | June 2015 |
NCT02836028 | Withdrawn | Phase 2 | A Study Evaluating Talazoparib in Relapsed Ovarian, Fallopian Tube, and Peritoneal Cancer | October 2016 | |
NCT01880996 | Withdrawn | Phase 1/Phase 2 | Tai-chi / Qi-gong in Patients With Patients With Gynecological Malignancies | August 2014 | August 2015 |
NCT00460200 | Withdrawn | Depression and Interleukin-6 Production in Patients With Ovarian Epithelial Cancer | December 2003 | ||
NCT05905341 | Withdrawn | Phase 1 | Study of PF-07224826, as a Single Agent or in Combination With Endocrine Therapy in Participants With Breast Cancer and Other Advanced Solid Tumors. | January 15, 2024 | April 13, 2028 |
NCT00693342 | Withdrawn | Phase 3 | Vaccine Therapy and OPT-821 or OPT-821 Alone in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer in Complete Remission | ||
NCT00323726 | Withdrawn | Trends in Incidence and Survivals for Ovarian Germ Cell Tumors: A 27-Year Population-Based Study | December 2005 | December 2006 | |
NCT04239014 | Withdrawn | Phase 2 | A Study to Evaluate the Effectiveness and Tolerability of a Second Maintenance Treatment in Participants With Ovarian Cancer, Who Have Previously Received Polyadenosine 5'Diphosphoribose [Poly (ADP Ribose)] Polymerase Inhibitor (PARPi) Treatment. | August 7, 2020 | January 25, 2021 |
NCT04795596 | Withdrawn | Phase 2/Phase 3 | Secondary Cytoreductive Surgery in Platinum-resistant Recurrent Ovarian Cancers | April 1, 2021 | April 9, 2022 |
NCT00477867 | Withdrawn | N/A | Economic Outcomes in Patients With Stage III Ovarian Cancer Receiving Paclitaxel and Cisplatin on Clinical Trial GOG-172 | ||
NCT03197584 | Withdrawn | Phase 1/Phase 2 | QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) Therapy | December 2017 | April 2019 |
NCT00634894 | Withdrawn | Phase 2 | Femara (Letrozole) Versus Placebo for Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | March 2008 | September 2008 |
NCT00603460 | Withdrawn | Phase 1/Phase 2 | DCVax-L Vaccination With CD3/CD28 Costimulated Autologous T-Cells for Recurrent Ovarian or Primary Peritoneal Cancer | January 2012 | March 2013 |
NCT05431582 | Withdrawn | Phase 1 | Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid Tumors | December 14, 2022 | December 14, 2022 |
NCT00003865 | Withdrawn | Phase 2 | Toremifene in Treating Patients With Ovarian Cancer | July 22, 1999 | February 22, 2017 |
NCT00118300 | Withdrawn | Phase 1 | Capecitabine and Radiation Therapy in Treating Patients With Locally Advanced Cervical Cancer or Other Pelvic Cancer | April 2005 | |
NCT02083536 | Withdrawn | Phase 1 | LDFWART With Docetaxel in Patients With Platinum-Resistant Recurrent Ovarian Carcinoma | May 2014 | |
NCT00093678 | Withdrawn | N/A | Celecoxib in Managing Pain, Weight Loss, and Weakness in Patients With Advanced Cancer | ||
NCT00610792 | Withdrawn | Phase 2 | Phase 2 Study of Twice Weekly VELCADE and CAELYX in Patients With Ovarian Cancer Failing Platinum Containing Regimens | July 2006 | |
NCT01017809 | Withdrawn | N/A | Prolonged Emend in a Study (NYU 03-67) of Oxaliplatin and Topotecan in Previously Treated Ovarian Cancer | December 2010 | December 2013 |
NCT00173407 | Withdrawn | N/A | PTEN and IGFBP-3 Correlation in Ovarian Carcinoma Invasion | January 2006 | October 2012 |
- Disase is a (Disease Ontology)
- DOID:120
- Cross Reference ID (Disease Ontology)
- GARD:7295
- Cross Reference ID (Disease Ontology)
- ICD10CM:C56
- Cross Reference ID (Disease Ontology)
- ICD9CM:183.0
- Cross Reference ID (Disease Ontology)
- MESH:D010051
- Cross Reference ID (Disease Ontology)
- MIM:167000
- Cross Reference ID (Disease Ontology)
- MIM:607893
- Cross Reference ID (Disease Ontology)
- NCI:C4984
- Cross Reference ID (Disease Ontology)
- NCI:C7431
- Cross Reference ID (Disease Ontology)
- ORDO:213500
- Cross Reference ID (Disease Ontology)
- ORDO:213517
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:123843001
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:372117006
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:93934004
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0919267
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C1140680
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C1299247
- Exact Synonym (Disease Ontology)
- malignant Ovarian tumor
- Exact Synonym (Disease Ontology)
- malignant tumour of ovary
- Exact Synonym (Disease Ontology)
- ovarian neoplasm
- Exact Synonym (Disease Ontology)
- ovary neoplasm
- Exact Synonym (Disease Ontology)
- primary ovarian cancer
- Exact Synonym (Disease Ontology)
- tumor of the Ovary